
<html lang="en"     class="pb-page"  data-request-id="a86a54d2-958a-4d38-9eaa-d5af83d184d7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2008.51.issue-6;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm701098w;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors¶" /></meta><meta name="dc.Creator" content="Matthew M.  Weiss" /></meta><meta name="dc.Creator" content="Jean-Christophe  Harmange" /></meta><meta name="dc.Creator" content="Anthony J.  Polverino" /></meta><meta name="dc.Creator" content="David  Bauer" /></meta><meta name="dc.Creator" content="Loren  Berry" /></meta><meta name="dc.Creator" content="Virginia  Berry" /></meta><meta name="dc.Creator" content="George  Borg" /></meta><meta name="dc.Creator" content="James  Bready" /></meta><meta name="dc.Creator" content="Danlin  Chen" /></meta><meta name="dc.Creator" content="Deborah  Choquette" /></meta><meta name="dc.Creator" content="Angela  Coxon" /></meta><meta name="dc.Creator" content="Tom  DeMelfi" /></meta><meta name="dc.Creator" content="Nicholas  Doerr" /></meta><meta name="dc.Creator" content="Juan  Estrada" /></meta><meta name="dc.Creator" content="Julie  Flynn" /></meta><meta name="dc.Creator" content="Russell F.  Graceffa" /></meta><meta name="dc.Creator" content="Shawn P.  Harriman" /></meta><meta name="dc.Creator" content="Stephen  Kaufman" /></meta><meta name="dc.Creator" content="Daniel S.  La" /></meta><meta name="dc.Creator" content="Alexander  Long" /></meta><meta name="dc.Creator" content="Sesha  Neervannan" /></meta><meta name="dc.Creator" content="Vinod F.  Patel" /></meta><meta name="dc.Creator" content="Michele  Potashman" /></meta><meta name="dc.Creator" content="Kelly  Regal" /></meta><meta name="dc.Creator" content="Phillip M.  Roveto" /></meta><meta name="dc.Creator" content="Michael L.  Schrag" /></meta><meta name="dc.Creator" content="Charlie  Starnes" /></meta><meta name="dc.Creator" content="Andrew  Tasker" /></meta><meta name="dc.Creator" content="Yohannes  Teffera" /></meta><meta name="dc.Creator" content="Douglas A.  Whittington" /></meta><meta name="dc.Creator" content="Roger  Zanon" /></meta><meta name="dc.Description" content="We have previously shown N-arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). N-Alkyl and N-unsubstituted naphthamides were prepared and found to yi..." /></meta><meta name="Description" content="We have previously shown N-arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). N-Alkyl and N-unsubstituted naphthamides were prepared and found to yi..." /></meta><meta name="dc.Publisher" content=" American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 7, 2008" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm701098w" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2008 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm701098w" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm701098w" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm701098w" /></link>
        
    
    

<title>Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm701098w" /></meta><meta property="og:title" content="Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors¶" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0012.jpeg" /></meta><meta property="og:description" content=" We have previously shown N-arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). N-Alkyl and N-unsubstituted naphthamides were prepared and found to yield nanomolar inhibitors of VEGFR-2 (KDR) with an improved selectivity profile against a panel of tyrosine and serine/threonine kinases. The inhibitory activity of this series was retained at the cellular level. Naphthamides 3, 20, and 22 exhibited good pharmacokinetics following oral dosing and showed potent inhibition of VEGF-induced angiogenesis in the rat corneal model. Once-daily oral administration of 22 for 14 days led to 85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectively." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm701098w"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm701098w">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm701098w&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm701098w&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm701098w&amp;href=/doi/10.1021/jm701098w" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2008</span><span class="cit-fg-volume">, 51</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 1668-1680</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/51/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm701097z" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm7010996" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors<a class="ref internalNav" href="#fnpdb" aria-label="¶">¶</a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+M.++Weiss">Matthew M. Weiss</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Christophe++Harmange">Jean-Christophe Harmange</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+J.++Polverino">Anthony J. Polverino</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Bauer">David Bauer</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Loren++Berry">Loren Berry</a></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Virginia++Berry">Virginia Berry</a></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George++Borg">George Borg</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Bready">James Bready</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danlin++Chen">Danlin Chen</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deborah++Choquette">Deborah Choquette</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Coxon">Angela Coxon</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tom++DeMelfi">Tom DeMelfi</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas++Doerr">Nicholas Doerr</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Estrada">Juan Estrada</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Flynn">Julie Flynn</a></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Russell+F.++Graceffa">Russell F. Graceffa</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shawn+P.++Harriman">Shawn P. Harriman</a></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Kaufman">Stephen Kaufman</a></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+S.++La">Daniel S. La</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Long">Alexander Long</a></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sesha++Neervannan">Sesha Neervannan</a></span><span class="author-xref-symbol "><sup>×</sup></span><span class="author-xref-symbol "><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vinod+F.++Patel">Vinod F. Patel</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michele++Potashman">Michele Potashman</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kelly++Regal">Kelly Regal</a></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Phillip+M.++Roveto">Phillip M. Roveto</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+L.++Schrag">Michael L. Schrag</a></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charlie++Starnes">Charlie Starnes</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Tasker">Andrew Tasker</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yohannes++Teffera">Yohannes Teffera</a></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+A.++Whittington">Douglas A. Whittington</a></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roger++Zanon">Roger Zanon</a></span><span class="author-xref-symbol "><sup>×</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div><div class="corresp-fn" id="fnpdb">¶The PDB accession codes for cocrystals of compounds 2 and 3 in the KDR ATP-binding pocket are 3B8Q and 3B8R, respectively.</div><div class="corresp-info"><strong>*</strong> To whom correspondence should be addressed. Phone: 617-444-5188 . Fax: 617-621-3908. E-mail: <a href="/cdn-cgi/l/email-protection#630e0e14060a101023020e04060d4d000c0e"><span class="__cf_email__" data-cfemail="503d3d273539232310313d37353e7e333f3d">[email protected]</span></a></div><div class="corresp-fn" id="afn1">†Department of Medicinal Chemistry.</div><div class="corresp-fn" id="afn2">‡Department of Oncology Research.</div><div class="corresp-fn" id="afn3">#Department of Pharmacokinetics and Drug Metabolism.</div><div class="corresp-fn" id="afn4">∥Department of Pathology.</div><div class="corresp-fn" id="afn5">§Department of Molecular Structure.</div><div class="corresp-fn" id="afn6">×Department of Pharmaceutics.</div><div class="corresp-fn" id="afn7">∞Present Address: Allergan, 2525 Dupont Drive, Irvine, CA 92623.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm701098w&amp;href=/doi/10.1021%2Fjm701098w" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2008</span></span><span class="cit-volume">, 51</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 1668–1680</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 7, 2008</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 September 2007</li><li><span class="item_label"><b>Published</b> online</span>7 March 2008</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 1 March 2008</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm701098w" title="DOI URL">https://doi.org/10.1021/jm701098w</a></div><div class="article_header-article-copyright"><strong>Copyright © 2008 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1668%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMatthew%2BM.%2BWeiss%252C%2BJean-Christophe%2BHarmange%252C%2BAnthony%2BJ.%2BPolverino%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D51%26issueNum%3D6%26contentID%3Djm701098w%26title%3DEvaluation%2Bof%2Ba%2BSeries%2Bof%2BNaphthamides%2Bas%2BPotent%252C%2BOrally%2BActive%2BVascular%2BEndothelial%2BGrowth%2BFactor%2BReceptor-2%2BTyrosine%2BKinase%2BInhibitors%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1680%26publicationDate%3DMarch%2B2008">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm701098w"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2683</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">26</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm701098w" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;M. Weiss&quot;},{&quot;first_name&quot;:&quot;Jean-Christophe&quot;,&quot;last_name&quot;:&quot;Harmange&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;J. Polverino&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Bauer&quot;},{&quot;first_name&quot;:&quot;Loren&quot;,&quot;last_name&quot;:&quot;Berry&quot;},{&quot;first_name&quot;:&quot;Virginia&quot;,&quot;last_name&quot;:&quot;Berry&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Borg&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Bready&quot;},{&quot;first_name&quot;:&quot;Danlin&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Deborah&quot;,&quot;last_name&quot;:&quot;Choquette&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Coxon&quot;},{&quot;first_name&quot;:&quot;Tom&quot;,&quot;last_name&quot;:&quot;DeMelfi&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;Doerr&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Estrada&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Flynn&quot;},{&quot;first_name&quot;:&quot;Russell&quot;,&quot;last_name&quot;:&quot;F. Graceffa&quot;},{&quot;first_name&quot;:&quot;Shawn&quot;,&quot;last_name&quot;:&quot;P. Harriman&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Kaufman&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;S. La&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Long&quot;},{&quot;first_name&quot;:&quot;Sesha&quot;,&quot;last_name&quot;:&quot;Neervannan&quot;},{&quot;first_name&quot;:&quot;Vinod&quot;,&quot;last_name&quot;:&quot;F. Patel&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;Potashman&quot;},{&quot;first_name&quot;:&quot;Kelly&quot;,&quot;last_name&quot;:&quot;Regal&quot;},{&quot;first_name&quot;:&quot;Phillip&quot;,&quot;last_name&quot;:&quot;M. Roveto&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;L. Schrag&quot;},{&quot;first_name&quot;:&quot;Charlie&quot;,&quot;last_name&quot;:&quot;Starnes&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Tasker&quot;},{&quot;first_name&quot;:&quot;Yohannes&quot;,&quot;last_name&quot;:&quot;Teffera&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;A. Whittington&quot;},{&quot;first_name&quot;:&quot;Roger&quot;,&quot;last_name&quot;:&quot;Zanon&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2008&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;51&quot;,&quot;pages&quot;:&quot;1668-1680&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm701098w&quot;},&quot;abstract&quot;:&quot;We have previously shown N-arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). N-Alkyl and N-unsubstituted naphthamides were prepared and found to yield nanomolar inhibitors of VEGFR-2 (KDR) with an improved selectivity profile against a panel of tyrosine and serine/threonine kinases. The inhibitory activity of this series was retained at the cellular level. Naphthamides 3, 20, and 22 exhibited good pharmacokinetics following oral dosing and showed potent inhibition of VEGF-induced angiogenesis in the rat corneal model. Once-daily oral administration of 22 for 14 days led to 85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectively.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm701098w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm701098w" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm701098w&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm701098w" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm701098w&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm701098w" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm701098w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm701098w&amp;href=/doi/10.1021/jm701098w" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm701098w" /></input><a href="/doi/pdf/10.1021/jm701098w" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (777 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm701098w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm701098w%26sid%3Dliteratum%253Aachs%26pmid%3D18324759%26genre%3Darticle%26aulast%3DWeiss%26date%3D2008%26atitle%3DEvaluation%2Bof%2Ba%2BSeries%2Bof%2BNaphthamides%2Bas%2BPotent%252C%2BOrally%2BActive%2BVascular%2BEndothelial%2BGrowth%2BFactor%2BReceptor-2%2BTyrosine%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D51%26issue%3D6%26spage%3D1668%26epage%3D1680%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/51/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We have previously shown <i>N-</i>arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). <i>N-</i>Alkyl and <i>N-</i>unsubstituted naphthamides were prepared and found to yield nanomolar inhibitors of VEGFR-2 (KDR) with an improved selectivity profile against a panel of tyrosine and serine/threonine kinases. The inhibitory activity of this series was retained at the cellular level. Naphthamides <b>3</b>, <b>20</b>, and <b>22</b> exhibited good pharmacokinetics following oral dosing and showed potent inhibition of VEGF-induced angiogenesis in the rat corneal model. Once-daily oral administration of <b>22</b> for 14 days led to 85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectively.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div id="ac_i2" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i2"> </h2><div class="NLM_p">Angiogenesis is of importance to many normal physiological processes but also contributes to pathological disorders and, in particular, has implications in the growth and metastasis of solid tumors.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Tumors smaller than 2 mm<sup>3</sup> in volume acquire nutrients and oxygen via passive diffusion; however, in order for growth beyond this critical size, an increase in vasculature is required.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Neovascularization results from a complex set of events involving a number of diverse stimuli; however, signaling induced by VEGF<a class="ref internalNav" href="#fn8" aria-label="a">a</a><div class="NLM_fn" id="fn8">a<p class="last">Abbreviations: VEGF, vascular endothelial growth factor; KDR, kinase domain region; PDGFR, platelet-derived growth factor receptor; HUVEC, human umbilical vein endothelial cells; STK, serine/threonine kinase; NRTK, nonreceptor tyrosine kinase; bFGF, basic fibroblast growth factor; FBS, fetal bovine serum; PBS, phosphate buffered saline; MRT, mean residence time; DMF, dimethylformamide; DMSO, dimethyl sulfoxide; DIPEA, diisopropylethylamine; DMAP, 4-dimethylaminopyridine; HATU, 2-(7-aza-1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HOAt, 1-hydroxy-7-azabenzotriazole; EDC, <i>N</i>-ethyl-<i>N</i>′-(3-dimethylaminopropyl)carbodiimide hydrochloride; MSA, methanesulfonic acid.</p></div>  is considered rate-limiting. VEGF drives the angiogenic cascade by promoting endothelial cell activation and proliferation and enhancing the migration and invasion of endothelial cells. Tumors can up-regulate VEGF expression or secretion via a number of pathways, including oncogene activation,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> loss of tumor suppressor function,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and changes in oxygen levels.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> VEGF binds to the receptor tyrosine kinase (RTK) receptors including VEGFR-2 (KDR) on endothelial cells, which initiates a dimerization event.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> The resulting conformational change induced in the receptor complex leads to the propagation of intracellular signaling cascades that result in altered gene expression and cellular function.</div><div class="NLM_p">Inhibition of angiogenesis by blocking the VEGF signaling pathway has attracted considerable interest as an approach to anticancer therapy.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>Indeed, this approach has recently been validated with the VEGF monoclonal antibody bevacizumab, which has been approved by the FDA for the treatment of metastatic colorectal cancer and non-small-cell lung cancer.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition to biological-based antiangiogenics, many small-molecule KDR inhibitors are currently in clinical development<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> and two inhibitors, sorafenib<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and sunitinib,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> have recently received approval for the treatment of renal cell carcinoma. Our program has targeted the development of small-molecule inhibitors of KDR, such as AMG 706 (<i>N</i>-(3,3-dimethyl-2,3-dihydro-1<i>H</i>-indol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide, motesanib diphosphate).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This compound was recently reported as a highly selective oral agent that is being evaluated for its ability to inhibit angiogenesis and lymphangiogenesis by targeting vascular endothelial growth factor receptors (VEGFR) 1–3.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> It is also under investigation for its potential direct antitumor activity by targeting platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor (c-Kit) signaling. Motesanib diphosphate is currently in phase 2 development as a monotherapy in thyroid cancer and in combination with other anticancer therapies to treat patients with non-small-cell lung cancer, breast cancer, and colorectal cancer.</div><div class="NLM_p">In the previous Article, we reported the design, synthesis, and evaluation of a series of <i>N-</i>arylnaphthamides (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> This scaffold provided access to low-nanomolar inhibitors of KDR and led to the identification of <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), which demonstrated robust preclinical in vivo activity in a human tumor xenograft model. While efficacious in several in vivo models, this agent lacked a high degree of selectivity against several kinases. Of particular concern was inhibitory activity against the serine/threonine kinase (STK) Aurora B, a mitotic kinase that has been implicated in centrosome separation and spindle formation,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and the nonreceptor tyrosine kinase (NRTK) Lck, a member of the Src family that has been shown to have important roles in T cell receptor signal transduction.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Furthermore, <b>2</b> possessed poor intrinsic physicochemical properties that included low aqueous solubility and high lipophilicity, as determined by cLogP (7.02).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> These features led to restricted cell permeability, which in turn limited inhibition at the cellular level.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Lead Discovery for <i>N-</i>alkylnaphthamides.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the course of identifying <b>2</b>, it was found that <i>N-</i>cyclopropylnaphthamide <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) was a potent inhibitor of KDR and displayed a more restrictive selectivity profile against a small panel of kinases (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In addition to improved selectivity, the reduced cLogP of <b>3</b> was expected to translate into improved cellular permeability and a more favorable pharmacokinetic profile.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Selectivity Profiles for <b>2</b> and <b>3</b></div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead valign="middle"><tr valign="top"><th align="center" valign="middle"> </th><th colspan="6" align="center" valign="middle" char=".">IC<sub>50</sub><a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a> (nM)</th><th align="center" valign="middle" char="."> </th></tr><tr valign="top" class="rowsep1"><th class="rowsep1" align="center" valign="middle">compd</th><th class="rowsep1" align="center" valign="middle" char=".">KDR</th><th class="rowsep1" align="center" valign="middle" char=".">Tie-2</th><th class="rowsep1" align="center" valign="middle" char=".">c-Met</th><th class="rowsep1" align="center" valign="middle" char=".">Lck</th><th class="rowsep1" align="center" valign="middle" char=".">Aurora A</th><th class="rowsep1" align="center" valign="middle" char=".">Aurora B</th><th class="rowsep1" align="center" valign="middle" char=".">cLogP<a class="ref internalNav" href="#tbl1-fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>2</b></td><td align="char" char=".">0.48</td><td align="char" char=".">580</td><td align="char" char=".">450</td><td align="char" char=".">38</td><td align="char" char=".">371</td><td align="char" char=".">18</td><td align="char" char=".">7.02</td></tr><tr valign="top"><td align="left"><b>3</b></td><td align="char" char=".">0.60</td><td align="char" char=".">25000</td><td align="char" char=".">20000</td><td align="char" char=".">330</td><td align="char" char=".">2000</td><td align="char" char=".">118</td><td align="char" char=".">4.61</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were averaged values determined by at least two independent experiments.</p></div><div class="footnote" id="tbl1-fn2"><sup>b</sup><p class="last">Determined using Daylight software, version 4.41.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></p></div></div></div><div class="NLM_p">In an effort to gain insight into the origin of the improved selectivity profile of <b>3</b>, we turned to the crystallographic structures of <b>2</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and <b>3</b> within the catalytic domain of KDR. As illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, both inhibitors bind to the enzyme in a similar manner, wherein the nitrogen of the dimethoxyquinoline ring participates in a hydrogen-bond interaction with the backbone amide-NH of Cys919 of the hinge region. The naphthyl core, which is oriented orthogonal to the quinoline ring, is accommodated in the mostly hydrophobic ATP-binding cleft. The carbonyl and NH groups of the amide make two interactions with the backbone NH of Asp1046 and the side chain of Glu885, respectively. Inspection of the two crystallographic structures, however, reveals a large conformational change in the highly conserved Asp-Phe-Gly (DFG) loop. When complexed with <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), KDR adopts an “inactive” kinase conformation and the DFG loop of KDR assumes a “DFG-out” conformation, allowing the <i>p</i>-Cl phenyl ring of <b>2</b> to penetrate into the extended hydrophobic pocket which exists between the N<i>-</i> and C-terminal regions (PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8Q">3B8Q</a>). This conformational change, wherein Phe1047 has shifted by about 10 Å, opens up this extended hydrophobic pocket which cannot be accessed when the enzyme is in the “active” conformation. In contrast, when complexed with <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), the DFG loop is maintained in a “DFG-in” conformation, preventing interactions between the inhibitor and the extended hydrophobic pocket (PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8R">3B8R</a>). Interestingly, while <b>3</b> is not able to leverage interactions in the extended hydrophobic pocket, it maintained the potent level of inhibition exhibited by <b>2</b>. Herein, we describe the structure–activity relationships and antitumor activity of <i>N-</i>alkyl and <i>N-</i>unsubstituted naphthamides.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystallographic analysis of compounds <b>2</b> (top) and <b>3</b> (bottom) in the ATP-binding pocket of KDR. Hydrogen bonds are shown between the inhibitors and KDR (dotted lines).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The compounds described in Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>−<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> were prepared by the general routes described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Commercially available 6-hydroxynaphthoic acid (<b>4</b>) was heated in the presence of cesium carbonate and the appropriately substituted 4-chloroquinoline<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> in DMSO to provide naphthoic acids <b>5a</b>–<b>c</b>. The naphthamides of interest (<b>6</b>) were then accessed via conversion of the acid to the desired amide functionality. Alternatively, 6-hydroxynaphthoic acid (<b>4</b>) could be converted to naphthamide <b>7</b>, which could then be transformed to the desired naphthamide (<b>6</b>) utilizing a modified Ullman procedure.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compounds wherein the 6,7-dimethoxyquinoline was replaced with a 6,7-dimethoxyquinazoline (i.e., <b>9</b>) could be accessed in a similar manner. To this end, coupling of 6-hydroxynapthoic acid (<b>4</b>) with 4-chloro-6,7-dimethoxyquinazoline<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> in the presence of cesium carbonate provided naphthoic acid <b>8</b>, which could subsequently be elaborated to the desired naphthamides of interest.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship (SAR): Variations of the Naphthamide</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0008.gif" alt="" id="gr4" /></img><div class="scrollable-table-wrap"><table class="table single-image frame_topbot"><colgroup><col align="left" /></col></colgroup><tbody><tr valign="top"><td align="left"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0009.gif" alt="" id="gr5" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were averaged values determined by at least two independent experiments. ND: Not Determined.</p></div><div class="footnote" id="tbl2-fn2"><sup>b</sup><p class="last">Human umbilical vein endothelial cells.</p></div><div class="footnote" id="tbl2-fn3"><sup>c</sup><p class="last">Determined using Daylight software, version 4.41.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR: Variations of the Quinoline Linker Binding Element</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0010.gif" alt="" id="gr6" /></img><div class="scrollable-table-wrap"><table class="table single-image frame_topbot"><colgroup><col align="left" /></col></colgroup><tbody><tr valign="top"><td align="left"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0011.gif" alt="" id="gr7" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were averaged values determined by at least two independent experiments. ND: not determined.</p></div><div class="footnote" id="tbl3-fn2"><sup>b</sup><p class="last">Human umbilical vein endothelial cells.</p></div></div></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0007.jpeg" id="gs1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Naphthamides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMSO, 140 °C; (b) SOCl<sub>2</sub>, benzene, 65 °C; base, RNH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; or oxalyl chloride, DMF, CH<sub>2</sub>Cl<sub>2</sub>; base, RNH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (c) HATU, DIPEA, RNH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (d) EDC, DIPEA, RNH<sub>2</sub> DMF; or HOAt, DIPEA, RNH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (e) Cu, KOH, pyridine, DMF 120 °C, microwave.</p></p></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To evaluate the aforementioned hypothesis that the improved selectivity profile of <b>3</b> was a result of the inhibitor binding the enzyme in a “DFG-in” conformation, a number of <i>N-</i>alkyl substituted and <i>N-</i>unsubstituted naphthamides were prepared. It was anticipated that inhibitors containing sterically unencumbered amides would bind KDR in a similar conformation as <b>3</b>. On the basis of previous work, initial structure–activity relationship (SAR) studies were investigated utilizing the 6,7-dimethoxyquinoline as the linker binding element. In addition to screening the naphthamides against a series of subfamilies of RTKs, including Tie-2 and c-Met, they were also screened against the NRTK Lck as well as the STKs Aurora A and B. Potency at the cellular level was evaluated by determining the inhibition of human umbilical vein endothelial cell (HUVEC) proliferation induced by either VEGF or basic fibroblast growth factor (bFGF). The cellular assay was carried out in the presence of 10% fetal bovine serum (FBS).</div><div class="NLM_p">Inhibitors wherein the amide was either unsubstituted or substituted with small alkyl groups were generally well tolerated (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). To this end, potent KDR inhibitors could be generated by incorporation of a linear alkyl group (<b>14</b>–<b>16</b>, <b>19</b>–<b>21</b>), a cycloalkyl group (<b>3</b>, <b>10</b>–<b>12</b>) or a branched alkyl group (<b>13</b>, <b>17</b>). The cyclopropylamide <b>3</b> and the free carboxamide <b>22</b> delivered the most KDR enzymatic potency, while cycloalkylamides <b>11</b> and <b>12</b> were slightly less potent and <i>tert</i>-butylamide <b>18</b> was not tolerated and exhibited drastically diminished potency. As eluded to previously, <b>3</b> demonstrated an improved selectivity profile when compared to naphthamide <b>2</b>. With the exception of Aurora B and Lck, the selectivity profile exhibited by <b>3</b> was well maintained within the series. The only compounds tested that were less than 400-fold selective for KDR over Tie-2 and c-Met were <b>11</b>, <b>12</b>, and <b>18</b>. Selectivity against Lck was less general; linear alkylamides <b>15</b>, <b>16</b>, and <b>19</b> as well as the small cycloalkylamides <b>3</b> and <b>10</b> demonstrated the highest degree of selectivity against Lck. With respect to Aurora B, compounds <b>12</b>, <b>13</b>, and <b>19</b> exhibited potent inhibition and were less than 6-fold selective for KDR over Aurora B.</div><div class="NLM_p">The kinase inhibitory activity of these compounds generally translated well into the inhibition of growth factor-dependent cell proliferation. With the exception of three compounds (<b>12</b>, <b>13</b>, and <b>19</b>) all of the compounds tested exhibited single-digit nanomolar inhibition of VEGF-driven HUVEC proliferation. The high lipophilicity of <b>2</b> led to limited cellular permeability, and this manifested itself in a relatively large shift (>15) between the enzymatic assay and the cellular VEGF-driven HUVEC proliferation assay. Carboxamide <b>22</b> and most of the <i>N-</i>alkylnaphthamides illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> are considerably less lipophilic than <b>2</b> and in turn exhibited a smaller shift between the enzymatic and cellular based assays. Furthermore, with the exception of <b>12</b>, <b>13</b>, <b>16</b>, and <b>19</b>, all the compounds tested showed preferential inhibition (>100-fold) of VEGF-dependent HUVEC proliferation when compared to their inhibition of bFGF-dependent proliferation.</div><div class="NLM_p">The improved physicochemical properties of the <i>N</i>-alkyl and <i>N-</i>unsubstituted naphthamides relative to <b>2</b> also manifest themselves in improved aqueous solubility. Compounds <b>3</b>, <b>20</b>, and <b>22</b> were considerably more soluble in 0.01 N HCl (>200 μg/mL) than <i>N</i>-arylnaphthamide <b>2</b> (1.1 μg/mL).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">Replacement of the dimethoxyquinoline nucleus was also investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). In general, modifications to this region of the molecule led to inhibitors that maintained a good selectivity profile but decreased potency in the VEGF-driven HUVEC assay. This trend is exemplified in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> wherein replacement of the 6,7-dimethoxyquinoline with 6,7-dimethoxyquinazoline and 7-methoxyquinoline resulted in inhibitors with diminished cellular potency. The exception to this trend were compounds containing the 7-methoxy-6-carboxamide quinoline core (<b>29</b>−<b>31</b>), which displayed similar potency to the respective compounds in the parent 6,7-dimethoxyquinoline series. This series of compounds maintained the moderate level of selectivity over Aurora B that was displayed by the 6,7-dimethoxyquinoline series.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vitro Metabolic Stability and Pharmacokinetic Profiles</h3><div class="NLM_p">On the basis of their in vitro potencies, the metabolic stability and pharmacokinetic profiles of several inhibitors were evaluated. Illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> are the in vitro stabilities and pharmacokinetic profiles following intravenous (iv) and oral (po) dosing in male Sprague–Dawley rats. With the exception of <b>30</b>, all of the compounds examined demonstrated acceptable metabolic stability in rat liver microsomes (RLM CL<sub>in vitro</sub> < 50 (µL/min)/mg) and in turn exhibited low iv clearance (CL ≤ 600 mL/(h·kg)). Compound <b>30</b>, which demonstrated a higher rate of clearance in vitro (RLM CL<sub>in vitro</sub> = 95 (µL/min)/mg), was cleared at a high rate (3,048 mL/(h·kg)) and in turn displayed a shorter plasma-elimination half-life (0.30 h). After oral dosing the compounds in the 6,7-dimethoxyquinoline series (<b>3</b>, <b>20</b>, and <b>22</b>) all demonstrated good bioavailability and exposure levels with a <i>t</i><sub>max</sub> in the range 1.6–2.5 h. In contrast, compounds <b>29</b> and <b>30</b> were less bioavailable and consequently exhibited diminished levels of exposure.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Metabolic Stability and Pharmacokinetic Parameters in Male Sprague–Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead valign="middle"><tr valign="top"><th rowspan="2" align="center" valign="bottom">compd</th><th rowspan="2" colspan="2" align="center" valign="bottom" char=".">metabolic stability RLM/HLM<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a>((µL/min)/mg)</th><th colspan="3" align="center" valign="middle" char=".">iv</th><th colspan="4" align="center" valign="middle" char=".">po</th></tr><tr valign="top"><th align="center" valign="bottom" char=".">Cl(mL/h·kg)</th><th align="center" valign="bottom" char="."><i>V</i><sub>ss</sub>(mL/kg)</th><th align="center" valign="bottom" char="."><i>t</i><sub>1/2</sub>(h)</th><th align="center" valign="bottom" char=".">AUC<sub>0-∞</sub>(ng·h/mL)</th><th align="center" valign="bottom" char="."><i>C</i><sub>max</sub>(ng/mL)</th><th align="center" valign="bottom" char="."><i>t</i><sub>max</sub>(h)</th><th align="center" valign="bottom" char="."><i>F</i>(%)</th></tr></thead><tbody><tr valign="top"><td align="left"><b>3</b></td><td align="char" char=".">21</td><td align="char" char=".">31</td><td align="char" char=".">131<a class="ref internalNav" href="#tbl4-fn2" aria-label="b">b</a></td><td align="char" char=".">1038</td><td align="char" char=".">8.4</td><td align="char" char=".">50228<a class="ref internalNav" href="#tbl4-fn4" aria-label="d">d</a></td><td align="char" char=".">6152</td><td align="char" char=".">2.5</td><td align="char" char=".">66</td></tr><tr valign="top"><td align="left"><b>20</b></td><td align="char" char=".">48</td><td align="char" char=".">32</td><td align="char" char=".">532<a class="ref internalNav" href="#tbl4-fn2" aria-label="b">b</a></td><td align="char" char=".">1133</td><td align="char" char=".">1.6</td><td align="char" char=".">3771<a class="ref internalNav" href="#tbl4-fn5" aria-label="e">e</a></td><td align="char" char=".">543</td><td align="char" char=".">2.0</td><td align="char" char=".">99</td></tr><tr valign="top"><td align="left"><b>22</b></td><td align="char" char=".">32</td><td align="char" char=".">7</td><td align="char" char=".">224<a class="ref internalNav" href="#tbl4-fn3" aria-label="c">c</a></td><td align="char" char=".">1065</td><td align="char" char=".">6.0</td><td align="char" char=".">8450<a class="ref internalNav" href="#tbl4-fn5" aria-label="e">e</a></td><td align="char" char=".">1689</td><td align="char" char=".">1.6</td><td align="char" char=".">96</td></tr><tr valign="top"><td align="left"><b>29</b></td><td align="char" char=".">16</td><td align="char" char=".">12</td><td align="char" char=".">508<a class="ref internalNav" href="#tbl4-fn3" aria-label="c">c</a></td><td align="char" char=".">379</td><td align="char" char=".">1.26</td><td align="char" char=".">900<a class="ref internalNav" href="#tbl4-fn5" aria-label="e">e</a></td><td align="char" char=".">715</td><td align="char" char=".">0.67</td><td align="char" char=".">39</td></tr><tr valign="top"><td align="left"><b>30</b></td><td align="char" char=".">95</td><td align="char" char=".">4</td><td align="char" char=".">3048<a class="ref internalNav" href="#tbl4-fn3" aria-label="c">c</a></td><td align="char" char=".">751</td><td align="char" char=".">0.31</td><td align="char" char=".">164<a class="ref internalNav" href="#tbl4-fn5" aria-label="e">e</a></td><td align="char" char=".">61</td><td align="char" char=".">0.30</td><td align="char" char=".">12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last">Rat liver microsomal (RLM) and human liver microsomal (HLM) clearance. Compound concentration = 1 µM. Microsomal protein concentration = 1 mg/mL.</p></div><div class="footnote" id="tbl4-fn2"><sup>b</sup><p class="last">Dosed iv at 1 mg/kg as a solution in DMSO.</p></div><div class="footnote" id="tbl4-fn3"><sup>c</sup><p class="last">Dosed iv at 0.5 mg/kg as a solution in DMSO.</p></div><div class="footnote" id="tbl4-fn4"><sup>d</sup><p class="last">Dosed po at 10 mg/kg as a suspension in 100% OraPlus.</p></div><div class="footnote" id="tbl4-fn5"><sup>e</sup><p class="last">Dosed po at 2 mg/kg as a suspension in 100% OraPlus.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Kinase Selectivity Profile</h3><div class="NLM_p">The inhibitory profiles of compounds <b>3</b>, <b>20</b>, and <b>22</b> were determined in a panel of in vitro kinase enzymes. As illustrated in the form of a heat map in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, the selectivity profiles for these compounds were similar among the kinases that were examined. Each compound demonstrated broad activity against the human VEGFR family (Flt-1/VEGFR1 and Flt-4/VEGFR3), with <b>20</b> being slightly less potent against Flt-1 (73 nM). Comparable levels of inhibitory activity were observed for the VEGFR and structurally related platelet-derived growth factor receptor (PDGFR) family of kinases. In this regard, all three compounds exhibited potent inhibition of c-Kit, c-fms, and PDGFRα; however, no inhibition of Flt-3 was observed. This selectivity is likely due to a disparity in the gatekeeper residue present in each of these kinases. This residue influences the accessibility of the hydrophobic pocket that flanks the ATP binding site, and its size can be a key factor in controlling kinase selectivity. In KDR this residue is a valine, while in c-Kit, c-fms, and PDGFRα it is a threonine. However, the gatekeeper residue in Flt-3 is a phenylalanine (Phe691). The compounds were highly selective against a broad range of other unrelated kinases tested, including EGFR, Src, and p38 kinase. As a whole, the compounds showed lower levels of selectivity for Abl and members of the Src-B family, including Lyn and FGR. Compound <b>3</b> has moderate potency for Abl (IC<sub>50</sub> = 466 nM) and FGR (IC<sub>50</sub> = 396 nM) and showed strong inhibition toward Lyn (IC<sub>50</sub> = 27 nM). Compound <b>20</b> has a slightly improved selectivity profile and showed only modest potency against Lyn (IC<sub>50</sub> = 275 nM). Compound <b>22</b> displayed moderate potency against both Lyn (IC<sub>50</sub> = 88 nM) and Abl (IC<sub>50</sub> = 110 nM).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinase selectivity profile for <b>3</b>, <b>20</b>, and <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vivo Inhibition of Vascular Permeability and Rat Corneal Angiogenesis</h3><div class="NLM_p">To confirm the results observed in the enzymatic assay and the VEGF-promoted HUVEC assay, the effects of <b>3</b>, <b>20</b>, and <b>22</b> were examined in a VEGF-induced vascular permeability assay and a rat corneal angiogenesis model. In the vascular permeability model, HEK293 cells overexpressing recombinant murine VEGF were cultured, suspended in Matrigel, and injected subcutaneously (sc) onto the ventral surface of CD-1 nu/nu mice.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Twenty four hours after implantation, mice were dosed by oral gavage with either drug or vehicle. Six hours after administration of compound, vascular permeability was assessed by quantitation of Evans blue dye in a 1 cm<sup>2</sup> piece of skin overlying the Matrigel plug. As illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, compounds <b>3</b>, <b>20</b>, and <b>22</b> significantly inhibited vascular permeability at doses of 10, 3, and 30 mg/kg, respectively.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibition of VEGF-Induced Vascular Permeability<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead valign="middle"><tr valign="top" class="rowsep1"><th class="rowsep1" align="center" valign="middle">compd</th><th class="rowsep1" align="center" valign="middle" char=".">active dose<a class="ref internalNav" href="#tbl5-fn2" aria-label="b">b</a> (mg/kg)</th><th class="rowsep1" align="center" valign="middle" char=".">concentration at active dose (µM)<a class="ref internalNav" href="#tbl5-fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>3</b></td><td align="char" char=".">10</td><td align="char" char=".">1.0</td></tr><tr valign="top"><td align="left"><b>20</b></td><td align="char" char=".">3</td><td align="char" char=".">0.2</td></tr><tr valign="top"><td align="left"><b>22</b></td><td align="char" char=".">30</td><td align="char" char=".">2.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup>a</sup><p class="last"><i>n</i> = 5 animals per group.</p></div><div class="footnote" id="tbl5-fn2"><sup>b</sup><p class="last">Dosed as a suspension in OraPlus.</p></div><div class="footnote" id="tbl5-fn3"><sup>c</sup><p class="last">Plasma concentration at <i>t</i> = 6 h.</p></div></div></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compounds <b>3</b>, <b>20</b>, and <b>22</b> on VEGF induced vascular permeability in mice (<i>n</i> = 5 animals per group). HEK 293 cells transfected with murine VEGF or vector were mixed with Matrigel and injected sc into CD-1 nu/nu mice. A single dose of compound was given and vascular permeability in the skin overlying the Matrigel plug assessed 6 h later. Data represent the mean ± standard error: (∗) <i>P</i> ≤ 0.0002.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To evaluate the antiangiogenic activity of <b>3</b>, <b>20</b>, and <b>22</b> in vivo, these compounds were examined in a rat corneal angiogenesis model (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Disks soaked with VEGF (10 µmol/L or BSA as a control) were implanted into a pocket in the corneal stroma of adult female Sprague–Dawley rats. The animals were dosed once daily (qd) with drug or vehicle. Following 7 days of treatment, the corneas were photographed and the number of vessels intersecting the midpoint between the disk and the limbus was measured. All three compounds inhibited VEGF-induced angiogenesis in a dose-responsive fashion, with the lowest ED<sub>50</sub> (0.01 mg/kg) being achieved with <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Compounds <b>20</b> and <b>22</b> each displayed an ED<sub>50</sub> of 0.04 mg/kg (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibition of VEGF-Induced Angiogenesis in Rats<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead valign="middle"><tr valign="top" class="rowsep1"><th class="rowsep1" align="center" valign="middle">compd</th><th class="rowsep1" align="center" valign="middle" char=".">ED<sub>50</sub><a class="ref internalNav" href="#tbl6-fn2" aria-label="b">b</a> (mg/kg)</th><th class="rowsep1" align="center" valign="middle" char="."><i>C</i><sub>max</sub> (µM)</th><th class="rowsep1" align="center" valign="middle" char=".">AUC<sub>0–24</sub> (µM·h)</th></tr></thead><tbody><tr valign="top"><td align="left"><b>3</b></td><td align="char" char=".">0.01</td><td align="char" char=".">0.02</td><td align="char" char=".">0.32</td></tr><tr valign="top"><td align="left"><b>20</b></td><td align="char" char=".">0.04</td><td align="char" char=".">0.04</td><td align="char" char=".">0.52</td></tr><tr valign="top"><td align="left"><b>22</b></td><td align="char" char=".">0.04</td><td align="char" char=".">0.05</td><td align="char" char=".">0.48</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last"><i>n</i> = 8 animals per group.</p></div><div class="footnote" id="tbl6-fn2"><sup>b</sup><p class="last">Dosed as a suspension in OraPlus.</p></div></div></div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of VEGF-induced angiogenesis in the rat cornea by <b>3</b>. Angiogenesis was induced by implanting a VEGF-soaked or BSA-soaked (control) nylon disk into the corneal stroma. The number of blood vessels intersecting the midpoint between the disk and the limbus was measured after 7 days of dosing vehicle or drug. Data represent the mean ± standard error (<i>n</i> = 8 animals per group): (∗) <i>P</i> < 0.005.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While the efficacy and initial pharmacokinetic screening of <b>3</b> was promising, the presence of the cyclopropylamide was of some concern. It has been demonstrated that cyclopropylamines have a propensity to undergo P450-mediated bioactivation to electrophilic and/or free radical intermediates capable of covalently reacting with biomacromolecules and inducing a toxicological response.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> It is generally recognized that covalent binding of reactive intermediates to proteins is an initial and crucial event in the etiology of many chemical-induced toxicities.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Hence, before evaluating <b>3</b> in an in vivo tumor growth setting, we evaluated <sup>14</sup>C-labeled <b>3</b> for the formation of reactive metabolites in the presence of rat and human liver microsomes.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Incubation of <sup>14</sup>C-labeled <b>3</b> with human liver microsomes led to moderate levels of covalent binding (357 (pmol/mg)/h) in an NADPH-dependent manner, indicating that metabolic activation was occurring (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Furthermore, the addition of glutathione (GSH) as an exogenous trapping agent in the microsomal incubation led to an approximate 2.5-fold reduction in observed radioactivity, suggesting the formation of an electrophilic intermediate.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro Covalent Binding Measurements for <sup>14</sup>C-Labeled <b>3</b>, <b>20</b>, and <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead valign="middle"><tr valign="top"><th align="center" valign="middle"> </th><th colspan="3" align="center" valign="middle" char=".">HLM<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a> ((pmol/mg)/h)</th><th colspan="3" align="center" valign="middle" char=".">RLM<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a> ((pmol/mg)/h)</th></tr><tr valign="top" class="rowsep1"><th class="rowsep1" align="center" valign="middle">compd</th><th class="rowsep1" align="center" valign="middle" char=".">+NADPH</th><th class="rowsep1" align="center" valign="middle" char=".">−NADPH</th><th class="rowsep1" align="center" valign="middle" char=".">+NADPH + GSH</th><th class="rowsep1" align="center" valign="middle" char=".">+NADPH</th><th class="rowsep1" align="center" valign="middle" char=".">−NADPH</th><th class="rowsep1" align="center" valign="middle" char=".">+NADPH + GSH</th></tr></thead><tbody><tr valign="top"><td align="left"><b>3</b></td><td align="char" char=".">357</td><td align="char" char=".">1.5</td><td align="char" char=".">153</td><td align="char" char=".">60</td><td align="char" char=".">0.1</td><td align="char" char=".">17</td></tr><tr valign="top"><td align="left"><b>20</b></td><td align="char" char=".">321</td><td align="char" char=".">125</td><td align="char" char=".">1.6</td><td align="char" char=".">353</td><td align="char" char=".">86</td><td align="char" char=".">2.3</td></tr><tr valign="top"><td align="left"><b>22</b></td><td align="char" char=".">36</td><td align="char" char=".">14</td><td align="char" char=".">3.2</td><td align="char" char=".">39</td><td align="char" char=".">24</td><td align="char" char=".">2.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">10 µM compound, 1 mg/mL protein, 1 h of incubation.</p></div></div></div><div class="NLM_p">In an effort to confirm that the metabolic activation of <b>3</b> was unique to this compound and was not common among other members of the naphthamide family, compounds <b>20</b> and <b>22</b> were also profiled in rat and human microsomal incubations for bioactivation. As is illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>, compound <b>20</b> displayed a moderate potential for NADPH-dependent metabolic activation in both rat and human microsomes. In contrast, compound <b>22</b> showed low levels of covalent binding in both rat and human microsomes, revealing a lower propensity to form reactive metabolites. The exact nature of the reactive intermediate generated from <b>20</b> is currently unclear.</div><div class="NLM_p">The superior metabolic profile of <b>22</b> coupled with its promising in vivo efficacy led to an evaluation of its pharmacokinetic parameters in mouse, dog, and cynomolgous monkey (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Compound <b>22</b> demonstrated a moderate <i>V</i><sub>ss</sub> and low rate of clearance in dog, whereas in mouse and cynomolgous monkey, a somewhat elevated <i>V</i><sub>ss</sub> and higher rate of clearance relative to the hepatic blood flow for the respective species were observed. In each case, <b>22</b> was well absorbed following oral administration of drug from suspension formulations at the doses denoted in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>. The compound exhibited a moderate to slightly elongated half-life (<i>t</i><sub>1/2</sub>) of 5.6−16 h across the three species. Favorable mean residence times (MRT) were observed in mouse and cynomolgous monkey, with the values being slightly elevated in dog. The measured oral bioavailabilities were acceptable in all species and ranged from 39% to 73%.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Plasma Protein Binding and Pharmacokinetic Parameters for <b>22</b> in Mouse, Dog, and Cyno</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead valign="middle"><tr valign="top" class="rowsep1"><th class="rowsep1" align="center" valign="middle">parameter</th><th class="rowsep1" align="center" valign="middle">mouse</th><th class="rowsep1" align="center" valign="middle">dog</th><th class="rowsep1" align="center" valign="middle">cyno</th></tr></thead><tbody><tr valign="top"><td align="left">plasma protein binding (%)</td><td align="left">97.3</td><td align="left">96.2</td><td align="left">99.2</td></tr><tr valign="top"><td align="left">iv dose (mg/kg)</td><td align="left">2<a class="ref internalNav" href="#tbl8-fn2" aria-label="b">b</a></td><td align="left">0.5<a class="ref internalNav" href="#tbl8-fn4" aria-label="d">d</a></td><td align="left">0.5<a class="ref internalNav" href="#tbl8-fn6" aria-label="f">f</a></td></tr><tr valign="top"><td align="left">po dose (mg/kg)</td><td align="left">10<a class="ref internalNav" href="#tbl8-fn3" aria-label="c">c</a></td><td align="left">0.5<a class="ref internalNav" href="#tbl8-fn5" aria-label="e">e</a></td><td align="left">2</td></tr><tr valign="top"><td align="left"><i>C</i><sub>max</sub> (ng/mL), po</td><td align="left">890</td><td align="left">464</td><td align="left">1049</td></tr><tr valign="top"><td align="left"><i>T</i><sub>max</sub> (h), po</td><td align="left">0.25</td><td align="left">0.75</td><td align="left">0.83</td></tr><tr valign="top"><td align="left">AUC (ng·h/mL), po<a class="ref internalNav" href="#tbl8-fn1" aria-label="a">a</a></td><td align="left">1498</td><td align="left">3647</td><td align="left">1358</td></tr><tr valign="top"><td align="left"><i>T</i><sub>1/2</sub>(h), po</td><td align="left">5.6</td><td align="left">16</td><td align="left">13</td></tr><tr valign="top"><td align="left">MRT (h), iv</td><td align="left">2.3</td><td align="left">18</td><td align="left">8.6</td></tr><tr valign="top"><td align="left">Cl ((mL/h)/kg), iv</td><td align="left">2541</td><td align="left">103</td><td align="left">778</td></tr><tr valign="top"><td align="left"><i>V</i><sub>ss</sub> (mL/kg), iv</td><td align="left">5739</td><td align="left">1859</td><td align="left">6823</td></tr><tr valign="top"><td align="left"><i>F</i><sub>po</sub> (%)</td><td align="left">39</td><td align="left">73</td><td align="left">51</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl8-fn1"><div class="footnote" id="tbl8-fn1"><sup>a</sup><p class="last">AUC<sub>(0–24 h)</sub>.</p></div><div class="footnote" id="tbl8-fn2"><sup>b</sup><p class="last">Vehicle: Peg 400.</p></div><div class="footnote" id="tbl8-fn3"><sup>c</sup><p class="last">Vehicle: OraPlus.</p></div><div class="footnote" id="tbl8-fn4"><sup>d</sup><p class="last">Vehicle: DMSO.</p></div><div class="footnote" id="tbl8-fn5"><sup>e</sup><p class="last">Vehicle: 1% Tween-80, 2% HPMC, 97% water.</p></div><div class="footnote" id="tbl8-fn6"><sup>f</sup><p class="last">Vehicle: propylene glycol.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Tumor Xenograft Growth Inhibition</h3><div class="NLM_p">On the basis of its selectivity and promising pharmacokinetic profile across species, compound <b>22</b> was examined in the HT29 colon cancer and Calu-6 lung cancer xenograft models (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>). Cancer cells were implanted into the hind flank of female CD-1 nu/nu mice and allowed to establish for 12–14 days into sizable tumors, as determined by caliper measurements. In both xenograft models, once daily administration of <b>22</b> in OraPlus for 14 days led to antitumor efficacy in a dose-dependent fashion. In the HT29 xenograft model, 85% tumor growth inhibition was achieved at 10 mg/kg with an observed <i>C</i><sub>max</sub> of 1.3 µM and AUC<sub>(0–24)</sub> of 3.9 µM·h. A similar level of tumor growth inhibition was seen in the Calu-6 model at a dose of 20 mg/kg. No overt toxicity as measured by weight loss or morbidity was observed at any dose level throughout the dosing regimen.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor activity upon treatment with <b>22</b> or vehicle in HT29 colon cancer xenograft and Calu-6 lung cancer xenograft in CD-1 nu/nu mice (<i>n</i> = 10 animals per group). Data represent the mean ± standard error: (∗) <i>P</i> < 0.05; (∗∗) <i>P</i> < 0.01; (∗∗∗) <i>P</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. In Vivo Antitumor Activity of <b>22</b> against Established Human HT29 Colon Cancer and Calu-6 Lung Cancer Xenografts Implanted Subcutaneously in CD-1 nu/nu Mice<a class="ref internalNav" href="#tbl9-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead valign="middle"><tr valign="top" class="rowsep1"><th class="rowsep1" align="center" valign="middle">dose (mg/kg)<a class="ref internalNav" href="#tbl9-fn2" aria-label="b">b</a></th><th class="rowsep1" align="center" valign="middle" char=".">TGI (%)<a class="ref internalNav" href="#tbl9-fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top"><td colspan="2" align="center">HT29 Tumor Model</td></tr><tr valign="top"><td align="left">3</td><td align="char" char=".">51</td></tr><tr valign="top"><td align="left">10</td><td align="char" char=".">85</td></tr><tr valign="top"><td align="left">30</td><td align="char" char=".">94</td></tr><tr valign="top"><td colspan="2" align="center">Calu-6 Tumor Model</td></tr><tr valign="top"><td align="left">6</td><td align="char" char=".">52</td></tr><tr valign="top"><td align="left">20</td><td align="char" char=".">85</td></tr><tr valign="top"><td align="left">60</td><td align="char" char=".">88</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl9-fn1"><div class="footnote" id="tbl9-fn1"><sup>a</sup><p class="last"><i>n</i> = 10 animals per group.</p></div><div class="footnote" id="tbl9-fn2"><sup>b</sup><p class="last">Methanesulfonic acid (MSA) salt was dosed qd, po as a suspension in OraPlus.</p></div><div class="footnote" id="tbl9-fn3"><sup>c</sup><p class="last">Tumor growth inhibition.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last"><i>N-</i>Alkyl and <i>N-</i>unsubstituted naphthamides were prepared and identified as potent and selective inhibitors of KDR. Their enzyme inhibitory profiles translated well into endothelial cells, as exemplified by nanomolar inhibition of VEGF-driven HUVEC proliferation. Naphthamides <b>3</b>, <b>20</b>, and <b>22</b> exhibited good pharmacokinetics following oral dosing in rats and showed potent inhibition of VEGF-induced angiogenesis in the rat cornea. While compounds <b>3</b> and <b>20</b> suffered from metabolic activation and in turn led to moderate levels of covalent binding, <b>22</b> displayed a superior metabolic profile. Compound <b>22</b> showed a favorable PK profile in a range of species and once daily oral administration of <b>22</b> led to >85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectively.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32163" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32163" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. Anhydrous solvents were purchased from Aldrich packaged under nitrogen in Sure/Seal bottles. Purity of final compounds was measured using Agilent 1100 series high-performance liquid chromatography (HPLC) systems with UV detection at 254 nm (system A consisting of Agilent Zorbax Eclipse XDB-C8 4.6 mm × 150 mm, 5 µm, 5–100% CH<sub>3</sub>CN in H<sub>2</sub>O with 0.1% TFA for 15 min at 1.5 mL/min; system B consisting of Waters Xterra 4.6 mm × 150 mm, 3.5 µm, 5–95% CH<sub>3</sub>CN in H<sub>2</sub>O with 0.1% TFA for 12 min at 1.0 mL/min). <sup>1</sup>H NMR spectra were recorded on a Bruker AV-4000 (400 MHz) spectrometer at ambient temperature. Chemical shifts are reported in ppm from the solvent resonance (DMSO-<i>d</i><sub>6</sub> 2.50 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants, and number of protons. Low-resolution mass spectral (MS) data were determined on an Agilent 1100 series LCMS with UV detection at 254 nm and a low-resonance electrospray mode (ESI). High-resolution mass spectra were obtained on a high-resonance electrospray time-of-flight mass spectrometer. Combustion analysis was performed by Galbraith Laboratories, Inc., Knoxville, TN, and was within 0.4% of the calculated mass unless otherwise noted.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 6,7-Dimethoxyquinolin-4-yloxy)-1-naphthoic Acid (<b>5a</b>)</h3><div class="NLM_p last">To a mixture of 6-hydroxy-1-napthoic acid (<b>4</b>) (14.34 g, 76.2 mmol) in 382 mL of dimethyl sulfoxide (DMSO) was added cesium carbonate (74.48 g, 228.6 mmol). After the mixture was stirred at room temperature for 15 min, 4-chloro-6,6-dimethoxyquinoline (20.46 g, 91.4 mmol) was added and the resulting mixture was heated at 140 °C for 3 h. The mixture was allowed to cool to room temperature and was poured into H<sub>2</sub>O (200 mL). The pH was adjusted to 6.5 with 6 N HCl, and the resulting precipitate was filtered. The derived solid was washed sequentially with H<sub>2</sub>O (2–250 mL), ether (2–250 mL), and CH<sub>2</sub>Cl<sub>2</sub> (2–250 mL) to provide 6,7-dimethoxyquinolin-4-yloxy)-1-naphthoic acid (<b>5a</b>) (24.23 g, 85%) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 13.30 (brs, 1 H), 9.05 (d, <i>J</i> = 9.35 Hz, 1 H), 8.56 (d, <i>J</i> = 5.43 Hz, 1 H), 8.12–8.25 (m, 2 H), 7.95 (s, 1 H), 7.56–7.71 (m, 3 H), 7.48 (s, 1 H), 6.67 (d, <i>J</i> = 5.43 Hz, 1 H), 3.98 (s, 3 H), 3.96 (s, 3 H). HRMS (C<sub>22</sub>H<sub>18</sub>NO<sub>5</sub>)<sup>+</sup>: calcd, 376.117 95; found, 376.118 93.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 6-(7-Methoxyquinolin-4-yloxy)-1-naphthoic Acid (<b>5b</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-hydroxy-1-napthoic acid (<b>4</b>) using a method analogous to the preparation of compound <b>5a</b>. Yield: 807 mg, 82%. <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 13.28 (br s, 1 H), 9.04 (d, <i>J</i> = 9.35 Hz, 1 H), 8.65 (d, <i>J</i> = 5.18 Hz, 1 H), 8.25 (d, <i>J</i> = 9.22 Hz, 1 H), 8.18 (d, <i>J</i> = 7.71 Hz, 2 H), 7.91 (d, <i>J</i> = 2.65 Hz, 1 H), 7.59–7.68 (m, 2 H), 7.46 (d, <i>J</i> = 2.53 Hz, 1 H), 7.32 (dd, <i>J</i> = 9.16, 2.59 Hz, 1 H), 6.62 (d, <i>J</i> = 5.18 Hz, 1 H), 3.96 (s, 3 H). MS, <i>m</i>/<i>z</i> (C<sub>21</sub>H<sub>15</sub>NO<sub>4</sub>): calcd, 345.1; found, 346.0 (MH).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 6-(6-Carbamoyl-7-methoxyquinolin-4-yloxy)-1-naphthoic Acid (<b>5c</b>)</h3><div class="NLM_p last">A suspension of methyl 4-amino-2-methoxybenzoate (10.00 g, 55.19 mmol) in 200 mL of isopropanol was heated at 50 °C for 10 min at which point 5-(methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (9.64 g, 51.78 mmol) was added. The resulting suspension was heated at 80 °C for 1 h before being cooled to room temperature. The solid was filtered, washed well with ether, and dried in vacuo to provide methyl 4-((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methylamino)-2-methoxybenzoate (15.25 g, 82%) as a brown solid that was immediately processed. A suspension of the derived aniline (15.00 g, 53.96 mmol) in 135 mL of diphenyl ether was heated at 250 °C for 8 h. The mixture was cooled to room temperature and filtered. The resulting brown solid was washed with ether and dried in vacuo to provide methyl 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylate (9.60 g, 76%) as a brown solid that was used without further purification. The derived dihydroquinoline (5.00 g, 21.46 mmol) was added to 20 mL of thionyl chloride. Three drops of dimethylformamide (DMF) were added, and the mixture was heated at 125 °C for 3 h. The mixture was cooled to room temperature, and the solvent was removed in vacuo. The derived solid was taken up in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) and poured into saturated NaHCO<sub>3</sub> (500 mL). The layers were separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (250 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated to provide a tan solid. Trituration of the solid with ether/hexanes provided methyl 4-chloro-7-methoxyquinoline-6-carboxylate (4.70 g, 87%) as a tan solid. The derived ester (1.00 g, 3.97 mmol) was added to ammonium hydroxide (20 mL), and the mixture was heated at 110 °C for 8 h before being cooled to room temperature. The mixture was filtered and the resulting solid was washed sequentially with water and ether to provide 4-chloro-7-methoxyquinoline-6-carboxamide (852 mg, 91%) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.82 (d, <i>J</i> = 4.80 Hz, 1 H), 8.49 (s, 1 H), 7.90 (br s, 1 H), 7.80 (br s, 1 H), 7.65 (d, <i>J</i> = 4.80 Hz, 1 H), 7.59 (s, 1 H), 4.03 (s, 3 H). The title compound was then prepared using a method analogous to the preparation of compound <b>5a</b>. Yield: 623 mg, 46%. <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 9.07 (d, <i>J</i> = 9.35 Hz, 1 H), 8.70–8.78 (m, 2 H), 8.20 (d, <i>J</i> = 7.58 Hz, 2 H), 7.99 (d, <i>J</i> = 2.40 Hz, 1 H), 7.93 (br s, 1 H), 7.80 (br s, 1 H), 7.63–7.71 (m, 2 H), 7.60 (s, 1 H), 6.71 (d, <i>J</i> = 5.43 Hz, 1 H), 4.07 (s, 3 H). MS, <i>m</i>/<i>z</i> (C<sub>22</sub>H<sub>16</sub>N<sub>2</sub>O<sub>5</sub>): calcd, 388.1; found, 389.1 (MH).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 6-(6,7-Dimethoxyquinazolin-4-yloxy)-1-naphthoic Acid (<b>8</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-hydroxy-1-napthoic acid (<b>4</b>) using a method analogous to the preparation of compound <b>5a</b>. Yield: 900 mg, 67%. <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.99 (d, <i>J</i> = 9.35 Hz, 1 H), 8.55 (s, 1 H), 8.16 (d, <i>J</i> = 7.45 Hz, 2 H), 7.98 (d, <i>J</i> = 2.40 Hz, 1 H), 7.55–7.69 (m, 3 H), 7.41 (s, 1 H), 4.01 (s, 3 H), 4.00 (s, 3 H). MS, <i>m</i>/<i>z</i> (C<sub>21</sub>H<sub>16</sub>N<sub>2</sub>O<sub>5</sub>): calcd, 376.1; found, 377.0 (MH).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N-</i>Cyclopropyl-6-(6,7-dimethoxyquinolin-4-yloxy)-1-naphthamide (<b>3</b>)</h3><div class="NLM_p last">To a solution of acid <b>5a</b> (2.50 g, 6.66 mmol) in 17 mL of DMF was added diisopropylethylamine (DIPEA) (4.64 mL, 26.6 mmol) followed by 2-(7-aza-1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (3.29 g, 8.66 mmol). After the mixture was stirred for 1 h, cyclopropylamine (923 µL, 13.3 mmol) was added and the mixture was maintained at room temperature for 8 h. The resulting mixture was filtered, and the resulting solid was washed sequentially with cold DMF and water. The solid was dried in vacuo to provide <b>3</b> (960 mg, 35%) as a white solid. The derived amine was taken up in ethanol and treated with 1 equiv of HCl (1 M in ether) to provide the hydrochloride salt as a white solid. HPLC purity: 98% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.79 (d, <i>J</i> = 6.57 Hz, 1 H), 8.68 (d, <i>J</i> = 4.29 Hz, 1 H), 8.45 (d, <i>J</i> = 9.22 Hz, 1 H), 8.07 (d, 2 H), 7.82 (s, 1 H), 7.55–7.71 (m, 4 H), 6.90 (d, <i>J</i> = 6.44 Hz, 1 H), 4.06 (s, 6 H), 2.88–3.02 (m, 1 H), 0.69–0.81 (m, 2 H), 0.55–0.65 (m, 2 H). HRMS (C<sub>25</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 415.165 23; found, 415.164 66. Anal. (C<sub>25</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub>·HCl) C, H, N.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N-</i>Cyclobutyl-6-(6,7-dimethoxyquinolin-4-yloxy)-1-naphthamide (<b>10</b>)</h3><div class="NLM_p last">Thionyl chloride (10 mL) was added to acid <b>5a</b> (1.00 mg, 2.67 mmol), and the whole was heated at reflux for 1 h at which point the reaction was concentrated. The derived solid was azeotroped with benzene (20 mL) to provide the hydrochloride salt of the corresponding acid chloride (1.14 g, 100%) as a tan solid that was used without further purification. To a portion of the derived acid chloride (400 mg, 0.930 mmol) in 2.5 mL of CH<sub>2</sub>Cl<sub>2</sub> were added DIPEA (810 µL, 4.65 mmol), cyclobutylamine (159 µL, 1.86 mmol), and a crystal of 4-dimethylaminopyridine (DMAP). Stirring was continued for 24 h at which point the mixture was diluted with 10 mL of dichloromethane and poured into 1 N NaOH. The layers were separated, and the organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated. Purification by silica gel chromatography (CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) or reverse-phase HPLC provided <b>10</b> (175 mg, 40%) as a white solid. HPLC purity: 99% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.84 (d, <i>J</i> = 7.83 Hz, 1 H), 8.51 (d, <i>J</i> = 5.18 Hz, 1 H), 8.33 (d, <i>J</i> = 9.22 Hz, 1 H), 8.03 (dd, <i>J</i> = 6.76, 2.84 Hz, 1 H), 7.87 (d, <i>J</i> = 2.65 Hz, 1 H), 7.56–7.64 (m, 3 H), 7.54 (dd, <i>J</i> = 9.16, 2.46 Hz, 1 H), 7.44 (s, 1 H), 6.56 (d, <i>J</i> = 5.18 Hz, 1 H), 4.41–4.61 (m, 1 H), 3.97 (s, 3 H), 3.95 (s, 3 H), 2.22–2.36 (m, 2 H), 2.08 (t, <i>J</i> = 9.28 Hz, 2 H), 1.60–1.78 (m, 2 H). HRMS (C<sub>26</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 429.180 88; found, 429.180 33. Anal. (C<sub>26</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>·H<sub>2</sub>O) C, H, N.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N-</i>Cyclopentyl-6-(6,7-dimethoxyquinolin-4-yloxy)-1-naphthamide (<b>11</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>10</b>. Yield: 113 mg, 24%. HPLC purity: 100% (system A); 99.1% (system B). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.57 (d, <i>J</i> = 6.95 Hz, 1 H), 8.51 (d, <i>J</i> = 4.93 Hz, 1 H), 8.33 (d, <i>J</i> = 9.09 Hz, 1 H), 7.98–8.05 (m, 1 H), 7.86 (s, 1 H), 7.50–7.65 (m, 4 H), 7.44 (s, 1 H), 6.56 (d, <i>J</i> = 4.80 Hz, 1 H), 4.26–4.40 (m, 1 H), 3.97 (s, 3 H), 3.95 (s, 3 H), 1.90–2.03 (m, 2 H), 1.50–1.77 (m, 6 H). HRMS (C<sub>27</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 443.196 53; found, 443.196 10.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-<i>N-</i>(1-methylcyclopropyl)-1-naphthamide (<b>12</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>10</b>. Yield: 70 mg, 16%. HPLC purity: 97% (system A); 97.8% (system B). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.79 (s, 1 H), 8.49 (d, 1 H), 8.31 (d, <i>J</i> = 9.35 Hz, 1 H), 8.00 (d, <i>J</i> = 8.08 Hz, 1 H), 7.85 (d, <i>J</i> = 2.27 Hz, 1 H), 7.48–7.61 (m, 4 H), 7.43 (s, 1 H), 6.54 (d, <i>J</i> = 5.31 Hz, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H), 1.47 (s, 3 H), 0.76–0.85 (m, 2 H), 0.58–0.70 (m, 2 H). HRMS (C<sub>26</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 429.180 88; found, 429.179 55.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N-</i>(Cyclopropylmethyl)-6-(6,7-dimethoxyquinolin-4-yloxy)-1-naphthamide (<b>13</b>)</h3><div class="NLM_p last">To a solution of the acid chloride derived from acid <b>5a</b> (120 mg, 0.305 mmol) and NaHCO<sub>3</sub> (76.8 mg, 0.914 mmol) in 5 mL of CH<sub>2</sub>Cl<sub>2</sub> was added cyclopropylmethylamine (0.048 µL, 0.549 mmol). Upon complete consumption of starting material the reaction was quenched with saturated NaHCO<sub>3</sub> (25 mL). The layers were separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2–10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. Concentration in vacuo and purification by silica gel chromatography (CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) provided <b>13</b> (66 mg, 51% yield) as an off-white solid. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.63–8.75 (m, 1 H), 8.49 (d, <i>J</i> = 5.18 Hz, 1 H), 8.37 (d, <i>J</i> = 9.22 Hz, 1 H), 7.95–8.10 (m, 1 H), 7.86 (d, <i>J</i> = 2.40 Hz, 1 H), 7.49–7.65 (m, 4 H), 7.43 (s, 1 H), 6.55 (d, <i>J</i> = 5.18 Hz, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H), 3.24 (t, <i>J</i> = 6.19 Hz, 2 H), 1.03–1.17 (m, 1 H), 0.41–0.53 (m, 2 H), 0.23–0.35 (m, 2 H). HRMS (C<sub>26</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 429.180 88; found, 429.181 22. Anal. Calcd for C<sub>26</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>: C, 72.88; H, 5.65; N, 6.54. Found: C, 73.37; H, 5.91; N, 6.40.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-<i>N-</i>methyl-1-naphthamide (<b>14</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>10</b>. Yield: 129 mg, 33%. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.53 (d, <i>J</i> = 4.67 Hz, 1 H), 8.50 (d, <i>J</i> = 5.18 Hz, 1 H), 8.38 (d, <i>J</i> = 9.22 Hz, 1 H), 8.03 (d, <i>J</i> = 7.71 Hz, 1 H), 7.86 (d, <i>J</i> = 2.53 Hz, 1 H), 7.55–7.64 (m, 3 H), 7.53 (dd, <i>J</i> = 9.28, 2.59 Hz, 1 H), 7.43 (s, 1 H), 6.56 (d, <i>J</i> = 5.18 Hz, 1 H), 3.97 (s, 3 H), 3.94 (s, 3 H), 2.87 (d, <i>J</i> = 4.67 Hz, 3 H). HRMS (C<sub>23</sub>H<sub>21</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 389.149 58; found, 389.147 39. Anal. (C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-<i>N-</i>ethyl-1-naphthamide (<b>15</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>13</b>. Yield: 30 mg, 29%. HPLC purity: 100% (system A); 99.5% (system B). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.54–8.64 (m, 1 H), 8.50 (d, <i>J</i> = 3.28 Hz, 1 H), 8.37 (d, <i>J</i> = 7.96 Hz, 1 H), 8.02 (d, <i>J</i> = 3.92 Hz, 1 H), 7.86 (s, 1 H), 7.49–7.64 (m, 4 H), 7.44 (s, 1 H), 6.56 (d, <i>J</i> = 3.41 Hz, 1 H), 3.97 (s, 3 H), 3.95 (s, 3 H), 3.30–3.43 (m, 2 H), 1.19 (t, <i>J</i> = 6.32 Hz, 3 H). HRMS (C<sub>24</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 403.165 23; found, 403.166 40.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-<i>N-</i>propyl-1-naphthamide (<b>16</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>10</b>. Yield: 190 mg, 43%. HPLC purity: 98% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.78 (d, <i>J</i> = 6.44 Hz, 1 H), 8.63 (t, <i>J</i> = 5.62 Hz, 1 H), 8.44 (d, <i>J</i> = 9.22 Hz, 1 H), 8.08 (d, <i>J</i> = 6.06 Hz, 1 H), 8.05 (d, <i>J</i> = 2.27 Hz, 1 H), 7.81 (s, 1 H), 7.59–7.71 (m, 4 H), 6.90 (d, <i>J</i> = 6.44 Hz, 1 H), 4.05 (s, 3 H), 4.05 (s, 3 H), 3.31 (q, <i>J</i> = 6.61 Hz, 2 H), 1.52–1.66 (m, 2 H), 0.96 (t, <i>J</i> = 7.39 Hz, 3 H). HRMS (C<sub>25</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 417.180 88; found, 417.181 36. Anal. (C<sub>25</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>·3H<sub>2</sub>O) C, H, N.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-<i>N-</i>isopropyl-1-naphthamide (<b>17</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>10</b>. Yield: 287 mg, 54%. HPLC purity: 99% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.49 (d, <i>J</i> = 5.18 Hz, 1 H), 8.46 (d, <i>J</i> = 7.58 Hz, 1 H), 8.33 (d, <i>J</i> = 9.22 Hz, 1 H), 8.01 (dd, <i>J</i> = 6.44, 3.16 Hz, 1 H), 7.86 (d, <i>J</i> = 2.53 Hz, 1 H), 7.55–7.62 (m, 3 H), 7.53 (dd, <i>J</i> = 9.28, 2.59 Hz, 1 H), 7.43 (s, 1 H), 6.54 (d, <i>J</i> = 5.31 Hz, 1 H), 4.10–4.24 (m, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H), 1.23 (s, 3 H), 1.21 (s, 3 H). HRMS (C<sub>25</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 417.180 88; found, 417.181 32. Anal. (C<sub>25</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N-tert</i>-Butyl-6-(6,7-dimethoxyquinolin-4-yloxy)-1-naphthamide (<b>18</b>)</h3><div class="NLM_p last">To a solution of 6-hydroxynapthoic acid (1.00 g, 5.32 mmol) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (1.20 g, 6.38 mmol), 1-hydroxy-7-azabenzotriazole (HOAt) (10.6 mL, 0.6 M in DMF), <i>tert</i>-butylamine (388 mg, 5.32 mmol), and DIPEA (1.40 mL, 7.98 mmol). The mixture was maintained at room temperature for 8 h at which point the mixture was concentrated in vacuo and purified by silica gel chromatography (CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to provide <i>N-tert</i>-butyl-6-hydroxynaphthamide (550 mg, 46%) as a light-pink solid. The derived amide (200 mg, 0.82 mmol) was dissolved in 1 mL of pyridine and 1.5 mL of DMF, and Cu (8.0 mg, 0.04 mmol) and potassium hydroxide 94 mg, 2.6 mmol) were added. The mixture was heated to 120 °C in a microwave for 20 min before being diluted with 10 mL of CHCl<sub>3</sub> and poured into 1 N NaOH (10 mL). The aqueous layer was extracted with CHCl<sub>3</sub> (3 × 10 mL). The combined aqueous layers were washed with water and brine and dried over sodium sulfate. Filtration and concentration provided a residue that was purified by silica gel chromatography CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to provide <i>N-tert</i>-butyl-6-(6,7-dimethoxyquinolin-4-yloxy)-1-naphthamide (<b>18</b>, 115 mg, 32%) as an off-white solid. HPLC purity: 97% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.49 (d, <i>J</i> = 5.31 Hz, 1 H), 8.26 (d, <i>J</i> = 9.22 Hz, 1 H), 8.17 (s, 1 H), 7.98 (d, <i>J</i> = 7.96 Hz, 1 H), 7.84 (d, <i>J</i> = 2.53 Hz, 1 H), 7.49–7.62 (m, 4 H), 7.43 (s, 1 H), 6.53 (d, <i>J</i> = 5.18 Hz, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H), 1.45 (s, 9 H). HRMS (C<sub>26</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 431.196 53; found, 431.196 04. Anal. (C<sub>26</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>·CH<sub>2</sub>Cl<sub>2</sub>) C, H, N.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-<i>N-</i>(2,2,2-trifluoroethyl)-1-naphthamide (<b>19</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>13</b>. Yield: 65 mg, 47%. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 9.30 (t, <i>J</i> = 6.32 Hz, 1 H), 8.50 (d, <i>J</i> = 5.18 Hz, 1 H), 8.30 (d, <i>J</i> = 9.22 Hz, 1 H), 8.08 (d, <i>J</i> = 6.69 Hz, 1 H), 7.89 (d, <i>J</i> = 2.53 Hz, 1 H), 7.51–7.70 (m, 4 H), 7.43 (s, 1 H), 6.57 (d, <i>J</i> = 5.18 Hz, 1 H), 4.10–4.28 (m, 2 H), 3.96 (s, 3 H), 3.94 (s, 3 H). HRMS (C<sub>24</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 457.137 52; found, 457.137 69. Anal. (C<sub>24</sub>H<sub>19</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>·CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-<i>N-</i>(2-methoxyethyl)-1-naphthamide (<b>20</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>10</b>. Yield: 190 mg, 21%. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.63 (t, <i>J</i> = 4.80 Hz, 1 H), 8.49 (d, <i>J</i> = 5.18 Hz, 1 H), 8.36 (d, <i>J</i> = 9.35 Hz, 1 H), 8.02 (dd, <i>J</i> = 5.94, 3.41 Hz, 1 H), 7.86 (d, <i>J</i> = 2.53 Hz, 1 H), 7.55–7.62 (m, 3 H), 7.53 (dd, <i>J</i> = 9.22, 2.53 Hz, 1 H), 7.43 (s, 1 H), 6.55 (d, <i>J</i> = 5.18 Hz, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H), 3.47–3.55 (m, 4 H), 3.32 (s, 3 H). HRMS (C<sub>25</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub>)<sup>+</sup>: calcd, 433.175 80; found, 433.175 81. Anal. (C<sub>25</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>·0.33CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-<i>N-</i>(3-methoxypropyl)-1-naphthamide (<b>21</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>10</b>. Yield: 246 mg, 52%. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.59 (t, <i>J</i> = 5.24 Hz, 1 H), 8.49 (d, <i>J</i> = 5.18 Hz, 1 H), 8.35 (d, <i>J</i> = 9.22 Hz, 1 H), 8.02 (dd, <i>J</i> = 6.88, 2.59 Hz, 1 H), 7.86 (d, <i>J</i> = 2.40 Hz, 1 H), 7.55–7.64 (m, 3 H), 7.53 (dd, <i>J</i> = 9.28, 2.46 Hz, 1 H), 7.43 (s, 1 H), 6.56 (d, <i>J</i> = 5.18 Hz, 1 H), 3.96 (s, 3 H), 3.94 (s, 3 H), 3.44 (t, <i>J</i> = 6.32 Hz, 2 H), 3.38 (q, <i>J</i> = 6.65 Hz, 2 H), 3.30 (s, 2 H), 3.27 (s, 3 H), 1.73–1.88 (m, 2 H). HRMS (C<sub>26</sub>H<sub>27</sub>N<sub>2</sub>O<sub>5</sub>)<sup>+</sup>: calcd, 447.191 45; found, 447.190 68. Anal. (C<sub>26</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>·0.33CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 6-(6,7-Dimethoxyquinolin-4-yloxy)-1-naphthamide methanesulfonate (<b>22</b>)</h3><div class="NLM_p last">The title compound was prepared from acid <b>5a</b> using a method analogous to the preparation of compound <b>10</b>. The derived amine was taken up in ethanol, treated with 1 equiv of methanesulfonic acid (MSA), and concentrated to provide the methanesulfonate salt of the derived amine. Yield: 180 mg, 46%. HPLC purity: 99% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.80 (d, <i>J</i> = 6.57 Hz, 1 H), 8.59 (d, <i>J</i> = 9.35 Hz, 1 H), 8.01–8.13 (m, 2 H), 7.83 (s, 1 H), 7.76 (d, <i>J</i> = 7.07 Hz, 1 H), 7.60–7.72 (m, 2 H), 7.57 (s, 1 H), 6.93 (d, <i>J</i> = 6.57 Hz, 1 H), 4.06 (s, 3 H), 4.05 (s, 3 H), 3.34–3.65 (br s, 2 H), 2.31 (s, 3 H). HRMS (C<sub>22</sub>H<sub>19</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 375.133 93; found, 375.134 29. Anal. (C<sub>22</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>·CH<sub>3</sub>SO<sub>3</sub>H) C, H, N.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N-</i>Cyclopropyl-6-(6,7-dimethoxyquinazolin-4-yloxy)-1-naphthamide (<b>23</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-(6,7-dimethoxyquinazolin-4-yloxy)-1-naphthoic acid using a method analogous to the preparation of compound <b>13</b>. Yield: 16 mg, 24%. HPLC purity: 99% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.64 (d, <i>J</i> = 4.55 Hz, 1 H), 8.54 (s, 1 H), 8.28 (d, <i>J</i> = 9.09 Hz, 1 H), 8.02 (t, <i>J</i> = 4.86 Hz, 1 H), 7.93 (d, <i>J</i> = 2.40 Hz, 1 H), 7.64 (s, 1 H), 7.53–7.60 (m, 2 H), 7.42 (s, 1 H), 4.01 (s, 3 H), 4.00 (s, 3 H), 2.92–2.99 (m, 1 H), 0.71–0.78 (m, 2 H), 0.60–0.64 (m, 2 H). HRMS (C<sub>24</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 416.161 03; found, 416.161 13. Anal. (C<sub>24</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 6-(6,7-Dimethoxyquinazolin-4-yloxy)-<i>N-</i>(2-methoxyethyl)-1-naphthamide (<b>24</b>)</h3><div class="NLM_p last">The title compound was prepared from (6,7-dimethoxyquinazolin-4-yloxy)-1-naphthoic acid using a method analogous to the preparation of compound <b>13</b>. Yield: 45 mg, 68%. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.65 (t, <i>J</i> = 4.67 Hz, 1 H), 8.54 (s, 1 H), 8.31 (d, <i>J</i> = 9.22 Hz, 1 H), 8.03 (dd, <i>J</i> = 5.75, 3.73 Hz, 1 H), 7.93 (d, <i>J</i> = 2.27 Hz, 1 H), 7.58–7.66 (m, 3 H), 7.56 (dd, <i>J</i> = 9.22, 2.40 Hz, 1 H), 7.42 (s, 1 H), 4.00 (d, <i>J</i> = 1.01 Hz, 6 H), 3.46–3.58 (m, 4 H), 3.32 (s, 3 H). HRMS (C<sub>24</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub>)<sup>+</sup>: calcd, 434.171 05; found, 434.171 31. Anal. (C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>) C, H, N.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 6-(6,7-Dimethoxyquinazolin-4-yloxy)-1-naphthamide (<b>25</b>)</h3><div class="NLM_p last">The title compound was prepared from (6,7-dimethoxyquinazolin-4-yloxy)-1-naphthoic acid using a method analogous to the preparation of compound <b>13</b>. The crude derived solid was rinsed well with water and methanol to provide <b>25</b> (17 mg, 53%) as a white solid. HPLC purity: 96% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.54 (s, 1 H), 8.42 (br s, 1 H), 7.98–8.13 (m, 2 H), 7.93 (s, 1 H), 7.49–7.73 (m, 3 H), 7.42 (s, 1 H), 4.00 (s, 6 H), 3.21–3.39 (br s, 2 H). HRMS (C<sub>21</sub>H<sub>18</sub>N<sub>3</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 376.129 18; found, 376.127 95. Anal. Calcd for C<sub>21</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>: N, 67.19; H, 4.56; N, 11.19. Found: C, 66.04; H, 4.51; N, 9.67.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N-</i>Cyclopropyl-6-(7-methoxyquinolin-4-yloxy)-1-naphthamide (<b>26</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-(7-methoxyquinolin-4-yloxy)-1-naphthoic acid (<b>5b</b>) using a method analogous to the preparation of compound <b>13</b>. Yield: 73 mg, 69%. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.59–8.67 (m, 2 H), 8.34 (d, <i>J</i> = 9.22 Hz, 1 H), 8.24 (d, <i>J</i> = 9.22 Hz, 1 H), 8.01 (t, <i>J</i> = 4.80 Hz, 1 H), 7.85 (d, <i>J</i> = 2.40 Hz, 1 H), 7.58 (d, <i>J</i> = 4.93 Hz, 2 H), 7.53 (dd, <i>J</i> = 9.16, 2.46 Hz, 1 H), 7.44 (d, <i>J</i> = 2.53 Hz, 1 H), 7.31 (dd, <i>J</i> = 9.03, 2.46 Hz, 1 H), 6.57 (d, <i>J</i> = 5.18 Hz, 1 H), 3.95 (s, 3 H), 3.32 (s, 1 H), 0.69–0.78 (m, 2 H), 0.56–0.64 (m, 2 H). HRMS (C<sub>24</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub>)<sup>+</sup>: calcd, 385.154 67; found, 385.155 13. Anal. Calcd for C<sub>24</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>: C, 74.98; H, 5.24; N, 7.29. Found: C, 74.97; H, 5.74; N, 7.27.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N-</i>(2-Methoxyethyl)-6-(7-methoxyquinolin-4-yloxy)-1-naphthamide (<b>27</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-(7-methoxyquinolin-4-yloxy)-1-naphthoic acid (<b>5b</b>) using a method analogous to the preparation of compound <b>13</b>. Yield: 68 mg, 62%. HPLC purity: 99% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.60–8.67 (m, 2 H), 8.36 (d, <i>J</i> = 9.22 Hz, 1 H), 8.24 (d, <i>J</i> = 9.22 Hz, 1 H), 8.02 (dd, <i>J</i> = 6.00, 3.35 Hz, 1 H), 7.86 (d, <i>J</i> = 2.53 Hz, 1 H), 7.57–7.62 (m, 2 H), 7.53 (dd, <i>J</i> = 9.22, 2.40 Hz, 1 H), 7.44 (d, <i>J</i> = 2.53 Hz, 1 H), 7.31 (dd, <i>J</i> = 9.22, 2.53 Hz, 1 H), 6.57 (d, <i>J</i> = 5.18 Hz, 1 H), 3.95 (s, 3 H), 3.46–3.57 (m, 4 H), 3.32 (s, 3 H). HRMS (C<sub>24</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 403.165 23; found, 403.166 40. Anal. (C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub>·0.5CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 6-(7-Methoxyquinolin-4-yloxy)-1-naphthamide (<b>28</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-(7-methoxyquinolin-4-yloxy)-1-naphthoic acid (<b>5b</b>) using a method analogous to the preparation of compound <b>13</b>. Yield: 31 mg, 56%. HPLC purity: 99% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.63 (d, <i>J</i> = 5.18 Hz, 1 H), 8.47 (d, <i>J</i> = 9.22 Hz, 1 H), 8.24 (d, <i>J</i> = 9.09 Hz, 1 H), 8.06 (br s, 1 H), 8.01 (d, <i>J</i> = 8.21 Hz, 1 H), 7.85 (d, <i>J</i> = 2.53 Hz, 1 H), 7.62–7.70 (m, 2 H), 7.59 (d, <i>J</i> = 7.71 Hz, 1 H), 7.54 (dd, <i>J</i> = 9.22, 2.40 Hz, 1 H), 7.44 (d, <i>J</i> = 2.40 Hz, 1 H), 7.31 (dd, <i>J</i> = 9.16, 2.46 Hz, 1 H), 6.58 (d, <i>J</i> = 5.18 Hz, 1 H), 3.95 (s, 3 H). HRMS (C<sub>21</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub>)<sup>+</sup>: calcd, 345.123 37; found, 345.122 81. Anal. (C<sub>21</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>·0.5CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-(5-(Cyclopropylcarbamoyl)naphthalen-2-yloxy)-7-methoxyquinoline-6-carboxamide (<b>29</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-1-naphthoic acid (<b>5c</b>) using a method analogous to the preparation of compound <b>10</b>. Yield: 189 mg, 55%. HPLC purity: 99% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.72 (s, 1 H), 8.68 (d, <i>J</i> = 5.18 Hz, 1 H), 8.64 (d, <i>J</i> = 4.42 Hz, 1 H), 8.35 (d, <i>J</i> = 9.09 Hz, 1 H), 7.97–8.05 (m, 1 H), 7.89 (d, <i>J</i> = 2.40 Hz, 1 H), 7.88 (br s, 1 H), 7.75 (br s, 1 H), 7.51–7.61 (m, 4 H), 6.59 (d, <i>J</i> = 5.18 Hz, 1 H), 4.04 (s, 3 H), 2.89–3.01 (m, 1 H), 0.74 (dd, <i>J</i> = 7.07, 2.27 Hz, 2 H), 0.55–0.64 (m, 2 H). HRMS (C<sub>25</sub>H<sub>22</sub>NaN<sub>3</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 450.142 43; found, 450.142 75. Anal. (C<sub>25</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>·CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-(5-((2-Methoxyethyl)carbamoyl)naphthalen-2-yloxy)-7-methoxyquinoline-6-carboxamide (<b>30</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-1-naphthoic acid (<b>5c</b>) using a method analogous to the preparation of compound <b>10</b>. Yield:153 mg, 70%. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.73 (s, 1 H), 8.69 (d, <i>J</i> = 5.18 Hz, 1 H), 8.65 (t, <i>J</i> = 5.18 Hz, 1 H), 8.38 (d, <i>J</i> = 9.35 Hz, 1 H), 8.03 (dd, <i>J</i> = 5.75, 3.85 Hz, 1 H), 7.91 (d, <i>J</i> = 2.53 Hz, 1 H), 7.88 (br s, 1 H), 7.76 (br s, 1 H), 7.53–7.64 (m, 4 H), 6.60 (d, <i>J</i> = 5.18 Hz, 1 H), 4.05 (s, 3 H), 3.46–3.56 (m, 4 H), 3.32 (s, 3 H). HRMS (C<sub>25</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub>)<sup>+</sup>: calcd, 446.171 05; found, 446.171 16. Anal. (C<sub>25</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>·0.5CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-(5-Carbamoylnaphthalen-2-yloxy)-7-methoxyquinoline-6-carboxamide (<b>31</b>)</h3><div class="NLM_p last">The title compound was prepared from 6-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-1-naphthoic acid (<b>5c</b>) using a method analogous to the preparation of compound <b>10</b>. Yield: 75 mg, 76%. HPLC purity: 100% (system A). <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.72 (s, 1 H), 8.68 (d, <i>J</i> = 5.18 Hz, 1 H), 8.48 (d, <i>J</i> = 9.35 Hz, 1 H), 8.07 (s, 1 H), 8.02 (d, <i>J</i> = 8.21 Hz, 1 H), 7.89 (d, <i>J</i> = 2.53 Hz, 1 H), 7.87 (s, 1 H), 7.75 (s, 1 H), 7.64–7.70 (m, 2 H), 7.60 (d, <i>J</i> = 7.83 Hz, 1 H), 7.52–7.58 (m, 2 H), 6.60 (d, <i>J</i> = 5.18 Hz, 1 H), 4.05 (s, 3 H). HRMS (C<sub>22</sub>H<sub>18</sub>N<sub>3</sub>O<sub>4</sub>)<sup>+</sup>: calcd, 388.129 18; found, 388.128 90. Anal. (C<sub>22</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>·0.5CH<sub>3</sub>OH) C, H, N.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> VEGFR-2 Kinase Assay<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></h3><div class="NLM_p last">In a 96-well plate, 5 nM/L of either the phosphorylated or nonphosphorylated form of the VEGFR-2 kinase domain was incubated with compound (10-point titration ranging from 3 µM to 0.15 nM), 1 µM/L gastrin substrate, 20 mM/L Tris-HCl, pH 7.5, 10 mM/L MgCl<sub>2</sub>, 100 mM/L NaCl, 1.5 mM/L EGTA, 1 mM/L DTT, 0.2 mM/L sodium orthovanadate, and 20 µg/mL BSA for 30 min at 25 °C. ATP was added at a final concentration of 11.8 µM and incubated for 60 min at room temperature. Eu-labeled antiphosphotyrosine pT66 antibody (Perkin-Elmer) was then used for detection.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> HUVEC Proliferation Assay<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></h3><div class="NLM_p last">Cells were cultured in endothelial growth medium-2 (Cambrex). HUVECs were seeded into flat-bottom, 96-well plates (BD Falcon) at 3000 cells per well in Dulbecco’s modified Eagleʼs medium (DMEM) with 10% fetal bovine serum (FBS), penicillin, and streptomycin. After culture for 22 h, media were removed and cells were preincubated for 2 h with serial dilutions of compound diluted 1:400 in DMEM with 10% FBS plus penicillin/streptomycin. HUVECs were then challenged with 50 ng/mL VEGF or 20 ng/mL bFGF and incubated for 72 h at 37 °C, 5% CO<sub>2</sub>. Cells were washed twice with DPBS, and plates were frozen at −70 °C for 24 h. Plates were thawed, incubated with CyQuant dye (Molecular Probes), and read on a Victor 1420 workstation (Perkin-Elmer Corporation). IC<sub>50</sub> data were calculated using the Levenburg−Marquardt algorithm in a four-parameter logistic equation (ID Business Solutions Ltd., Alameda, CA).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> In Vitro Metabolism and CL<sub>int</sub> Calculations</h3><div class="NLM_p last">The in vitro intrinsic clearances, CL<sub>int</sub>, of the test compounds were determined by incubations with human and rat liver microsomes purchased from BD Biosciences (San Jose, CA). The 400 µL incubations contained 0.25 mg of microsomal protein/mL, 1 mM NADPH, 2 mM MgCl<sub>2</sub> in 50 mM potassium phosphate buffer, pH 7.4. Test compounds were added to the prewarmed (37 °C) incubation mixtures at the final concentration of 1 µM. At 0, 10, 20, 30, and 40 min following addition of test compound, aliquots of the incubation mixture (35 µL) were collected into an equal volume of acetonitrile plus internal standard (1 µM tolbutamide). The samples were centrifuged at 3500<i>g</i> for 15 min and analyzed on a liquid chromatography tandem mass spectrometry system consisting of two Shimadzu LC-10AD HPLC pumps and a DGU-14A degasser (Shimadzu, Columbia, MD), CTC PAL autoinjector (Leap Technologies, Carrboro, NC), and an API3000 LC−MSMS system. Chromatography was conducted on a Sprite Armor C18 (20 mm × 2.1 mm, 10 µm) analytical column (Analytical Sales and Products, Pompton Plains, NJ) with a 0.5 µm PEEK guard filter, using the following mobile phase gradient program: MPA = H<sub>2</sub>0 with 0.1% formic acid; MPB = acetonitrile with 0.1% formic acid; 0 min = 98% MPA, 2% MPB; 0.3 min = 98% MPA, 2% MPB; 0.7 min = 5% MPA, 95% MPB; 1.3 min = 5% MPA, 95% MPB; 1.4 min = 98% MPA, 2% MPB; 1.7 min = end of run; approximately 2 min between sample injections. For each compound, peak areas at each time point were converted to the natural log of the percentage remaining relative to the 0 min samples.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The resulting slope of these values relative to time (<i>k</i>) was converted to in vitro <i>T</i><sub>1/2</sub> where <i>T</i><sub>1/2</sub> = −0.693/<i>k</i>. CL<sub>int</sub> was calculated using the following relationship: CL<sub>int</sub> = (0.693/<i>T</i><sub>1/2</sub>)(1/0.25 mg/mL).</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> In Vivo Vascular Permeability Assay</h3><div class="NLM_p last">Vascular permeability was induced using a modified Miles assay<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and was conducted as previously described.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Rat Corneal Angiogenesis Model</h3><div class="NLM_p last">Corneal angiogenesis was evaluated in adult female Sprague–Dawley rats as previously described.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Pharmacokinetic Studies</h3><div class="NLM_p last">Male Sprague–Dawley rats were dosed via femoral vein (intravenous, DMSO solution, dose 1 mg/kg) or via oral gavage (suspensions in OraPlus, pH adjusted to a range of 2.0–2.2 using methanesulfonic acid, dose 10 mg/kg). Concentrations of all formulations were selected to allow for dose volumes in accordance with the highest scientific, humane, and ethical principals as defined by IACUC (Institutional Animal Care and Use Committees). Serial blood samples were collected from jugular vein into heparized tubes over a 12–24 h period. Plasma was separated by centrifugation, and the sample was prepared for analysis by protein precipitation with acetonitrile. Quantitation of the test compounds was accomplished by reverse-phase liquid chromatography with mass spectral detection in multiple reaction monitoring mode, with an appropriate internal standard. Pharmacokinetic parameters such as clearance, volume of distribution, and terminal half-life were calculated by a noncompartmental method.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Tumor Xenograft Models</h3><div class="NLM_p last">Both the Calu-6 and HT29 cell lines were originally obtained from ATCC. HT29 cells were maintained at 37 °C in DMEM high glucose, 5% FBS, 1× NEAA, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine (Gibco/BRL, Grand Island, NY) under standard tissue culture conditions. In like manner, Calu-6 cells were maintained in RPMI 1640 10% FBS, 1× NEAA, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine (Gibco/BRL, Grand Island, NY). CD1 nu/nu mice within approximately 4–8 weeks of age were challenged with subcutaneous implants of cultured HT29 (human colon carcinoma) or Calu-6 (human NSCLC) cells (1 × 10<sup>7</sup> cells per mouse). After 13−14 days, when tumors had reached approximately 300 mm<sup>3</sup>, animals began continuous daily treatment with compound <b>22</b> administered po, qd at the indicated dose levels. Tumor volumes as established by caliper measurements were recorded twice per week, along with body weights as an index of toxicity. Data are expressed as mean values plus or minus standard errors as a function of time. Statistical significance of observed differences was evaluated by repeated measures analysis of variance (RMANOVA) followed by Scheffé post hoc testing for multiple comparisons.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Covalent Binding Studies</h3><div class="NLM_p">Human and rat liver microsomes (20 mg/mL) were purchased from Xenotech, LLC (Lenexa, KS). NADPH and glutathione were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). H<sub>2</sub><sup>18</sup>O was ordered from Cambridge Isotope Laboratories Inc. (Andover, MA), and SOLVABLE was purchased from Perkin-Elmer Life Sciences (Boston, MA).</div><div id="ssec4_35_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Microsomal Incubations</h4><div class="NLM_p last"><sup>14</sup>C compound (10 µM) and liver microsomes (1 mg/mL) were mixed with 0.1 M potassium phosphate buffer (pH 7.4) for a final volume of 0.5 mL. The samples were preincubated at 37 °C for 3 min, and then 1 mM NADPH was added. The incubations were quenched with 1.0 mL of ice-cold acetonitrile after 60 min followed by vortex mixing and centrifugation. The supernatant was dried under a steady stream of N<sub>2</sub> and reconstituted in the initial mobile phase described below. A 50 µL injection was made using the LCMS method described below.</div></div><div id="sec4_35_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> In Vitro Covalent Binding Assay</h4><div class="NLM_p last"><sup>14</sup>C compound (10 µM) was again incubated with liver microsomes (1 mg/mL), (±)-glutathione (1 mM), 0.1 M potassium phosphate buffer (pH 7.4), and NADPH (1 mM) in a final volume of 0.2 mL The incubations were quenched with 0.4 mL of ice-cold acetonitrile after 60 min followed by vortex mixing, centrifugation, and removal of the supernatant. The pellet was washed three times with 80% methanol, twice with 3:1 ethanol/ether, and twice with 80% methanol. The total radioactivity in the final supernatant was determined by liquid scintillation counting and was not more than background. The pellet was dried overnight and then solubilized in 0.5 mL of 60% SOLVABLE. The protein concentration was determined using a standard BCA protein assay, and 0.375 mL of the solubilized protein was used for liquid scintillation counting</div></div><div id="sec4_35_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> LCMS Assay</h4><div class="NLM_p last">HPLC analyses were carried out on an Agilent 1100 gradient system (Palo Alto, CA). Separation was achieved on a Waters YMC ODS-AQ 4.6 mm × 150 mm column with a flow rate of 1 mL/min. The mobile phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). The gradient started at 95% A and linearly ramped to 50% A over 30 min. The flow was split so that 0.8 mL/min flowed through an INUS β-RAM (Rivera Beach, FL; scintillation cocktail flow rate of 2.4 mL/min) and 0.2 mL/min flowed into a Thermo Electron ion trap mass spectrometer (LCQ-Deca XP plus or LTQ; San Jose, CA).</div></div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Protein Binding Assay</h3><div class="NLM_p last">Plasma filtrate was used for the calibration curve and QC samples. To generate plasma filtrate, an aliquot of plasma was filtered through Millipore Centriplus (a filter) by spinning at 3000<i>g</i> (4980 rpm) at 4 °C for 24 h with a Beckman Avanti J-251 ultracentrifuge. An aliquot of 10 µL of test compound (1 mg/mL in DMSO) was added to 1990 µL of human, rat, dog, and mouse plasma to give a final concentration of 5 mg/mL (12.9 µM). Separate QC samples were prepared by adding 10 µL of the test compound spiked plasma sample (5 µg/mL) to 490 µL of plasma filtrate, in duplicate. The plasma samples including the QC samples were then incubated at 37 °C for 15 min. Following incubation, 800 µL was transferred to the centrifuge tube (in duplicate) and spun at 120 000 rpm for 3 h at 37 °C with a TLA-120.2 rotor (Optima TLX ultracentrifuge, Beckman Coulter). The top portion below the lipid layer of the centrifuged plasma sample was aspirated (100 µL in triplicate) for LCMS analysis. The QC samples (100 µL in duplicate) were also aspirated for LCMS analysis. The concentrations of the samples (<i>n</i> = 6) and QCs (<i>n</i> = 2) were determined from a linear regression of peak area ratios (analyte peak area/IS peak area) versus the theoretical concentrations of the calibration standards. The percent of binding was calculated as <span class="NLM_disp-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/jm-2007-01098w_m001.gif" alt="" /></img></span></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="si1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61"><a href="/doi/suppl/10.1021/jm701098w">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Tables of elemental analysis, HPLC anlysis, and X-ray data. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm701098w/suppl_file/jm701098w-file002.pdf">jm701098w-file002.pdf (102.13 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm701098w" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew M. Weiss</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5934342e3c302a2a1938343e3c37773a3634"><span class="__cf_email__" data-cfemail="1b76766c7e7268685b7a767c7e7535787476">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Christophe Harmange</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony J. Polverino</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Bauer</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Loren Berry</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Virginia Berry</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Borg</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Bready</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danlin Chen</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deborah Choquette</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Coxon</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tom DeMelfi</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas Doerr</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Estrada</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Flynn</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Russell F. Graceffa</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shawn P. Harriman</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Kaufman</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel S. La</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Long</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sesha Neervannan</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vinod F. Patel</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele Potashman</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kelly Regal</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phillip M. Roveto</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael L. Schrag</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charlie Starnes</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Tasker</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yohannes Teffera</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas A. Whittington</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roger Zanon</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, Department of Molecular Structure, and Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, and Department of Oncology Research, Department of Toxicology, and Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank our colleagues Angela Bretz and Victor Chi in PKDM, and Ingrid Fellows for the preparation of compound <b>18</b>.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Anti-angiogenesis: new concept for therapy of solid tumors</span> <span class="citation_source-journal">Ann. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1972&pages=409-416&author=J.+Folkman&title=Anti-angiogenesis%3A+new+concept+for+therapy+of+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAnti-angiogenesis%253A%2520new%2520concept%2520for%2520therapy%2520of%2520solid%2520tumors%26jtitle%3DAnn.%2520Surg.%26date%3D1972%26volume%3D175%26spage%3D409%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">VEGF and the quest for tumour angiogenesis factors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1038%2Fnrc909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=12360282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVGrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=795-803&author=N.+Ferrara&title=VEGF+and+the+quest+for+tumour+angiogenesis+factors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: VEGF and the quest for tumor angiogenesis factors</span></div><div class="casAuthors">Ferrara, Napoleone</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">795-803</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The ability of tumors to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be central to this process.  The quest for VEGF and other factors that promote tumor angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these mols. as anticancer agents.  How did this field begin, and how have we arrived at our present understanding of the role of VEGF in tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHN1T3vtAELVg90H21EOLACvtfcHk0liFIdMcxf3Nkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVGrtbk%253D&md5=b0f6d2bde63351fae496d743a9a7e4bf</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fnrc909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc909%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DVEGF%2520and%2520the%2520quest%2520for%2520tumour%2520angiogenesis%2520factors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D795%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strawn, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawver, L. K.</span><span> </span><span class="NLM_article-title">New paradigms for the treatment of cancer: the role of anti-angiogenesis agents</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2000&pages=1-38&author=J.+M.+Cherringtonauthor=L.+M.+Strawnauthor=L.+K.+Shawver&title=New+paradigms+for+the+treatment+of+cancer%3A+the+role+of+anti-angiogenesis+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DStrawn%26aufirst%3DL.%2BM.%26aulast%3DShawver%26aufirst%3DL.%2BK.%26atitle%3DNew%2520paradigms%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520the%2520role%2520of%2520anti-angiogenesis%2520agents%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2000%26volume%3D79%26spage%3D1%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span> </span><span class="NLM_article-title">Vascular-targeting therapies for treatment of malignant disease</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2491</span><span class="NLM_x">–</span> <span class="NLM_lpage">2499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2004&pages=2491-2499&author=D.+W.+Siemannauthor=D.+J.+Chaplinauthor=M.+R.+Horsman&title=Vascular-targeting+therapies+for+treatment+of+malignant+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26atitle%3DVascular-targeting%2520therapies%2520for%2520treatment%2520of%2520malignant%2520disease%26jtitle%3DCancer%26date%3D2004%26volume%3D100%26spage%3D2491%26epage%3D2499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Mechanisms of angiogenesis and arteriogenesis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1038%2F74651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=10742145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVOrur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=389-395&author=P.+Carmeliet&title=Mechanisms+of+angiogenesis+and+arteriogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of angiogenesis and arteriogenesis</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-395</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">A review with 71 refs., on the cellular and mol. mechanisms underlying the formation of endothelium-lined channels (angiogenesis) and their maturation via recruitment of smooth muscle cells (arteriogenesis) during physiol. and pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC5duTZ_-aV7Vg90H21EOLACvtfcHk0liFIdMcxf3Nkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVOrur4%253D&md5=a8a3874f286a4e46a9eeaaa9ff8b17dc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F74651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F74651%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DMechanisms%2520of%2520angiogenesis%2520and%2520arteriogenesis%26jtitle%3DNat.%2520Med.%26date%3D2000%26volume%3D6%26spage%3D389%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Rak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuhashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filmus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirasawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasazuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4575</span><span class="NLM_x">–</span> <span class="NLM_lpage">4580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=4575-4580&author=J.+Rakauthor=Y.+Mitsuhashiauthor=L.+Baykoauthor=J.+Filmusauthor=S.+Shirasawaauthor=T.+Sasazukiauthor=R.+S.+Kerbel&title=Mutant+ras+oncogenes+upregulate+VEGF%2FVPF+expression%3A+implications+for+induction+and+inhibition+of+tumor+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRak%26aufirst%3DJ.%26aulast%3DMitsuhashi%26aufirst%3DY.%26aulast%3DBayko%26aufirst%3DL.%26aulast%3DFilmus%26aufirst%3DJ.%26aulast%3DShirasawa%26aufirst%3DS.%26aulast%3DSasazuki%26aufirst%3DT.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DMutant%2520ras%2520oncogenes%2520upregulate%2520VEGF%252FVPF%2520expression%253A%2520implications%2520for%2520induction%2520and%2520inhibition%2520of%2520tumor%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D4575%26epage%3D4580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Mukhopadhyay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knebelmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukhatme, V. P.</span><span> </span><span class="NLM_article-title">The von Hippel−Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5629</span><span class="NLM_x">–</span> <span class="NLM_lpage">5639</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=9271438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADyaK2sXlslaru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=5629-5639&author=D.+Mukhopadhyayauthor=B.+Knebelmannauthor=H.+T.+Cohenauthor=S.+Ananthauthor=V.+P.+Sukhatme&title=The+von+Hippel%E2%88%92Lindau+tumor+suppressor+gene+product+interacts+with+Sp1+to+repress+vascular+endothelial+growth+factor+promoter+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity</span></div><div class="casAuthors">Mukhopadhyay, Debabrata; Knebelmann, Bertrand; Cohen, Herbert T.; Ananth, Subbian; Sukhatme, Vikas P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5629-5639</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The von Hippel-Lindau tumor suppressor gene (VHL) has a crit. role in the pathogenesis of clear-cell renal cell carcinoma (RCC), as VHL mutations have been found in both von Hippel-Lindau disease-assocd. and sporadic RCCs.  Recent studies suggest that vascular endothelial growth factor (VEGF) mRNA is upregulated in RCC- and von Hippel-Lindau disease-assocd. tumors.  We have therefore assessed the effect of the VHL gene product on VEGF expression.  VEGF promoter-luciferase constructs were transiently cotransfected with a wild-type VHL (wt-VHL) vector in several cell lines, including 293 embryonic kidney and RCC cell lines.  Wt-VHL protein inhibited VEGF promoter activity in a dose-dependent manner up to 5- to 10-fold.  Deletion anal. defined a 144-bp region of the VEGF promoter necessary for VHL repression.  This VHL-responsive element is GC rich and specifically binds the transcription factor Sp1 in crude nuclear exts.  In Drosophila cells, cotransfected VHL represses Sp1-mediated activation but not basal activity of the VEGF promoter.  We next demonstrated in coimmunoppts. that VHL and Sp1 were part of the same complex and, by using a glutathione-S-transferase-VHL fusion protein and purified Sp1, that VHL and Sp1 directly interact.  Furthermore, endogenous VEGF mRNA levels were suppressed in permanent RCC cell lines expressing wt-VHL, and nuclear run-on studies indicated that VHL regulation of VEGF occurs at least partly at the transcriptional level.  These observations support a new mechanism for VHL-mediated transcriptional repression via a direct inhibitory action on Sp1 and suggest that loss of Sp1 inhibition may be important in the pathogenesis of von Hippel-Lindau disease and RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozMX34jMUc0LVg90H21EOLACvtfcHk0ljmxNdikO_2OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlslaru74%253D&md5=2e18d74a863ae242e05185b808c8052b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DD.%26aulast%3DKnebelmann%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DH.%2BT.%26aulast%3DAnanth%26aufirst%3DS.%26aulast%3DSukhatme%26aufirst%3DV.%2BP.%26atitle%3DThe%2520von%2520Hippel%25E2%2588%2592Lindau%2520tumor%2520suppressor%2520gene%2520product%2520interacts%2520with%2520Sp1%2520to%2520repress%2520vascular%2520endothelial%2520growth%2520factor%2520promoter%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1997%26volume%3D17%26spage%3D5629%26epage%3D5639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Shweiki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neeman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshet, E.</span><span> </span><span class="NLM_article-title">Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">768</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=768-772&author=D.+Shweikiauthor=M.+Neemanauthor=A.+Itinauthor=E.+Keshet&title=Induction+of+vascular+endothelial+growth+factor+expression+by+hypoxia+and+by+glucose+deficiency+in+multicell+spheroids%3A+implications+for+tumor+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShweiki%26aufirst%3DD.%26aulast%3DNeeman%26aufirst%3DM.%26aulast%3DItin%26aufirst%3DA.%26aulast%3DKeshet%26aufirst%3DE.%26atitle%3DInduction%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520expression%2520by%2520hypoxia%2520and%2520by%2520glucose%2520deficiency%2520in%2520multicell%2520spheroids%253A%2520implications%2520for%2520tumor%2520angiogenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1995%26volume%3D92%26spage%3D768%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christinger, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vos, A. M.</span><span> </span><span class="NLM_article-title">Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1016%2FS0092-8674%2800%2980456-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=9393862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1997&pages=695-704&author=C.+Wiesmannauthor=G.+Fuhauthor=H.+W.+Christingerauthor=C.+Eigenbrotauthor=J.+A.+Wellsauthor=A.+M.+de+Vos&title=Crystal+structure+at+1.7+%C3%85+resolution+of+VEGF+in+complex+with+domain+2+of+the+Flt-1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor</span></div><div class="casAuthors">Wiesmann, Christian; Fuh, Germaine; Christinger, Hans W.; Eigenbrot, Charles; Wells, James A.; De Vos, Abraham M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-704</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) is a homodimeric hormone that induces proliferation of endothelial cells through binding to the kinase domain receptor and the Fms-like tyrosine kinase receptor (Flt-1), the extracellular portions of which consist of seven Ig domains.  We show that the second and third domains of Flt-1 are necessary and sufficient for binding VEGF with near-native affinity, and that domain 2 alone binds only 60-fold less tightly than wild-type.  The crystal structure of the complex between VEGF and the second domain of Flt-1 shows domain 2 in a predominantly hydrophobic interaction with the "poles" of the VEGF dimer.  Based on this structure and on mutational data, we present a model of VEGF bound to the first four domains of Flt-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZYD3KG--Kg7Vg90H21EOLACvtfcHk0ljmxNdikO_2OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWrtr4%253D&md5=0775fe6ced8d68e2db5d2900a2d5c3e4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980456-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980456-0%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DFuh%26aufirst%3DG.%26aulast%3DChristinger%26aufirst%3DH.%2BW.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26atitle%3DCrystal%2520structure%2520at%25201.7%2520%25C3%2585%2520resolution%2520of%2520VEGF%2520in%2520complex%2520with%2520domain%25202%2520of%2520the%2520Flt-1%2520receptor%26jtitle%3DCell%26date%3D1997%26volume%3D91%26spage%3D695%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Terman, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougher-Vermazen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrion, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armellino, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gospodarowicz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span> </span><span class="NLM_article-title">Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">187</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1992&pages=1579-1586&author=B.+I.+Termanauthor=M.+Dougher-Vermazenauthor=M.+E.+Carrionauthor=D.+Dimitrovauthor=D.+C.+Armellinoauthor=D.+Gospodarowiczauthor=P.+Bohlen&title=Identification+of+the+KDR+tyrosine+kinase+as+a+receptor+for+vascular+endothelial+cell+growth+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTerman%26aufirst%3DB.%2BI.%26aulast%3DDougher-Vermazen%26aufirst%3DM.%26aulast%3DCarrion%26aufirst%3DM.%2BE.%26aulast%3DDimitrov%26aufirst%3DD.%26aulast%3DArmellino%26aufirst%3DD.%2BC.%26aulast%3DGospodarowicz%26aufirst%3DD.%26aulast%3DBohlen%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520the%2520KDR%2520tyrosine%2520kinase%2520as%2520a%2520receptor%2520for%2520vascular%2520endothelial%2520cell%2520growth%2520factor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1992%26volume%3D187%26spage%3D1579%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_contrib-group">Kim, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armanini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillett, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=1993&pages=841-844&author=K.+J.+Kimauthor=B.+Liauthor=J.+Winerauthor=M.+Armaniniauthor=N.+Gillettauthor=H.+S.+Phillipsauthor=N.+Ferrara&title=Inhibition+of+vascular+endothelial+growth+factor-induced+angiogenesis+suppresses+tumour+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWiner%26aufirst%3DJ.%26aulast%3DArmanini%26aufirst%3DM.%26aulast%3DGillett%26aufirst%3DN.%26aulast%3DPhillips%26aufirst%3DH.%2BS.%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DInhibition%2520of%2520vascular%2520endothelial%2520growth%2520factor-induced%2520angiogenesis%2520suppresses%2520tumour%2520growth%2520in%2520vivo%26jtitle%3DNature%26date%3D1993%26volume%3D362%26spage%3D841%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fyfe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">–</span> <span class="NLM_lpage">2342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0lhmAx-8uh38kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilenbaum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span> </span><span class="NLM_article-title">Paclitaxel−carboplatin alone or with bevacizumab for non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2542</span><span class="NLM_x">–</span> <span class="NLM_lpage">2550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1056%2FNEJMoa061884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=17167137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlWqsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2542-2550&author=A.+Sandlerauthor=R.+Grayauthor=M.+C.+Perryauthor=J.+Brahmerauthor=J.+H.+Schillerauthor=A.+Dowlatiauthor=R.+Lilenbaumauthor=D.+H.+Johnson&title=Paclitaxel%E2%88%92carboplatin+alone+or+with+bevacizumab+for+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</span></div><div class="casAuthors">Sandler, Alan; Gray, Robert; Perry, Michael C.; Brahmer, Julie; Schiller, Joan H.; Dowlati, Afshin; Lilenbaum, Rogerio; Johnson, David H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2542-2550</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers.  Between July 2001 and Apr. 2004, the Eastern Cooperative Oncol. Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434).  Chemotherapy was administered every 3 wk for six cycles, and bevacizumab was administered every 3 wk until disease progression was evident or toxic effects were intolerable.  Patients with squamous-cell tumors, brain metastases, clin. significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded.  The primary end point was overall survival.  The median survival was 12.3 mo in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 mo in the chemotherapy-alone group (hazard ratio for death, 0.79; P = 0.003).  The median progression-free survival in the two groups was 6.2 and 4.5 mo, resp. (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001).  Rates of clin. significant bleeding were 4.4% and 0.7%, resp. (P<0.001).  There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage.  The addn. of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHrplr-EnyyrVg90H21EOLACvtfcHk0lhmAx-8uh38kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlWqsbzI&md5=f94c013f3961561feb564b2bf7148df4</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa061884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa061884%26sid%3Dliteratum%253Aachs%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DPerry%26aufirst%3DM.%2BC.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DLilenbaum%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26atitle%3DPaclitaxel%25E2%2588%2592carboplatin%2520alone%2520or%2520with%2520bevacizumab%2520for%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2542%26epage%3D2550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Novel small-molecule inhibitors of the vascular endothelial growth factor receptor</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">S74</span><span class="NLM_x">–</span> <span class="NLM_lpage">S78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=S74-S78&issue=Suppl.+2&author=A.+A.+Adjei&title=Novel+small-molecule+inhibitors+of+the+vascular+endothelial+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DNovel%2520small-molecule%2520inhibitors%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2007%26volume%3D8%26issue%3DSuppl.%25202%26spage%3DS74%26epage%3DS78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Thomas, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreves, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiedenmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward, W. P.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1016%2FS0093-7754%2803%2900123-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=12802793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFelt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=32-38&issue=Suppl.+6&author=A.+L.+Thomasauthor=B.+Morganauthor=J.+Drevesauthor=C.+Ungerauthor=B.+Wiedenmannauthor=U.+Vanhoeferauthor=D.+Laurentauthor=M.+Duganauthor=W.+P.+Steward&title=Vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitors%3A+PTK787%2FZK+222584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584</span></div><div class="casAuthors">Thomas, Anne L.; Morgan, Bruno; Drevs, Joachim; Unger, Clemens; Wiedenmann, Bertram; Vanhoefer, Udo; Laurent, Dirk; Dugan, Margaret; Steward, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3, Suppl. 6</span>),
    <span class="NLM_cas:pages">32-38</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  PTK787/ZK 222584 (PTK/ZK) is an oral potent and selective inhibitor of the vascular endothelial growth factor (VEGF)-mediated Flt-I and KDR receptor tyrosine kinases.  PTK/ZK has been shown to reduce growth and microvasculature in s.c. implanted human tumor xenografts in nude mice.  A clin. difficulty in evaluating angiogenesis inhibitors has been the usefulness of conventional study endpoints.  Therefore, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been studied as a pharmacodynamic marker of efficacy of PTK/ZK.  Phase I studies are under way evaluating the optimum dose and schedule of oral PTK/ZK administered continuously to patients with advanced cancers of types known to overexpress VEGF.  To date, particularly in patients with liver metastases from colorectal cancer treated with PTK/ZK, DCE-MRI has been a useful predictor of the biol. response of VEGF-receptor inhibition.  Toxicities have been manageable and have included lightheadedness, ataxia, nausea, vomiting, and hypertension.  Stabilization of disease for ≥6 mo has been seen in heavily pretreated patients receiving PTK/ZK at higher doses.  Preliminary data suggest that PTK/ZK can be administered safely on a continuous daily dosing schedule, efficacy data look promising, and DCE-MRI correlates with biol. response.  DCE-MRI will be used to guide dose optimization of PTK/ZK and perhaps of other angiogenesis inhibitors in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN14homMHopbVg90H21EOLACvtfcHk0lhmAx-8uh38kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFelt7w%253D&md5=068ee79572e3b628894f3c9cc9a602e6</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2FS0093-7754%2803%2900123-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0093-7754%252803%252900123-4%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DMorgan%26aufirst%3DB.%26aulast%3DDreves%26aufirst%3DJ.%26aulast%3DUnger%26aufirst%3DC.%26aulast%3DWiedenmann%26aufirst%3DB.%26aulast%3DVanhoefer%26aufirst%3DU.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DSteward%26aufirst%3DW.%2BP.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520PTK787%252FZK%2520222584%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26issue%3DSuppl.%25206%26spage%3D32%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span> </span><span class="NLM_article-title">ZD6474, a novel inhibitor of VEGFR and EGFR tyrosine kinase activity</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S6</span><span class="NLM_x">–</span> <span class="NLM_lpage">S13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=S6-S13&issue=Suppl.+1&author=A.+J.+Ryanauthor=S.+R.+Wedge&title=ZD6474%2C+a+novel+inhibitor+of+VEGFR+and+EGFR+tyrosine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26atitle%3DZD6474%252C%2520a%2520novel%2520inhibitor%2520of%2520VEGFR%2520and%2520EGFR%2520tyrosine%2520kinase%2520activity%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26issue%3DSuppl.%25201%26spage%3DS6%26epage%3DS13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo- 1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-+1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-%25201%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5375</span><span class="NLM_x">–</span> <span class="NLM_lpage">5388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0301641" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5375-5388&author=D.+E.+Gingrichauthor=D.+R.+Reddyauthor=M.+A.+Iqbalauthor=J.+Singhauthor=L.+D.+Aimoneauthor=T.+S.+Angelesauthor=M.+Albomauthor=S.+Yangauthor=M.+A.+Atorauthor=S.+L.+Meyerauthor=C.+Robinsonauthor=B.+A.+Ruggeriauthor=C.+A.+Dionneauthor=J.+L.+Vaughtauthor=J.+P.+Mallamoauthor=R.+L.+Hudkins&title=A+new+class+of+potent+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitors%3A+structure+activity+relationships+for+a+series+of+9-alkoxymethyl-12-%283-hydroxypropyl%29indeno%5B2%2C1-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole-5-ones+and+the+identification+of+CEP-5214+and+its+dimethylglycine+ester+prodrug+clinical+candidate+CEP-7055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1021%2Fjm0301641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0301641%26sid%3Dliteratum%253Aachs%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DReddy%26aufirst%3DD.%2BR.%26aulast%3DIqbal%26aufirst%3DM.%2BA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26aulast%3DVaught%26aufirst%3DJ.%2BL.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DA%2520new%2520class%2520of%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520structure%2520activity%2520relationships%2520for%2520a%2520series%2520of%25209-alkoxymethyl-12-%25283-hydroxypropyl%2529indeno%255B2%252C1-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole-5-ones%2520and%2520the%2520identification%2520of%2520CEP-5214%2520and%2520its%2520dimethylglycine%2520ester%2520prodrug%2520clinical%2520candidate%2520CEP-7055%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5375%26epage%3D5388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, E. S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span> </span><span class="NLM_article-title">Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1300</span><span class="NLM_x">–</span> <span class="NLM_lpage">1312</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm011022e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1300-1312&author=L.+F.+Hennequinauthor=E.+S.+E.+Stokesauthor=A.+P.+Thomasauthor=C.+Johnstoneauthor=P.+A.+Pleauthor=D.+J.+Ogilvieauthor=M.+Dukesauthor=S.+R.+Wedgeauthor=J.+Kendrewauthor=J.+O.+Curwen&title=Novel+4-anilinoquinazolines+with+C-7+basic+side+chains%3A+design+and+structure+activity+relationship+of+a+series+of+potent%2C+orally+active%2C+VEGF+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=10.1021%2Fjm011022e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011022e%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DStokes%26aufirst%3DE.%2BS.%2BE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26atitle%3DNovel%25204-anilinoquinazolines%2520with%2520C-7%2520basic%2520side%2520chains%253A%2520design%2520and%2520structure%2520activity%2520relationship%2520of%2520a%2520series%2520of%2520potent%252C%2520orally%2520active%252C%2520VEGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1300%26epage%3D1312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbet, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span> </span><span class="NLM_article-title">CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">5978</span><span class="NLM_x">–</span> <span class="NLM_lpage">5991</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=5978-5991&author=B.+Ruggeriauthor=J.+Singhauthor=D.+Gingrichauthor=T.+Angelesauthor=M.+Albomauthor=H.+Changauthor=C.+Robinsonauthor=K.+Hunterauthor=P.+Dobrzanskiauthor=S.+Jones-Bolinauthor=L.+Aimoneauthor=A.+Klein-Szantoauthor=J.-M.+Herbetauthor=F.+Bonoauthor=P.+Schaefferauthor=P.+Casellasauthor=B.+Bourieauthor=R.+Piliauthor=J.+Isaacsauthor=M.+Atorauthor=R.+Hudkinsauthor=J.+Vaughtauthor=J.+Mallamoauthor=C.+Dionne&title=CEP-7055%3A+a+novel%2C+orally+active+pan+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases+with+potent+antiangiogenic+activity+and+antitumor+efficacy+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DAimone%26aufirst%3DL.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DHerbet%26aufirst%3DJ.-M.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DSchaeffer%26aufirst%3DP.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DBourie%26aufirst%3DB.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DIsaacs%26aufirst%3DJ.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DVaught%26aufirst%3DJ.%26aulast%3DMallamo%26aufirst%3DJ.%26aulast%3DDionne%26aufirst%3DC.%26atitle%3DCEP-7055%253A%2520a%2520novel%252C%2520orally%2520active%2520pan%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520antiangiogenic%2520activity%2520and%2520antitumor%2520efficacy%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D5978%26epage%3D5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Beebe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jani, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higdon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkelstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atherton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soderstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastinejad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, W. G.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7301</span><span class="NLM_x">–</span> <span class="NLM_lpage">7309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7301-7309&author=J.+S.+Beebeauthor=J.+P.+Janiauthor=E.+Knauthauthor=P.+Goodwinauthor=C.+Higdonauthor=A.+M.+Rossiauthor=E.+Emersonauthor=M.+Finkelsteinauthor=E.+Floydauthor=S.+Harrimanauthor=J.+Athertonauthor=S.+Hillermanauthor=C.+Soderstromauthor=K.+Kouauthor=T.+Gantauthor=M.+C.+Noeauthor=B.+Fosterauthor=F.+Rastinejadauthor=M.+A.+Marxauthor=T.+Schaefferauthor=P.+M.+Whalenauthor=W.+G.+Roberts&title=Pharmacological+characterization+of+CP-547%2C632%2C+a+novel+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeebe%26aufirst%3DJ.%2BS.%26aulast%3DJani%26aufirst%3DJ.%2BP.%26aulast%3DKnauth%26aufirst%3DE.%26aulast%3DGoodwin%26aufirst%3DP.%26aulast%3DHigdon%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DEmerson%26aufirst%3DE.%26aulast%3DFinkelstein%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DE.%26aulast%3DHarriman%26aufirst%3DS.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DHillerman%26aufirst%3DS.%26aulast%3DSoderstrom%26aufirst%3DC.%26aulast%3DKou%26aufirst%3DK.%26aulast%3DGant%26aufirst%3DT.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DFoster%26aufirst%3DB.%26aulast%3DRastinejad%26aufirst%3DF.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DSchaeffer%26aufirst%3DT.%26aulast%3DWhalen%26aufirst%3DP.%2BM.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26atitle%3DPharmacological%2520characterization%2520of%2520CP-547%252C632%252C%2520a%2520novel%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7301%26epage%3D7309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drevs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marme, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennig, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guenther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, C.</span><span> </span><span class="NLM_article-title">Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1291</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=1291-1299&author=K.+Mrossauthor=J.+Drevsauthor=M.+Mullerauthor=M.+Medingerauthor=D.+Marmeauthor=J.+Hennigauthor=B.+Morganauthor=D.+Lebwohlauthor=E.+Massonauthor=Y.+Y.+Hoauthor=C.+Guentherauthor=D.+Laurentauthor=C.+Unger&title=Phase+I+clinical+and+pharmacokinetic+study+of+PTK%2FZK%2C+a+multiple+VEGF+receptor+inhibitor%2C+in+patients+with+liver+metastases+from+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMross%26aufirst%3DK.%26aulast%3DDrevs%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DMedinger%26aufirst%3DM.%26aulast%3DMarme%26aufirst%3DD.%26aulast%3DHennig%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DB.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DMasson%26aufirst%3DE.%26aulast%3DHo%26aufirst%3DY.%2BY.%26aulast%3DGuenther%26aufirst%3DC.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DUnger%26aufirst%3DC.%26atitle%3DPhase%2520I%2520clinical%2520and%2520pharmacokinetic%2520study%2520of%2520PTK%252FZK%252C%2520a%2520multiple%2520VEGF%2520receptor%2520inhibitor%252C%2520in%2520patients%2520with%2520liver%2520metastases%2520from%2520solid%2520tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D1291%26epage%3D1299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Thomas, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsfield, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higginson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccio-Pick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward, W. P.</span><span> </span><span class="NLM_article-title">Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4162</span><span class="NLM_x">–</span> <span class="NLM_lpage">4171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1200%2FJCO.2005.09.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=15867205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1els78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=4162-4171&author=A.+L.+Thomasauthor=B.+Morganauthor=M.+A.+Horsfieldauthor=A.+Higginsonauthor=A.+Kayauthor=L.+Leeauthor=E.+Massonauthor=M.+Puccio-Pickauthor=D.+Laurentauthor=W.+P.+Steward&title=Phase+I+study+of+the+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+PTK787%2FZK+222584+administered+twice+daily+in+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer</span></div><div class="casAuthors">Thomas, Anne L.; Morgan, Bruno; Horsfield, Mark A.; Higginson, Anthony; Kay, Andrea; Lee, Lucy; Masson, Eric; Puccio-Pick, Marie; Laurent, Dirk; Steward, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4162-4171</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: PTK787/ZK 222584 (PTK/ZK) is an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor (VEGF) receptor tyrosine kinases, including VEGFR-1/Flt-1, VEGFR-2/KDR, VEGFR-3/Flt-4, the platelet-derived growth factor receptor tyrosine kinase, and the c-kit protein tyrosine kinase.  In this phase I dose-escalating study, PTK/ZK was administered bid to exploit the theor. advantage of maintaining const. drug levels above a threshold known from preclin. data to interfere with VEGF receptor signaling.  Patients and Methods: Forty-three patients with advanced cancers received single-agent PTK/ZK at doses of 150 to 1,000 mg orally bid.  Assessments for safety and pharmacokinetics were performed.  Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used as a pharmacodynamic marker of response.  Results: At 1,000 mg bid, the dose-limiting toxicity of reversible grade 3 lightheadedness was obsd.  Dose-related grade 3 fatigue and vomiting were obsd. but these were not dose-limiting.  Pharmacokinetic data confirmed that PTK/ZK exposure increased with increasing dose up to 500 mg bid and appeared to plateau at higher doses.  A greater than 40% redn. in the DCE-MRI bidirectional transfer const. (Ki) at day 2 predicted for nonprogression of disease.  Conclusion: The max.-tolerated oral dose of PTK/ZK is 750 mg orally bid.  DCE-MRI and pharmacokinetic data indicate that PTK/ZK ≥ 1,000 mg total daily dose is the biol. active dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Yk4cEJN4lLVg90H21EOLACvtfcHk0lhELlhhWMjVjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1els78%253D&md5=3fb3917babe4a29e3e3d49788cf7ded6</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.034%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DMorgan%26aufirst%3DB.%26aulast%3DHorsfield%26aufirst%3DM.%2BA.%26aulast%3DHigginson%26aufirst%3DA.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMasson%26aufirst%3DE.%26aulast%3DPuccio-Pick%26aufirst%3DM.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DSteward%26aufirst%3DW.%2BP.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520PTK787%252FZK%2520222584%2520administered%2520twice%2520daily%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D4162%26epage%3D4171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Rini, B. I.</span><span> </span><span class="NLM_article-title">Sorafenib</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1517%2F14656566.7.4.453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=16503817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=453-461&author=B.+I.+Rini&title=Sorafenib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib</span></div><div class="casAuthors">Rini, Brian I.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Sorafenib is a small mol. inhibitor of several kinases involved in tumor proliferation and tumor angiogenesis including Raf, VEGFR and platelet derived growth factor receptor.  In vivo Raf kinase inhibition has been obsd. in pharmacodynamic studies.  Sorafenib is one of several VEGF-targeting compds. with recently demonstrated substantial anti-tumor effects in metastatic renal cell carcinoma.  Delay in time to disease progression has been demonstrated in cytokine-refractory metastatic renal cell carcinoma, and further investigation is ongoing in a wide variety of tumor types.  Sorafenib is well tolerated, with common toxicities including rash, diarrhea, hand-foot skin reaction, fatigue and hypertension, when administered as the std. dose of 400 mg b.i.d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTbL_e_cFYVbVg90H21EOLACvtfcHk0lhELlhhWMjVjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVKgu78%253D&md5=07dddaf18041f4885a535485fa0dfa8a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F14656566.7.4.453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.7.4.453%26sid%3Dliteratum%253Aachs%26aulast%3DRini%26aufirst%3DB.%2BI.%26atitle%3DSorafenib%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2006%26volume%3D7%26spage%3D453%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Atkins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Sunitinib maleate</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=279-280&author=M.+Atkinsauthor=C.+A.+Jonesauthor=P.+Kirkpatrick&title=Sunitinib+maleate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAtkins%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BA.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DSunitinib%2520maleate%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D279%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwittay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottmann, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massimini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scigalla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossfeld, D. K.</span><span> </span><span class="NLM_article-title">A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">986</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=986-993&issue=3&author=W.+Fiedlerauthor=H.+Serveauthor=H.+Doehnerauthor=M.+Schwittayauthor=O.+G.+Ottmannauthor=A.+M.+O%E2%80%99Farrellauthor=C.+L.+Belloauthor=R.+Allredauthor=W.+C.+Manningauthor=J.+M.+Cherringtonauthor=S.+G.+Louieauthor=W.+Hongauthor=N.+M.+Bregaauthor=G.+Massiminiauthor=P.+Scigallaauthor=W.+E.+Berdelauthor=D.+K.+Hossfeld&title=A+phase+1+study+of+SU11248+in+the+treatment+of+patients+with+refractory+or+resistant+acute+myeloid+leukemia+%28AML%29+or+not+amenable+to+conventional+therapy+for+the+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DDoehner%26aufirst%3DH.%26aulast%3DSchwittay%26aufirst%3DM.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DAllred%26aufirst%3DR.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DBrega%26aufirst%3DN.%2BM.%26aulast%3DMassimini%26aufirst%3DG.%26aulast%3DScigalla%26aufirst%3DP.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DHossfeld%26aufirst%3DD.%2BK.%26atitle%3DA%2520phase%25201%2520study%2520of%2520SU11248%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520refractory%2520or%2520resistant%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520or%2520not%2520amenable%2520to%2520conventional%2520therapy%2520for%2520the%2520disease%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26issue%3D3%26spage%3D986%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talvenheimo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montestruque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span> </span><span class="NLM_article-title">AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8715</span><span class="NLM_x">–</span> <span class="NLM_lpage">8721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8715-8721&author=A.+Polverinoauthor=A.+Coxonauthor=C.+Starnesauthor=Z.+Diazauthor=T.+DeMelfiauthor=L.+Wangauthor=J.+Breadyauthor=J.+Estradaauthor=R.+Cattleyauthor=S.+Kaufmanauthor=D.+Chenauthor=Y.+Ganauthor=G.+Kumarauthor=J.+Meyerauthor=S.+Neervannanauthor=G.+Alvaauthor=J.+Talvenheimoauthor=S.+Montestruqueauthor=A.+Taskerauthor=V.+Patelauthor=R.+Radinskyauthor=R.+Kendall&title=AMG+706%2C+an+oral%2C+multikinase+inhibitor+that+selectively+targets+vascular+endothelial+growth+factor%2C+platelet-derived+growth+factor%2C+and+Kit+receptors%2C+potently+inhibits+angiogenesis+and+induces+regression+in+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DZ.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DCattley%26aufirst%3DR.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DGan%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DAlva%26aufirst%3DG.%26aulast%3DTalvenheimo%26aufirst%3DJ.%26aulast%3DMontestruque%26aufirst%3DS.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26atitle%3DAMG%2520706%252C%2520an%2520oral%252C%2520multikinase%2520inhibitor%2520that%2520selectively%2520targets%2520vascular%2520endothelial%2520growth%2520factor%252C%2520platelet-derived%2520growth%2520factor%252C%2520and%2520Kit%2520receptors%252C%2520potently%2520inhibits%2520angiogenesis%2520and%2520induces%2520regression%2520in%2520tumor%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8715%26epage%3D8721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span> <span class="citation_source-book">Daylight</span>, version <span class="NLM_edition">4.41</span>; <span class="NLM_publisher-name">Daylight Chemical Information Systems, Inc.</span>: <span class="NLM_publisher-loc">Irvine, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">1995</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Daylight%2C+version+4.41%3B+Daylight+Chemical+Information+Systems%2C+Inc.%3A+Irvine%2C+CA%2C+1995."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DDaylight%26pub%3DDaylight%2520Chemical%2520Information%2520Systems%252C%2520Inc%26date%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPietro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, R.</span><span> </span><span class="NLM_article-title">Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1667</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701097z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1649-1667&author=J.-C.+Harmangeauthor=M.+M.+Weissauthor=J.+Germainauthor=A.+J.+Polverinoauthor=G.+Borgauthor=J.+Breadyauthor=D.+Chenauthor=D.+Choquetteauthor=A.+Coxonauthor=T.+DeMelfiauthor=L.+DiPietroauthor=N.+Doerrauthor=J.+Estradaauthor=J.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=S.+Kaufmanauthor=D.+S.+Laauthor=A.+Longauthor=M.+W.+Martinauthor=S.+Neervannanauthor=V.+F.+Patelauthor=M.+Potashmanauthor=K.+Regalauthor=P.+M.+Rovetoauthor=M.+L.+Schragauthor=C.+Starnesauthor=A.+Taskerauthor=Y.+Tefferaauthor=L.+Wangauthor=R.+D.+Whiteauthor=D.+Whittingtonauthor=R.+Zanon&title=Naphthamides+as+novel+and+potent+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitors%3A+design%2C+synthesis%2C+and+evaluation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation</span></div><div class="casAuthors">Harmange, Jean-Christophe; Weiss, Matthew M.; Germain, Julie; Polverino, Anthony J.; Borg, George; Bready, James; Chen, Danlin; Choquette, Deborah; Coxon, Angela; DeMelfi, Tom; DiPietro, Lucian; Doerr, Nicholas; Estrada, Juan; Flynn, Julie; Graceffa, Russell F.; Harriman, Shawn P.; Kaufman, Stephen; La, Daniel S.; Long, Alexander; Martin, Matthew W.; Neervannan, Sesha; Patel, Vinod F.; Potashman, Michele; Regal, Kelly; Roveto, Phillip M.; Schrag, Michael L.; Starnes, Charlie; Tasker, Andrew; Teffera, Yohannes; Wang, Ling; White, Ryan D.; Whittington, Douglas A.; Zanon, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1649-1667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of naphthyl-based compds. were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors.  Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family.  Numerous analogs demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compds. possessed favorable pharmacokinetic (PK) profiles.  In particular, compd. I demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice.  A full account of the prepn., structure-activity relationships, pharmacokinetic properties, and pharmacol. of analogs within this series is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1vrmtgp3_m7Vg90H21EOLACvtfcHk0ljkxOEJ7ZfSKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D&md5=25685f28450b2ab132ffd278e6c53598</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm701097z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701097z%26sid%3Dliteratum%253Aachs%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DBorg%26aufirst%3DG.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDiPietro%26aufirst%3DL.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLong%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DSchrag%26aufirst%3DM.%2BL.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DZanon%26aufirst%3DR.%26atitle%3DNaphthamides%2520as%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1649%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Mitotic kinases as regulators of cell division and its checkpoints</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1038%2F35048096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=11413462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=21-32&author=E.+A.+Nigg&title=Mitotic+kinases+as+regulators+of+cell+division+and+its+checkpoints"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic kinases as regulators of cell division and its checkpoints</span></div><div class="casAuthors">Nigg, Erich A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-32</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 115 refs.  Mitosis and cytokinesis are undoubtedly the most spectacular parts of the cell cycle.  Errors in the choreog. of these processes can lead to aneuploidy or genetic instability, fostering cell death or disease.  Here, I give an overview of the many mitotic kinases that regulate cell division and the fidelity of chromosome transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj12LIFIQmjrVg90H21EOLACvtfcHk0ljkxOEJ7ZfSKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWms7o%253D&md5=b9eaea70872a755eb7c8c335c1919e84</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2F35048096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35048096%26sid%3Dliteratum%253Aachs%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DMitotic%2520kinases%2520as%2520regulators%2520of%2520cell%2520division%2520and%2520its%2520checkpoints%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D21%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Palacios, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, A.</span><span> </span><span class="NLM_article-title">Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">7990</span><span class="NLM_x">–</span> <span class="NLM_lpage">8000</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1038%2Fsj.onc.1208074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=15489916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosFyltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=7990-8000&author=E.+H.+Palaciosauthor=A.+Weiss&title=Function+of+the+Src-family+kinases%2C+Lck+and+Fyn%2C+in+T-cell+development+and+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation</span></div><div class="casAuthors">Palacios, Emil H.; Weiss, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">7990-8000</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The function of the Src-family kinases (SFKs) Lck and Fyn in T cells has been intensively studied over the past 15 yr.  Animal models and cell line studies both indicate a crit. role for Lck and Fyn in proximal T-cell antigen receptor (TCR) signal transduction.  Recruited SFKs phosphorylate TCR ITAMs (immunoreceptor tyrosine-based activation motifs) in the CD3 and ζ chains, which then serve as docking sites for Syk-family kinases.  SFKs then phosphorylate and activate the recruited Syk-family kinase.  Lck and Fyn are spatially segregated in cell membranes due to differential lipid raft localization, and may undergo sequential activation.  In addn. to the CD4 and CD8 coreceptors, a recently described adaptor, Unc119, may link SFKs to the TCR.  CD45 and Csk provide pos. and neg. regulatory control of SFK functions, resp., and Csk is constitutively bound to the transmembrane adapter protein, PAG/Cbp.  TCR-based signaling is required at several stages of T-cell development, including at least pre-TCR signaling, pos. selection, peripheral maintenance of naive T cells, and lymphopenia-induced proliferation.  SFKs are required for each of these TCR-based signals, and Lck seems to be the major contributor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC2s7PGSwBibVg90H21EOLACvtfcHk0lhuH5WEmj8IQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosFyltb8%253D&md5=d9d1f2697ef4008ee8c8426ac806bd11</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208074%26sid%3Dliteratum%253Aachs%26aulast%3DPalacios%26aufirst%3DE.%2BH.%26aulast%3DWeiss%26aufirst%3DA.%26atitle%3DFunction%2520of%2520the%2520Src-family%2520kinases%252C%2520Lck%2520and%2520Fyn%252C%2520in%2520T-cell%2520development%2520and%2520activation%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D7990%26epage%3D8000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">He, M.; Kania, R. S.; Lou, J.; Zhou, R.</span><span> </span><span class="NLM_article-title">Preparation of Naphthalenecarboxamides and Their Derivatives as New Antiangiogenic Agents</span>. WO 2005/021553 A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+He&author=R.+S.+Kania&author=J.+Lou&author=R.+Zhou&title=Preparation+of+Naphthalenecarboxamides+and+Their+Derivatives+as+New+Antiangiogenic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Naphthalenecarboxamides%2520and%2520Their%2520Derivatives%2520as%2520New%2520Antiangiogenic%2520Agents%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Potashman, M.; Kim, T.; Bellon, S.; Booker, S.; Cheng, Y.; Kim, J. L.; Tasker, A.; Xi, N.; Xu, S.; Harmange, J.-C.; Borg, G.; Weiss, M.; Hodous, B. L.; Graceffa, R.; Buckner, W. H.; Masse, C. E.; Choquette, D.; Martin, M. W.; Germain, J.; Dipietro, L. V.; Chaffee, S. C.; Nunes, J. J.; Buchanan, J. L.; Habgood, G. J.; McGowan, D. C.; Whittington, D. A.</span><span> </span><span class="NLM_article-title">Preparation of Heteroaryl Substituted Naphthalenes as Inhibitors of Lck, VEGFR and/or HGF Related Activity</span>. WO 2005/070891 A2,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Potashman&author=T.+Kim&author=S.+Bellon&author=S.+Booker&author=Y.+Cheng&author=J.+L.+Kim&author=A.+Tasker&author=N.+Xi&author=S.+Xu&author=J.-C.+Harmange&author=G.+Borg&author=M.+Weiss&author=B.+L.+Hodous&author=R.+Graceffa&author=W.+H.+Buckner&author=C.+E.+Masse&author=D.+Choquette&author=M.+W.+Martin&author=J.+Germain&author=L.+V.+Dipietro&author=S.+C.+Chaffee&author=J.+J.+Nunes&author=J.+L.+Buchanan&author=G.+J.+Habgood&author=D.+C.+McGowan&author=D.+A.+Whittington&title=Preparation+of+Heteroaryl+Substituted+Naphthalenes+as+Inhibitors+of+Lck%2C+VEGFR+and%2For+HGF+Related+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Heteroaryl%2520Substituted%2520Naphthalenes%2520as%2520Inhibitors%2520of%2520Lck%252C%2520VEGFR%2520and%252For%2520HGF%2520Related%2520Activity%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">De, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogstad, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogstad, D. J.</span><span> </span><span class="NLM_article-title">Structure−activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">4918</span><span class="NLM_x">–</span> <span class="NLM_lpage">4926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980146x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4918-4926&author=D.+Deauthor=F.+M.+Krogstadauthor=L.+D.+Byersauthor=D.+J.+Krogstad&title=Structure%E2%88%92activity+relationships+for+antiplasmodial+activity+among+7-substituted+4-aminoquinolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm980146x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980146x%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DD.%26aulast%3DKrogstad%26aufirst%3DF.%2BM.%26aulast%3DByers%26aufirst%3DL.%2BD.%26aulast%3DKrogstad%26aufirst%3DD.%2BJ.%26atitle%3DStructure%25E2%2588%2592activity%2520relationships%2520for%2520antiplasmodial%2520activity%2520among%25207-substituted%25204-aminoquinolines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4918%26epage%3D4926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lindley, J.</span><span> </span><span class="NLM_article-title">Copper assisted nucleophilic substitution of aryl halogen</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1984&pages=1433-1456&author=J.+Lindley&title=Copper+assisted+nucleophilic+substitution+of+aryl+halogen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindley%26aufirst%3DJ.%26atitle%3DCopper%2520assisted%2520nucleophilic%2520substitution%2520of%2520aryl%2520halogen%26jtitle%3DTetrahedron%26date%3D1984%26volume%3D40%26spage%3D1433%26epage%3D1456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Nomoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teranishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span> </span><span class="NLM_article-title">Studies on cardiotonic agents. I. Synthesis of some quinazoline derivatives</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1990&pages=1591-1595&author=Y.+Nomotoauthor=H.+Obaseauthor=H.+Takaiauthor=T.+Hirataauthor=M.+Teranishiauthor=J.+Nakamuraauthor=K.+Kubo&title=Studies+on+cardiotonic+agents.+I.+Synthesis+of+some+quinazoline+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNomoto%26aufirst%3DY.%26aulast%3DObase%26aufirst%3DH.%26aulast%3DTakai%26aufirst%3DH.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DTeranishi%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKubo%26aufirst%3DK.%26atitle%3DStudies%2520on%2520cardiotonic%2520agents.%2520I.%2520Synthesis%2520of%2520some%2520quinazoline%2520derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1990%26volume%3D38%26spage%3D1591%26epage%3D1595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheetham, J.</span><span> </span><span class="NLM_article-title">An automated screening assay for determination of aqueous equilibrium solubility enabling SPR study during drug lead optimization</span> <span class="citation_source-journal">J. Assoc. Lab. Autom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1016%2Fj.jala.2005.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsFygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=364-373&issue=6&author=H.+Tanauthor=D.+Seminauthor=M.+Wackerauthor=J.+Cheetham&title=An+automated+screening+assay+for+determination+of+aqueous+equilibrium+solubility+enabling+SPR+study+during+drug+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An automated screening assay for determination of aqueous equilibrium solubility enabling SPR study during drug lead optimization</span></div><div class="casAuthors">Tan, Helming; Semin, David; Wacker, Maggie; Cheetham, Janet</div><div class="citationInfo"><span class="NLM_cas:title">JALA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">364-373</span>CODEN:
                <span class="NLM_cas:coden">JALLFO</span>;
        ISSN:<span class="NLM_cas:issn">1535-5535</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Aq. soly. is one of the most crit. physicochem. properties to be detd. in the process of drug lead optimization.  Particularly, an equil. soly. method is highly valuable to the study of structure property relationship (SPR), while meeting the needs of anal. sensitivity, reproducibility, and throughput.  In this report, an automated soly. assay in a 96-well library format was designed and developed by means of robotic liq. handling, centrifugal sepn., and HPLC-UV quantification.  Requiring 1 mg of solid compd., this assay was used to det. the equil. soly. in three user-selected media, i.e., 0.01 N HCl, phosphate buffer saline (PBS), and fasted state simulated intestinal fluid (SIF), with a throughput of up to 192 compds. a week.  The assay parameters, including the equilibration time and the sepn. technique, were optimized to ensure that the thermodn. soly. was measured at the presence of excess solid compd.  A fast gradient HPLC method was developed with single-point on-plate calibration for each compd., followed by a customized 96-well chromatog. data anal.  The reporting soly. range was 1-200 μg/mL, appropriate for oral drug candidate selection at the stage of discovery lead optimization.  Based on the test results obtained on the com. available drugs and Amgen research compds., this assay was considered to be equiv. to the conventional shake-flask methods.  Examples were given to demonstrate that the thermodn. soly. detd. by this assay enabled the SPR study to support drug lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXZS8kMVkXPrVg90H21EOLACvtfcHk0lgPJVeA-1Qe2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsFygsw%253D%253D&md5=0084938410823379c2bf44ae09e33f19</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jala.2005.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jala.2005.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DH.%26aulast%3DSemin%26aufirst%3DD.%26aulast%3DWacker%26aufirst%3DM.%26aulast%3DCheetham%26aufirst%3DJ.%26atitle%3DAn%2520automated%2520screening%2520assay%2520for%2520determination%2520of%2520aqueous%2520equilibrium%2520solubility%2520enabling%2520SPR%2520study%2520during%2520drug%2520lead%2520optimization%26jtitle%3DJ.%2520Assoc.%2520Lab.%2520Autom.%26date%3D2005%26volume%3D10%26issue%3D6%26spage%3D364%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanzlik, R. P.</span><span> </span><span class="NLM_article-title">Enzymatic N-dealkylation of an <i>N</i>-cyclopropylamine: an unusual fate for the cyclopropyl group</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja003048l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2001&pages=349-350&author=C.+L.+Shafferauthor=M.+D.+Mortonauthor=R.+P.+Hanzlik&title=Enzymatic+N-dealkylation+of+an+N-cyclopropylamine%3A+an+unusual+fate+for+the+cyclopropyl+group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fja003048l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja003048l%26sid%3Dliteratum%253Aachs%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DMorton%26aufirst%3DM.%2BD.%26aulast%3DHanzlik%26aufirst%3DR.%2BP.%26atitle%3DEnzymatic%2520N-dealkylation%2520of%2520an%2520N-cyclopropylamine%253A%2520an%2520unusual%2520fate%2520for%2520the%2520cyclopropyl%2520group%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2001%26volume%3D123%26spage%3D349%26epage%3D350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic functional groups</span> <span class="citation_source-journal">Curr. Drug. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+functional+groups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lgq4Q_w5SoEyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520functional%2520groups%26jtitle%3DCurr.%2520Drug.%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Evans, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Drug−protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug%E2%88%92protein+adducts%3A+an+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug%25E2%2588%2592protein%2520adducts%253A%2520an%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><div class="note"><p class="first last">Radiolabeled compounds were prepared wherein the carbon of amide carbonyl was labeled with <sup>14</sup>C.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Radiolabeled+compounds+were+prepared+wherein+the+carbon+of+amide+carbonyl+was+labeled+with+14C."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0lgq4Q_w5SoEyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Miles, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, E. M.</span><span> </span><span class="NLM_article-title">Vascular reactions to histamine, histamine-liberator,and leukotaxine in the skin of guinea pigs</span> <span class="citation_source-journal">J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1952</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=13000707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADyaG3sXmvVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1952&pages=228-257&author=A.+A.+Milesauthor=E.+M.+Miles&title=Vascular+reactions+to+histamine%2C+histamine-liberator%2Cand+leukotaxine+in+the+skin+of+guinea+pigs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular reactions to histamine, histamine-liberator, and leucotaxine in the skin of guinea pigs</span></div><div class="casAuthors">Miles, A. A.; Miles, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">1952</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-57</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">Capillary permeability increase in the depilated skin of the trunk and ear of albino guinea pigs was measured by estg. the size and intensity of the blue lesion induced in animals with Pontamine Sky Blue 6X in their circulation, by intradermal injection of hisamine (I), histamine-liberator 48/80 (a condensation product of p-methoxyphenethylmethylamine and HCHO (cf. Baltzly, et al., C.A. 43, 6593h)) (II), and leucotaxine (III).  In the dorsal trunk skin, the mean diams. of lesions from graded doses of I, II, and III in a const. vol., or for a const. dose in graded injection vols., were proportional to the log vol.  Both II and III were more strongly adsorbed by the skin than I as measured by a derived assay method employing const. dose measurements for estg. skin tissue affinity for I, II, and III; thus I spread readily to subcutaneous tissues and lymphatic channels.  I, II, and III all increased capillary permeability beginning 3-5 min. and ending 30 min. following injection.  The following antagonized I bluing: ether, chloroform, chloralose, bromethol, and Na pentobarbital anesthesia; cooling to 10°; shocking doses of Proteus vulgaris and Bacterium coli endotoxins; adenosine triphosphate, insulin, or intraperitoneal hypertonic glucose; and circulating (intravenous) neoantergan (mepyramine maleate) (IV).  These antagonistic effects appeared to be through a decrease in local intravascular pressures, except for direct antagonism by IV to I, II, and III.  High local concns. of I inhibited bluing, through local vasoconstriction during the period of increased permeability; high local concns. of II inhibited bluing by thrombosing the blood vessels.  I, II, and III injections induced considerable cross-immunity to one another, presumably owing to I release by II and III, causing immunization of the blood vessels, or exhaustion of I, or inhibition of the I-release mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIE5ggOAHowLVg90H21EOLACvtfcHk0lgq4Q_w5SoEyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG3sXmvVejug%253D%253D&md5=c2f5f333cec9f155ad4aa9b0666ebb78</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiles%26aufirst%3DA.%2BA.%26aulast%3DMiles%26aufirst%3DE.%2BM.%26atitle%3DVascular%2520reactions%2520to%2520histamine%252C%2520histamine-liberator%252Cand%2520leukotaxine%2520in%2520the%2520skin%2520of%2520guinea%2520pigs%26jtitle%3DJ.%2520Physiol.%26date%3D1952%26volume%3D118%26spage%3D228%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scully, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duryea, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feige, U.</span><span> </span><span class="NLM_article-title">Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2604</span><span class="NLM_x">–</span> <span class="NLM_lpage">2612</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1002%2Fart.10546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=12384918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVWitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=2604-2612&author=A.+Coxonauthor=B.+Bolonauthor=J.+Estradaauthor=S.+Kaufmanauthor=S.+Scullyauthor=A.+Rattanauthor=D.+Duryeaauthor=Y.+L.+Huauthor=K.+Rexauthor=E.+Pachecoauthor=G.+Vanauthor=D.+Zackauthor=U.+Feige&title=Inhibition+of+interleukin-1+but+not+tumor+necrosis+factor+suppresses+neovascularization+in+rat+models+of+corneal+angiogenesis+and+adjuvant+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis</span></div><div class="casAuthors">Coxon, Angela; Bolon, Brad; Estrada, Juan; Kaufman, Stephen; Scully, Sheila; Rattan, Alana; Duryea, Diane; Hu, Yi-Ling; Rex, Karen; Pacheco, Efrain; Van, Gwyneth; Zack, Debra; Feige, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2604-2612</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To assess the capacities of the cytokine inhibitors interleukin-1 receptor antagonist (IL-1Ra; anakinra) and PEGylated sol. tumor necrosis factor receptor I (PEG sTNFRI; pegsunercept) to suppress neovascularization.  Methods: A corneal angiogenesis assay was performed by implanting nylon disks impregnated with an angiogenic stimulator (basic fibroblast growth factor or vascular endothelial growth factor) into one cornea of female Sprague-Dawley rats.  Animals were treated with IL-1Ra or PEG sTNFRI for 7 days, after which new vessels were quantified.  In a parallel study, male Lewis rats with mycobacteria-induced adjuvant-induced arthritis were treated with IL-1Ra or PEG sTNFRI for 7 days beginning at disease onset, after which scores for inflammation and bone erosion as well as capillary counts were acquired from sections of arthritic hind paws.  Results: Treatment with IL-1Ra yielded a dose-dependent redn. in growth factor-induced corneal angiogenesis, while PEG sTNFRI did not.  IL-1Ra, but not PEG sTNFRI, significantly reduced the no. of capillaries in arthritic paws, even though both anticytokines reduced inflammation and bone erosion to a similar degree.  Conclusion: These data support a major role for IL-1, but not TNFα, in angiogenesis and suggest that an addnl. antiarthritic mechanism afforded by IL-1 inhibitors, but not anti-TNF agents, is the suppression of the angiogenic component of pannus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbU43QxFbpkLVg90H21EOLACvtfcHk0lgrypYFm8E1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVWitrs%253D&md5=eb8cb76d17205401e1b0e12b1cbc7625</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fart.10546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.10546%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBolon%26aufirst%3DB.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DScully%26aufirst%3DS.%26aulast%3DRattan%26aufirst%3DA.%26aulast%3DDuryea%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DY.%2BL.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DPacheco%26aufirst%3DE.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DZack%26aufirst%3DD.%26aulast%3DFeige%26aufirst%3DU.%26atitle%3DInhibition%2520of%2520interleukin-1%2520but%2520not%2520tumor%2520necrosis%2520factor%2520suppresses%2520neovascularization%2520in%2520rat%2520models%2520of%2520corneal%2520angiogenesis%2520and%2520adjuvant%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2002%26volume%3D46%26spage%3D2604%26epage%3D2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c','cit12d','cit12e','cit12f','cit12g'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 26 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oscar P. J.  van Linden</span>, <span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">Iwan J. P.  de Esch</span>, and <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>  . </span><span class="cited-content_cbyCitation_article-title">KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (2)
                                     , 249-277. <a href="https://doi.org/10.1021/jm400378w" title="DOI URL">https://doi.org/10.1021/jm400378w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400378w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400378w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKLIFS%25253A%252BA%252BKnowledge-Based%252BStructural%252BDatabase%252BTo%252BNavigate%252BKinase%2525E2%252580%252593Ligand%252BInteraction%252BSpace%26aulast%3Dvan%2BLinden%26aufirst%3DOscar%2BP.%2BJ.%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D14032013%26date%3D20092013%26date%3D23012014%26date%3D13082013%26volume%3D57%26issue%3D2%26spage%3D249%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Marco  Radi</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, and <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>  . </span><span class="cited-content_cbyCitation_article-title">Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (24)
                                     , 10797-10822. <a href="https://doi.org/10.1021/jm301085w" title="DOI URL">https://doi.org/10.1021/jm301085w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301085w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301085w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DVascular%252BEndothelial%252BGrowth%252BFactor%252B%252528VEGF%252529%252BReceptors%25253A%252BDrugs%252Band%252BNew%252BInhibitors%26aulast%3DMusumeci%26aufirst%3DFrancesca%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D25072012%26date%3D06112012%26date%3D27122012%26date%3D25102012%26volume%3D55%26issue%3D24%26spage%3D10797%26epage%3D10822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Norman</span>, <span class="hlFld-ContribAuthor ">Anne-Kathrin  Schott</span>, <span class="hlFld-ContribAuthor ">David M.  Andrews</span>, <span class="hlFld-ContribAuthor ">Jason  Breed</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Foote</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Garner</span>, <span class="hlFld-ContribAuthor ">Derek  Ogg</span>, <span class="hlFld-ContribAuthor ">Jonathon P.  Orme</span>, <span class="hlFld-ContribAuthor ">Jennifer H.  Pink</span>, <span class="hlFld-ContribAuthor ">Karen  Roberts</span>, <span class="hlFld-ContribAuthor ">David A.  Rudge</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Thomas</span>, and <span class="hlFld-ContribAuthor ">Andrew G.  Leach</span>  . </span><span class="cited-content_cbyCitation_article-title">Protein–Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (11)
                                     , 5003-5012. <a href="https://doi.org/10.1021/jm3004043" title="DOI URL">https://doi.org/10.1021/jm3004043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm3004043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm3004043%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProtein%2525E2%252580%252593Ligand%252BCrystal%252BStructures%252BCan%252BGuide%252Bthe%252BDesign%252Bof%252BSelective%252BInhibitors%252Bof%252Bthe%252BFGFR%252BTyrosine%252BKinase%26aulast%3DNorman%26aufirst%3DRichard%2BA.%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D15112011%26date%3D21052012%26date%3D14062012%26volume%3D55%26issue%3D11%26spage%3D5003%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabio  Zuccotto</span>, <span class="hlFld-ContribAuthor ">Elena  Ardini</span>, <span class="hlFld-ContribAuthor ">Elena  Casale</span> and <span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>  . </span><span class="cited-content_cbyCitation_article-title">Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (7)
                                     , 2681-2694. <a href="https://doi.org/10.1021/jm901443h" title="DOI URL">https://doi.org/10.1021/jm901443h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901443h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThrough%252Bthe%252B%2525E2%252580%25259CGatekeeper%252BDoor%2525E2%252580%25259D%25253A%252BExploiting%252Bthe%252BActive%252BKinase%252BConformation%26aulast%3DZuccotto%26aufirst%3DFabio%26date%3D2010%26date%3D2009%26date%3D2009%26date%3D29092009%26date%3D14122009%26date%3D08042010%26volume%3D53%26issue%3D7%26spage%3D2681%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yohannes  Teffera</span>, <span class="hlFld-ContribAuthor ">Adria E.  Colletti</span>, <span class="hlFld-ContribAuthor ">Jean Christophe  Harmange</span>, <span class="hlFld-ContribAuthor ">L. Steven  Hollis</span>, <span class="hlFld-ContribAuthor ">Brian K.  Albrecht</span>, <span class="hlFld-ContribAuthor ">Alessandro A.  Boezio</span>, <span class="hlFld-ContribAuthor ">Jingzhou  Liu</span> and <span class="hlFld-ContribAuthor ">Zhiyang  Zhao</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemical Reactivity of Methoxy 4-O-Aryl Quinolines: Identification of Glutathione Displacement Products in Vitro and in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2008,</strong> <em>21 </em>
                                    (11)
                                     , 2216-2222. <a href="https://doi.org/10.1021/tx800307n" title="DOI URL">https://doi.org/10.1021/tx800307n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/tx800307n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Ftx800307n%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DChemical%252BReactivity%252Bof%252BMethoxy%252B4-O-Aryl%252BQuinolines%25253A%252BIdentification%252Bof%252BGlutathione%252BDisplacement%252BProducts%252Bin%252BVitro%252Band%252Bin%252BVivo%26aulast%3DTeffera%26aufirst%3DYohannes%26date%3D2008%26date%3D2008%26date%3D2008%26date%3D17%252011%25202008%26date%3D07%252010%25202008%26date%3D12%252008%25202008%26volume%3D21%26issue%3D11%26spage%3D2216%26epage%3D2222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Christophe  Harmange</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Weiss</span>, <span class="hlFld-ContribAuthor ">Julie  Germain</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Polverino</span>, <span class="hlFld-ContribAuthor ">George  Borg</span>, <span class="hlFld-ContribAuthor ">James  Bready</span>, <span class="hlFld-ContribAuthor ">Danlin  Chen</span>, <span class="hlFld-ContribAuthor ">Deborah  Choquette</span>, <span class="hlFld-ContribAuthor ">Angela  Coxon</span>, <span class="hlFld-ContribAuthor ">Tom  DeMelfi</span>, <span class="hlFld-ContribAuthor ">Lucian  DiPietro</span>, <span class="hlFld-ContribAuthor ">Nicholas  Doerr</span>, <span class="hlFld-ContribAuthor ">Juan  Estrada</span>, <span class="hlFld-ContribAuthor ">Julie  Flynn</span>, <span class="hlFld-ContribAuthor ">Russell F.  Graceffa</span>, <span class="hlFld-ContribAuthor ">Shawn P.  Harriman</span>, <span class="hlFld-ContribAuthor ">Stephen  Kaufman</span>, <span class="hlFld-ContribAuthor ">Daniel S.  La</span>, <span class="hlFld-ContribAuthor ">Alexander  Long</span>, <span class="hlFld-ContribAuthor ">Matthew W.  Martin</span>, <span class="hlFld-ContribAuthor ">Sesha  Neervannan</span>, <span class="hlFld-ContribAuthor ">Vinod F.  Patel</span>, <span class="hlFld-ContribAuthor ">Michele  Potashman</span>, <span class="hlFld-ContribAuthor ">Kelly  Regal</span>, <span class="hlFld-ContribAuthor ">Phillip M.  Roveto</span>, <span class="hlFld-ContribAuthor ">Michael L.  Schrag</span>, <span class="hlFld-ContribAuthor ">Charlie  Starnes</span>, <span class="hlFld-ContribAuthor ">Andrew  Tasker</span>, <span class="hlFld-ContribAuthor ">Yohannes  Teffera</span>, <span class="hlFld-ContribAuthor ">Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Ryan D.  White</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Whittington</span> and <span class="hlFld-ContribAuthor ">Roger  Zanon</span>. </span><span class="cited-content_cbyCitation_article-title">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2008,</strong> <em>51 </em>
                                    (6)
                                     , 1649-1667. <a href="https://doi.org/10.1021/jm701097z" title="DOI URL">https://doi.org/10.1021/jm701097z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm701097z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm701097z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNaphthamides%252Bas%252BNovel%252Band%252BPotent%252BVascular%252BEndothelial%252BGrowth%252BFactor%252BReceptor%252BTyrosine%252BKinase%252BInhibitors%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%26aulast%3DHarmange%26aufirst%3DJean-Christophe%26date%3D2008%26date%3D2008%26date%3D2007%26date%3D27%252003%25202008%26date%3D07%252003%25202008%26date%3D04%252009%25202007%26volume%3D51%26issue%3D6%26spage%3D1649%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Yang</span>, <span class="hlFld-ContribAuthor ">Yi-Xin  Jiang</span>, <span class="hlFld-ContribAuthor ">Ye  Wu</span>, <span class="hlFld-ContribAuthor ">Dong  Lu</span>, <span class="hlFld-ContribAuthor ">Rui  Huang</span>, <span class="hlFld-ContribAuthor ">Long-Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Shi-Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Ying-Yun  Guan</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Luan</span>. </span><span class="cited-content_cbyCitation_article-title">Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.682735" title="DOI URL">https://doi.org/10.3389/fphar.2021.682735</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.682735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.682735%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DResibufogenin%252BSuppresses%252BTriple-Negative%252BBreast%252BCancer%252BAngiogenesis%252Bby%252BBlocking%252BVEGFR2-Mediated%252BSignaling%252BPathway%26aulast%3DYang%26aufirst%3DTing%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 257-274. <a href="https://doi.org/10.1002/9781118696194.ch2.5" title="DOI URL">https://doi.org/10.1002/9781118696194.ch2.5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118696194.ch2.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118696194.ch2.5%26sid%3Dliteratum%253Aachs%26atitle%3DKinase%252BInhibitors%26date%3D2017%26date%3D2017%26spage%3D257%26epage%3D274%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DAnticancer%252BTherapeutics%26aulast%3DTodd%26aufirst%3DAdam%26date%3D2018%26volume%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Murat  Bingul</span>, <span class="hlFld-ContribAuthor ">Owen  Tan</span>, <span class="hlFld-ContribAuthor ">Christopher  Gardner</span>, <span class="hlFld-ContribAuthor ">Selina  Sutton</span>, <span class="hlFld-ContribAuthor ">Greg  Arndt</span>, <span class="hlFld-ContribAuthor ">Glenn  Marshall</span>, <span class="hlFld-ContribAuthor ">Belamy  Cheung</span>, <span class="hlFld-ContribAuthor ">Naresh  Kumar</span>, <span class="hlFld-ContribAuthor ">David  Black</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Characterization and Anti-Cancer Activity of Hydrazide Derivatives Incorporating a Quinoline Moiety. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (7)
                                     , 916. <a href="https://doi.org/10.3390/molecules21070916" title="DOI URL">https://doi.org/10.3390/molecules21070916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21070916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21070916%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%25252C%252BCharacterization%252Band%252BAnti-Cancer%252BActivity%252Bof%252BHydrazide%252BDerivatives%252BIncorporating%252Ba%252BQuinoline%252BMoiety%26aulast%3DBingul%26aufirst%3DMurat%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D7%26spage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Mao  Shu</span>, <span class="hlFld-ContribAuthor ">Xiaorong  Wen</span>, <span class="hlFld-ContribAuthor ">Yuanliang  Wang</span>, <span class="hlFld-ContribAuthor ">Yuanqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Hu</span>, <span class="hlFld-ContribAuthor ">Zhihua  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of vascular endothelial growth factor receptor tyrosine kinase inhibitors by quantitative structure–activity relationships, molecular dynamics simulation and free energy calculation. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (42)
                                     , 35402-35415. <a href="https://doi.org/10.1039/C6RA03743G" title="DOI URL">https://doi.org/10.1039/C6RA03743G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA03743G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA03743G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscovery%252Bof%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Bby%252Bquantitative%252Bstructure%2525E2%252580%252593activity%252Brelationships%25252C%252Bmolecular%252Bdynamics%252Bsimulation%252Band%252Bfree%252Benergy%252Bcalculation%26aulast%3DWang%26aufirst%3DJuan%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D42%26spage%3D35402%26epage%3D35415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Obaid  Afzal</span>, <span class="hlFld-ContribAuthor ">Suresh  Kumar</span>, <span class="hlFld-ContribAuthor ">Md Rafi  Haider</span>, <span class="hlFld-ContribAuthor ">Md Rahmat  Ali</span>, <span class="hlFld-ContribAuthor ">Rajiv  Kumar</span>, <span class="hlFld-ContribAuthor ">Manu  Jaggi</span>, <span class="hlFld-ContribAuthor ">Sandhya  Bawa</span>. </span><span class="cited-content_cbyCitation_article-title">A review on anticancer potential of bioactive heterocycle quinoline. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>97 </em>, 871-910. <a href="https://doi.org/10.1016/j.ejmech.2014.07.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Banticancer%252Bpotential%252Bof%252Bbioactive%252Bheterocycle%252Bquinoline%26aulast%3DAfzal%26aufirst%3DObaid%26date%3D2015%26volume%3D97%26spage%3D871%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">XiaoYun  Wu</span>, <span class="hlFld-ContribAuthor ">ShanHe  Wan</span>, <span class="hlFld-ContribAuthor ">GuangFa  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Jin</span>, <span class="hlFld-ContribAuthor ">ZhongHuang  Li</span>, <span class="hlFld-ContribAuthor ">YuanXin  Tian</span>, <span class="hlFld-ContribAuthor ">ZhengGuang  Zhu</span>, <span class="hlFld-ContribAuthor ">JiaJie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2015,</strong> <em>56 </em>, 103-112. <a href="https://doi.org/10.1016/j.jmgm.2014.12.006" title="DOI URL">https://doi.org/10.1016/j.jmgm.2014.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2014.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2014.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DMolecular%252Bdynamics%252Bsimulation%252Band%252Bfree%252Benergy%252Bcalculation%252Bstudies%252Bof%252Bkinase%252Binhibitors%252Bbinding%252Bto%252Bactive%252Band%252Binactive%252Bconformations%252Bof%252BVEGFR-2%26aulast%3DWu%26aufirst%3DXiaoYun%26date%3D2015%26volume%3D56%26spage%3D103%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Audrey  Branch</span>, <span class="hlFld-ContribAuthor ">Anastasia  Bobilev</span>, <span class="hlFld-ContribAuthor ">Nuria Waddington  Negrao</span>, <span class="hlFld-ContribAuthor ">Haini  Cai</span>, <span class="hlFld-ContribAuthor ">Ping  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Prevention of palatable diet-induced hyperphagia in rats by central injection of a VEGFR kinase inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Behavioural Brain Research</span><span> <strong>2015,</strong> <em>278 </em>, 506-513. <a href="https://doi.org/10.1016/j.bbr.2014.10.004" title="DOI URL">https://doi.org/10.1016/j.bbr.2014.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbr.2014.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbr.2014.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBehavioural%2520Brain%2520Research%26atitle%3DPrevention%252Bof%252Bpalatable%252Bdiet-induced%252Bhyperphagia%252Bin%252Brats%252Bby%252Bcentral%252Binjection%252Bof%252Ba%252BVEGFR%252Bkinase%252Binhibitor%26aulast%3DBranch%26aufirst%3DAudrey%26date%3D2015%26volume%3D278%26spage%3D506%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kingkan  Sanphanya</span>, <span class="hlFld-ContribAuthor ">Suvara K.  Wattanapitayakul</span>, <span class="hlFld-ContribAuthor ">Suwadee  Phowichit</span>, <span class="hlFld-ContribAuthor ">Valery V.  Fokin</span>, <span class="hlFld-ContribAuthor ">Opa  Vajragupta</span>. </span><span class="cited-content_cbyCitation_article-title">Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (10)
                                     , 2962-2967. <a href="https://doi.org/10.1016/j.bmcl.2013.03.042" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.03.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.03.042%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252BVEGFR-2%252Bkinase%252Binhibitors%252Bidentified%252Bby%252Bthe%252Bback-to-front%252Bapproach%26aulast%3DSanphanya%26aufirst%3DKingkan%26date%3D2013%26volume%3D23%26issue%3D10%26spage%3D2962%26epage%3D2967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David C.  Evans</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Drug-Protein Adducts: An Exploration of Their Role in Drug-Induced Liver and General Organ Toxicity. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,<a href="https://doi.org/10.1002/9780470921920.edm075" title="DOI URL">https://doi.org/10.1002/9780470921920.edm075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9780470921920.edm075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9780470921920.edm075%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BDrug-Protein%252BAdducts%25253A%252BAn%252BExploration%252Bof%252BTheir%252BRole%252Bin%252BDrug-Induced%252BLiver%252Band%252BGeneral%252BOrgan%252BToxicity%26aulast%3DEvans%26aufirst%3DDavid%2BC.%26date%3D2012%26date%3D2012%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DEncyclopedia%252Bof%252BDrug%252BMetabolism%252Band%252BInteractions%26aulast%3DLyubimov%26aufirst%3DAlexander%2BV.%26date%3D2011%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingyi  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Bai</span>, <span class="hlFld-ContribAuthor ">Rui  Xie</span>, <span class="hlFld-ContribAuthor ">Liping  Sun</span>, <span class="hlFld-ContribAuthor ">Kejiang  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Development and strategies of VEGFR-2/KDR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (14)
                                     , 1839-1852. <a href="https://doi.org/10.4155/fmc.12.121" title="DOI URL">https://doi.org/10.4155/fmc.12.121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.12.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.12.121%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Band%252Bstrategies%252Bof%252BVEGFR-2%25252FKDR%252Binhibitors%26aulast%3DHuang%26aufirst%3DLingyi%26date%3D2012%26volume%3D4%26issue%3D14%26spage%3D1839%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingjun  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Selected Applications of Pd- and Cu-Catalyzed Carbon-Heteroatom Cross-Coupling Reactions in the Pharmaceutical Industry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 97-163. <a href="https://doi.org/10.1002/9781118309872.ch3" title="DOI URL">https://doi.org/10.1002/9781118309872.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118309872.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118309872.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DSelected%252BApplications%252Bof%252BPd-%252Band%252BCu-Catalyzed%252BCarbon-Heteroatom%252BCross-Coupling%252BReactions%252Bin%252Bthe%252BPharmaceutical%252BIndustry%26aulast%3DYin%26aufirst%3DJingjun%26date%3D2012%26date%3D2012%26spage%3D97%26epage%3D163%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DApplications%252Bof%252BTransition%252BMetal%252BCatalysis%252Bin%252BDrug%252BDiscovery%252Band%252BDevelopment%26aulast%3DCrawley%26aufirst%3DMatthew%2BL.%26date%3D2012%26volume%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun-Young  Han</span>, <span class="hlFld-ContribAuthor ">Jie Won  Choi</span>, <span class="hlFld-ContribAuthor ">Jeon  Yang</span>, <span class="hlFld-ContribAuthor ">Chong Hack  Chae</span>, <span class="hlFld-ContribAuthor ">Jongkook  Lee</span>, <span class="hlFld-ContribAuthor ">Heejung  Jung</span>, <span class="hlFld-ContribAuthor ">Kwangho  Lee</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (8)
                                     , 2837-2842. <a href="https://doi.org/10.1016/j.bmcl.2012.02.073" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.02.073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.02.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.02.073%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B3-%2525284%25252C5%25252C6%25252C7-tetrahydro-3H-imidazo%25255B4%25252C5-c%25255Dpyridin-2-yl%252529-1H-quinolin-2-ones%252Bas%252BVEGFR-2%252Bkinase%252Binhibitors%26aulast%3DHan%26aufirst%3DSun-Young%26date%3D2012%26volume%3D22%26issue%3D8%26spage%3D2837%26epage%3D2842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui M. V.  Abreu</span>, <span class="hlFld-ContribAuthor ">Hugo J. C.  Froufe</span>, <span class="hlFld-ContribAuthor ">Maria-João R. P.  Queiroz</span>, <span class="hlFld-ContribAuthor ">Isabel C. F. R.  Ferreira</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Flexibility of Side-Chain Residues Improves VEGFR-2 Docking Score using AutoDock Vina. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2012,</strong> <em>79 </em>
                                    (4)
                                     , 530-534. <a href="https://doi.org/10.1111/j.1747-0285.2011.01313.x" title="DOI URL">https://doi.org/10.1111/j.1747-0285.2011.01313.x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/j.1747-0285.2011.01313.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fj.1747-0285.2011.01313.x%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSelective%252BFlexibility%252Bof%252BSide-Chain%252BResidues%252BImproves%252BVEGFR-2%252BDocking%252BScore%252Busing%252BAutoDock%252BVina%26aulast%3DAbreu%26aufirst%3DRui%2BM.%2BV.%26date%3D2012%26date%3D2012%26volume%3D79%26issue%3D4%26spage%3D530%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew W  Martin</span>, <span class="hlFld-ContribAuthor ">Michelle R  Machacek</span>. </span><span class="cited-content_cbyCitation_article-title">Update on lymphocyte specific kinase inhibitors: a patent survey. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2010,</strong> <em>20 </em>
                                    (11)
                                     , 1573-1593. <a href="https://doi.org/10.1517/13543776.2010.517749" title="DOI URL">https://doi.org/10.1517/13543776.2010.517749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2010.517749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2010.517749%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DUpdate%252Bon%252Blymphocyte%252Bspecific%252Bkinase%252Binhibitors%25253A%252Ba%252Bpatent%252Bsurvey%26aulast%3DMartin%26aufirst%3DMatthew%2BW%26date%3D2010%26date%3D2010%26volume%3D20%26issue%3D11%26spage%3D1573%26epage%3D1593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Yang</span>, <span class="hlFld-ContribAuthor ">Lei  Shi</span>, <span class="hlFld-ContribAuthor ">Yang  Zhou</span>, <span class="hlFld-ContribAuthor ">Huan-Qiu  Li</span>, <span class="hlFld-ContribAuthor ">Zhen-Wei  Zhu</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (22)
                                     , 6653-6656. <a href="https://doi.org/10.1016/j.bmcl.2010.09.014" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.09.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.09.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bquinoline%252Bamide%252Bderivatives%252Bas%252Bnovel%252BVEGFR-2%252Binhibitors%26aulast%3DYang%26aufirst%3DYing%26date%3D2010%26volume%3D20%26issue%3D22%26spage%3D6653%26epage%3D6656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Y  Lei</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of Radix Ginseng and Radix Notoginseng formula on secretion of vascular endothelial growth factor and expression of vascular endothelial growth factor receptor-2 in human umbilical vein endothelial cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chinese Integrative Medicine</span><span> <strong>2010,</strong> <em>8 </em>
                                    (4)
                                     , 368-372. <a href="https://doi.org/10.3736/jcim20100412" title="DOI URL">https://doi.org/10.3736/jcim20100412</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3736/jcim20100412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3736%2Fjcim20100412%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chinese%2520Integrative%2520Medicine%26atitle%3DEffects%252Bof%252BRadix%252BGinseng%252Band%252BRadix%252BNotoginseng%252Bformula%252Bon%252Bsecretion%252Bof%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Band%252Bexpression%252Bof%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor-2%252Bin%252Bhuman%252Bumbilical%252Bvein%252Bendothelial%252Bcells%26aulast%3DLei%26aufirst%3DY%26date%3D2010%26volume%3D8%26issue%3D4%26spage%3D368%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore Guided 3D-QSAR CoMFA Analysis of Amino Substituted Nitrogen Heterocycle Ureas as KDR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">QSAR & Combinatorial Science</span><span> <strong>2009,</strong> <em>28 </em>
                                    (11-12)
                                     , 1524-1536. <a href="https://doi.org/10.1002/qsar.200960032" title="DOI URL">https://doi.org/10.1002/qsar.200960032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/qsar.200960032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fqsar.200960032%26sid%3Dliteratum%253Aachs%26jtitle%3DQSAR%2520%2526%2520Combinatorial%2520Science%26atitle%3DPharmacophore%252BGuided%252B3D-QSAR%252BCoMFA%252BAnalysis%252Bof%252BAmino%252BSubstituted%252BNitrogen%252BHeterocycle%252BUreas%252Bas%252BKDR%252BInhibitors%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2009%26date%3D2009%26volume%3D28%26issue%3D11-12%26spage%3D1524%26epage%3D1536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra W  Cowan-Jacob</span>, <span class="hlFld-ContribAuthor ">Henrik  Möbitz</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>. </span><span class="cited-content_cbyCitation_article-title">Structural biology contributions to tyrosine kinase drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Cell Biology</span><span> <strong>2009,</strong> <em>21 </em>
                                    (2)
                                     , 280-287. <a href="https://doi.org/10.1016/j.ceb.2009.01.012" title="DOI URL">https://doi.org/10.1016/j.ceb.2009.01.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ceb.2009.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ceb.2009.01.012%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Cell%2520Biology%26atitle%3DStructural%252Bbiology%252Bcontributions%252Bto%252Btyrosine%252Bkinase%252Bdrug%252Bdiscovery%26aulast%3DCowan-Jacob%26aufirst%3DSandra%2BW%26date%3D2009%26volume%3D21%26issue%3D2%26spage%3D280%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Du</span>, <span class="hlFld-ContribAuthor ">Beilei  Lei</span>, <span class="hlFld-ContribAuthor ">Jin  Qin</span>, <span class="hlFld-ContribAuthor ">Huanxiang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2009,</strong> <em>27 </em>
                                    (5)
                                     , 642-654. <a href="https://doi.org/10.1016/j.jmgm.2008.10.006" title="DOI URL">https://doi.org/10.1016/j.jmgm.2008.10.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2008.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2008.10.006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DMolecular%252Bmodeling%252Bstudies%252Bof%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Busing%252BQSAR%252Band%252Bdocking%26aulast%3DDu%26aufirst%3DJuan%26date%3D2009%26volume%3D27%26issue%3D5%26spage%3D642%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deborah  Choquette</span>, <span class="hlFld-ContribAuthor ">Yohannes  Teffera</span>, <span class="hlFld-ContribAuthor ">Anthony  Polverino</span>, <span class="hlFld-ContribAuthor ">Jean-Christophe  Harmange</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: Synthesis, SAR, and pharmacokinetic properties. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2008,</strong> <em>18 </em>
                                    (14)
                                     , 4054-4058. <a href="https://doi.org/10.1016/j.bmcl.2008.05.114" title="DOI URL">https://doi.org/10.1016/j.bmcl.2008.05.114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2008.05.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2008.05.114%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252B1%25252C2%25252C3%25252C4-tetrahydroisoquinolines%252Band%252B3%25252C4-dihydroisoquinoline-1%2525282H%252529-ones%252Bas%252Bpotent%252Band%252Bselective%252Binhibitors%252Bof%252BKDR%25253A%252BSynthesis%25252C%252BSAR%25252C%252Band%252Bpharmacokinetic%252Bproperties%26aulast%3DChoquette%26aufirst%3DDeborah%26date%3D2008%26volume%3D18%26issue%3D14%26spage%3D4054%26epage%3D4058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Lead Discovery for <i>N-</i>alkylnaphthamides.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystallographic analysis of compounds <b>2</b> (top) and <b>3</b> (bottom) in the ATP-binding pocket of KDR. Hydrogen bonds are shown between the inhibitors and KDR (dotted lines).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0007.jpeg" id="rightTab-gs1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Naphthamides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMSO, 140 °C; (b) SOCl<sub>2</sub>, benzene, 65 °C; base, RNH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; or oxalyl chloride, DMF, CH<sub>2</sub>Cl<sub>2</sub>; base, RNH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (c) HATU, DIPEA, RNH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (d) EDC, DIPEA, RNH<sub>2</sub> DMF; or HOAt, DIPEA, RNH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (e) Cu, KOH, pyridine, DMF 120 °C, microwave.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinase selectivity profile for <b>3</b>, <b>20</b>, and <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compounds <b>3</b>, <b>20</b>, and <b>22</b> on VEGF induced vascular permeability in mice (<i>n</i> = 5 animals per group). HEK 293 cells transfected with murine VEGF or vector were mixed with Matrigel and injected sc into CD-1 nu/nu mice. A single dose of compound was given and vascular permeability in the skin overlying the Matrigel plug assessed 6 h later. Data represent the mean ± standard error: (∗) <i>P</i> ≤ 0.0002.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of VEGF-induced angiogenesis in the rat cornea by <b>3</b>. Angiogenesis was induced by implanting a VEGF-soaked or BSA-soaked (control) nylon disk into the corneal stroma. The number of blood vessels intersecting the midpoint between the disk and the limbus was measured after 7 days of dosing vehicle or drug. Data represent the mean ± standard error (<i>n</i> = 8 animals per group): (∗) <i>P</i> < 0.005.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/medium/jm-2007-01098w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor activity upon treatment with <b>22</b> or vehicle in HT29 colon cancer xenograft and Calu-6 lung cancer xenograft in CD-1 nu/nu mice (<i>n</i> = 10 animals per group). Data represent the mean ± standard error: (∗) <i>P</i> < 0.05; (∗∗) <i>P</i> < 0.01; (∗∗∗) <i>P</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-6/jm701098w/production/images/large/jm-2007-01098w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm701098w&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01371" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01371" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Anti-angiogenesis: new concept for therapy of solid tumors</span> <span class="citation_source-journal">Ann. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1972&pages=409-416&author=J.+Folkman&title=Anti-angiogenesis%3A+new+concept+for+therapy+of+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAnti-angiogenesis%253A%2520new%2520concept%2520for%2520therapy%2520of%2520solid%2520tumors%26jtitle%3DAnn.%2520Surg.%26date%3D1972%26volume%3D175%26spage%3D409%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">VEGF and the quest for tumour angiogenesis factors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1038%2Fnrc909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=12360282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVGrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=795-803&author=N.+Ferrara&title=VEGF+and+the+quest+for+tumour+angiogenesis+factors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: VEGF and the quest for tumor angiogenesis factors</span></div><div class="casAuthors">Ferrara, Napoleone</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">795-803</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The ability of tumors to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be central to this process.  The quest for VEGF and other factors that promote tumor angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these mols. as anticancer agents.  How did this field begin, and how have we arrived at our present understanding of the role of VEGF in tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHN1T3vtAELVg90H21EOLACvtfcHk0lhSC9AoQk6eLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVGrtbk%253D&md5=b0f6d2bde63351fae496d743a9a7e4bf</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fnrc909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc909%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DVEGF%2520and%2520the%2520quest%2520for%2520tumour%2520angiogenesis%2520factors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D795%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strawn, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawver, L. K.</span><span> </span><span class="NLM_article-title">New paradigms for the treatment of cancer: the role of anti-angiogenesis agents</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2000&pages=1-38&author=J.+M.+Cherringtonauthor=L.+M.+Strawnauthor=L.+K.+Shawver&title=New+paradigms+for+the+treatment+of+cancer%3A+the+role+of+anti-angiogenesis+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DStrawn%26aufirst%3DL.%2BM.%26aulast%3DShawver%26aufirst%3DL.%2BK.%26atitle%3DNew%2520paradigms%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520the%2520role%2520of%2520anti-angiogenesis%2520agents%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2000%26volume%3D79%26spage%3D1%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span> </span><span class="NLM_article-title">Vascular-targeting therapies for treatment of malignant disease</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2491</span><span class="NLM_x">–</span> <span class="NLM_lpage">2499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2004&pages=2491-2499&author=D.+W.+Siemannauthor=D.+J.+Chaplinauthor=M.+R.+Horsman&title=Vascular-targeting+therapies+for+treatment+of+malignant+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26atitle%3DVascular-targeting%2520therapies%2520for%2520treatment%2520of%2520malignant%2520disease%26jtitle%3DCancer%26date%3D2004%26volume%3D100%26spage%3D2491%26epage%3D2499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Mechanisms of angiogenesis and arteriogenesis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1038%2F74651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=10742145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVOrur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=389-395&author=P.+Carmeliet&title=Mechanisms+of+angiogenesis+and+arteriogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of angiogenesis and arteriogenesis</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-395</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">A review with 71 refs., on the cellular and mol. mechanisms underlying the formation of endothelium-lined channels (angiogenesis) and their maturation via recruitment of smooth muscle cells (arteriogenesis) during physiol. and pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC5duTZ_-aV7Vg90H21EOLACvtfcHk0lgHTGtDPtsNCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVOrur4%253D&md5=a8a3874f286a4e46a9eeaaa9ff8b17dc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F74651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F74651%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DMechanisms%2520of%2520angiogenesis%2520and%2520arteriogenesis%26jtitle%3DNat.%2520Med.%26date%3D2000%26volume%3D6%26spage%3D389%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Rak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuhashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filmus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirasawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasazuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4575</span><span class="NLM_x">–</span> <span class="NLM_lpage">4580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=4575-4580&author=J.+Rakauthor=Y.+Mitsuhashiauthor=L.+Baykoauthor=J.+Filmusauthor=S.+Shirasawaauthor=T.+Sasazukiauthor=R.+S.+Kerbel&title=Mutant+ras+oncogenes+upregulate+VEGF%2FVPF+expression%3A+implications+for+induction+and+inhibition+of+tumor+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRak%26aufirst%3DJ.%26aulast%3DMitsuhashi%26aufirst%3DY.%26aulast%3DBayko%26aufirst%3DL.%26aulast%3DFilmus%26aufirst%3DJ.%26aulast%3DShirasawa%26aufirst%3DS.%26aulast%3DSasazuki%26aufirst%3DT.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DMutant%2520ras%2520oncogenes%2520upregulate%2520VEGF%252FVPF%2520expression%253A%2520implications%2520for%2520induction%2520and%2520inhibition%2520of%2520tumor%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D4575%26epage%3D4580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Mukhopadhyay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knebelmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukhatme, V. P.</span><span> </span><span class="NLM_article-title">The von Hippel−Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5629</span><span class="NLM_x">–</span> <span class="NLM_lpage">5639</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=9271438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADyaK2sXlslaru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=5629-5639&author=D.+Mukhopadhyayauthor=B.+Knebelmannauthor=H.+T.+Cohenauthor=S.+Ananthauthor=V.+P.+Sukhatme&title=The+von+Hippel%E2%88%92Lindau+tumor+suppressor+gene+product+interacts+with+Sp1+to+repress+vascular+endothelial+growth+factor+promoter+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity</span></div><div class="casAuthors">Mukhopadhyay, Debabrata; Knebelmann, Bertrand; Cohen, Herbert T.; Ananth, Subbian; Sukhatme, Vikas P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5629-5639</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The von Hippel-Lindau tumor suppressor gene (VHL) has a crit. role in the pathogenesis of clear-cell renal cell carcinoma (RCC), as VHL mutations have been found in both von Hippel-Lindau disease-assocd. and sporadic RCCs.  Recent studies suggest that vascular endothelial growth factor (VEGF) mRNA is upregulated in RCC- and von Hippel-Lindau disease-assocd. tumors.  We have therefore assessed the effect of the VHL gene product on VEGF expression.  VEGF promoter-luciferase constructs were transiently cotransfected with a wild-type VHL (wt-VHL) vector in several cell lines, including 293 embryonic kidney and RCC cell lines.  Wt-VHL protein inhibited VEGF promoter activity in a dose-dependent manner up to 5- to 10-fold.  Deletion anal. defined a 144-bp region of the VEGF promoter necessary for VHL repression.  This VHL-responsive element is GC rich and specifically binds the transcription factor Sp1 in crude nuclear exts.  In Drosophila cells, cotransfected VHL represses Sp1-mediated activation but not basal activity of the VEGF promoter.  We next demonstrated in coimmunoppts. that VHL and Sp1 were part of the same complex and, by using a glutathione-S-transferase-VHL fusion protein and purified Sp1, that VHL and Sp1 directly interact.  Furthermore, endogenous VEGF mRNA levels were suppressed in permanent RCC cell lines expressing wt-VHL, and nuclear run-on studies indicated that VHL regulation of VEGF occurs at least partly at the transcriptional level.  These observations support a new mechanism for VHL-mediated transcriptional repression via a direct inhibitory action on Sp1 and suggest that loss of Sp1 inhibition may be important in the pathogenesis of von Hippel-Lindau disease and RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozMX34jMUc0LVg90H21EOLACvtfcHk0lgHTGtDPtsNCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlslaru74%253D&md5=2e18d74a863ae242e05185b808c8052b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DD.%26aulast%3DKnebelmann%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DH.%2BT.%26aulast%3DAnanth%26aufirst%3DS.%26aulast%3DSukhatme%26aufirst%3DV.%2BP.%26atitle%3DThe%2520von%2520Hippel%25E2%2588%2592Lindau%2520tumor%2520suppressor%2520gene%2520product%2520interacts%2520with%2520Sp1%2520to%2520repress%2520vascular%2520endothelial%2520growth%2520factor%2520promoter%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1997%26volume%3D17%26spage%3D5629%26epage%3D5639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Shweiki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neeman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshet, E.</span><span> </span><span class="NLM_article-title">Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">768</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=768-772&author=D.+Shweikiauthor=M.+Neemanauthor=A.+Itinauthor=E.+Keshet&title=Induction+of+vascular+endothelial+growth+factor+expression+by+hypoxia+and+by+glucose+deficiency+in+multicell+spheroids%3A+implications+for+tumor+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShweiki%26aufirst%3DD.%26aulast%3DNeeman%26aufirst%3DM.%26aulast%3DItin%26aufirst%3DA.%26aulast%3DKeshet%26aufirst%3DE.%26atitle%3DInduction%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520expression%2520by%2520hypoxia%2520and%2520by%2520glucose%2520deficiency%2520in%2520multicell%2520spheroids%253A%2520implications%2520for%2520tumor%2520angiogenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1995%26volume%3D92%26spage%3D768%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christinger, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vos, A. M.</span><span> </span><span class="NLM_article-title">Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1016%2FS0092-8674%2800%2980456-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=9393862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1997&pages=695-704&author=C.+Wiesmannauthor=G.+Fuhauthor=H.+W.+Christingerauthor=C.+Eigenbrotauthor=J.+A.+Wellsauthor=A.+M.+de+Vos&title=Crystal+structure+at+1.7+%C3%85+resolution+of+VEGF+in+complex+with+domain+2+of+the+Flt-1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor</span></div><div class="casAuthors">Wiesmann, Christian; Fuh, Germaine; Christinger, Hans W.; Eigenbrot, Charles; Wells, James A.; De Vos, Abraham M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-704</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) is a homodimeric hormone that induces proliferation of endothelial cells through binding to the kinase domain receptor and the Fms-like tyrosine kinase receptor (Flt-1), the extracellular portions of which consist of seven Ig domains.  We show that the second and third domains of Flt-1 are necessary and sufficient for binding VEGF with near-native affinity, and that domain 2 alone binds only 60-fold less tightly than wild-type.  The crystal structure of the complex between VEGF and the second domain of Flt-1 shows domain 2 in a predominantly hydrophobic interaction with the "poles" of the VEGF dimer.  Based on this structure and on mutational data, we present a model of VEGF bound to the first four domains of Flt-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZYD3KG--Kg7Vg90H21EOLACvtfcHk0lgJuYyFg8_kFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWrtr4%253D&md5=0775fe6ced8d68e2db5d2900a2d5c3e4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980456-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980456-0%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DFuh%26aufirst%3DG.%26aulast%3DChristinger%26aufirst%3DH.%2BW.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BVos%26aufirst%3DA.%2BM.%26atitle%3DCrystal%2520structure%2520at%25201.7%2520%25C3%2585%2520resolution%2520of%2520VEGF%2520in%2520complex%2520with%2520domain%25202%2520of%2520the%2520Flt-1%2520receptor%26jtitle%3DCell%26date%3D1997%26volume%3D91%26spage%3D695%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Terman, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougher-Vermazen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrion, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armellino, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gospodarowicz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span> </span><span class="NLM_article-title">Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">187</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1992&pages=1579-1586&author=B.+I.+Termanauthor=M.+Dougher-Vermazenauthor=M.+E.+Carrionauthor=D.+Dimitrovauthor=D.+C.+Armellinoauthor=D.+Gospodarowiczauthor=P.+Bohlen&title=Identification+of+the+KDR+tyrosine+kinase+as+a+receptor+for+vascular+endothelial+cell+growth+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTerman%26aufirst%3DB.%2BI.%26aulast%3DDougher-Vermazen%26aufirst%3DM.%26aulast%3DCarrion%26aufirst%3DM.%2BE.%26aulast%3DDimitrov%26aufirst%3DD.%26aulast%3DArmellino%26aufirst%3DD.%2BC.%26aulast%3DGospodarowicz%26aufirst%3DD.%26aulast%3DBohlen%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520the%2520KDR%2520tyrosine%2520kinase%2520as%2520a%2520receptor%2520for%2520vascular%2520endothelial%2520cell%2520growth%2520factor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1992%26volume%3D187%26spage%3D1579%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_contrib-group">Kim, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armanini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillett, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=1993&pages=841-844&author=K.+J.+Kimauthor=B.+Liauthor=J.+Winerauthor=M.+Armaniniauthor=N.+Gillettauthor=H.+S.+Phillipsauthor=N.+Ferrara&title=Inhibition+of+vascular+endothelial+growth+factor-induced+angiogenesis+suppresses+tumour+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWiner%26aufirst%3DJ.%26aulast%3DArmanini%26aufirst%3DM.%26aulast%3DGillett%26aufirst%3DN.%26aulast%3DPhillips%26aufirst%3DH.%2BS.%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DInhibition%2520of%2520vascular%2520endothelial%2520growth%2520factor-induced%2520angiogenesis%2520suppresses%2520tumour%2520growth%2520in%2520vivo%26jtitle%3DNature%26date%3D1993%26volume%3D362%26spage%3D841%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fyfe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">–</span> <span class="NLM_lpage">2342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0lgJuYyFg8_kFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilenbaum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span> </span><span class="NLM_article-title">Paclitaxel−carboplatin alone or with bevacizumab for non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2542</span><span class="NLM_x">–</span> <span class="NLM_lpage">2550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1056%2FNEJMoa061884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=17167137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlWqsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2542-2550&author=A.+Sandlerauthor=R.+Grayauthor=M.+C.+Perryauthor=J.+Brahmerauthor=J.+H.+Schillerauthor=A.+Dowlatiauthor=R.+Lilenbaumauthor=D.+H.+Johnson&title=Paclitaxel%E2%88%92carboplatin+alone+or+with+bevacizumab+for+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</span></div><div class="casAuthors">Sandler, Alan; Gray, Robert; Perry, Michael C.; Brahmer, Julie; Schiller, Joan H.; Dowlati, Afshin; Lilenbaum, Rogerio; Johnson, David H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2542-2550</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers.  Between July 2001 and Apr. 2004, the Eastern Cooperative Oncol. Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434).  Chemotherapy was administered every 3 wk for six cycles, and bevacizumab was administered every 3 wk until disease progression was evident or toxic effects were intolerable.  Patients with squamous-cell tumors, brain metastases, clin. significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded.  The primary end point was overall survival.  The median survival was 12.3 mo in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 mo in the chemotherapy-alone group (hazard ratio for death, 0.79; P = 0.003).  The median progression-free survival in the two groups was 6.2 and 4.5 mo, resp. (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001).  Rates of clin. significant bleeding were 4.4% and 0.7%, resp. (P<0.001).  There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage.  The addn. of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHrplr-EnyyrVg90H21EOLACvtfcHk0ljZB6ufZ26JjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlWqsbzI&md5=f94c013f3961561feb564b2bf7148df4</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa061884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa061884%26sid%3Dliteratum%253Aachs%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DPerry%26aufirst%3DM.%2BC.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DLilenbaum%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26atitle%3DPaclitaxel%25E2%2588%2592carboplatin%2520alone%2520or%2520with%2520bevacizumab%2520for%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2542%26epage%3D2550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Novel small-molecule inhibitors of the vascular endothelial growth factor receptor</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">S74</span><span class="NLM_x">–</span> <span class="NLM_lpage">S78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=S74-S78&issue=Suppl.+2&author=A.+A.+Adjei&title=Novel+small-molecule+inhibitors+of+the+vascular+endothelial+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DNovel%2520small-molecule%2520inhibitors%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2007%26volume%3D8%26issue%3DSuppl.%25202%26spage%3DS74%26epage%3DS78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Thomas, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreves, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiedenmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward, W. P.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1016%2FS0093-7754%2803%2900123-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=12802793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFelt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=32-38&issue=Suppl.+6&author=A.+L.+Thomasauthor=B.+Morganauthor=J.+Drevesauthor=C.+Ungerauthor=B.+Wiedenmannauthor=U.+Vanhoeferauthor=D.+Laurentauthor=M.+Duganauthor=W.+P.+Steward&title=Vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitors%3A+PTK787%2FZK+222584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584</span></div><div class="casAuthors">Thomas, Anne L.; Morgan, Bruno; Drevs, Joachim; Unger, Clemens; Wiedenmann, Bertram; Vanhoefer, Udo; Laurent, Dirk; Dugan, Margaret; Steward, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3, Suppl. 6</span>),
    <span class="NLM_cas:pages">32-38</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  PTK787/ZK 222584 (PTK/ZK) is an oral potent and selective inhibitor of the vascular endothelial growth factor (VEGF)-mediated Flt-I and KDR receptor tyrosine kinases.  PTK/ZK has been shown to reduce growth and microvasculature in s.c. implanted human tumor xenografts in nude mice.  A clin. difficulty in evaluating angiogenesis inhibitors has been the usefulness of conventional study endpoints.  Therefore, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been studied as a pharmacodynamic marker of efficacy of PTK/ZK.  Phase I studies are under way evaluating the optimum dose and schedule of oral PTK/ZK administered continuously to patients with advanced cancers of types known to overexpress VEGF.  To date, particularly in patients with liver metastases from colorectal cancer treated with PTK/ZK, DCE-MRI has been a useful predictor of the biol. response of VEGF-receptor inhibition.  Toxicities have been manageable and have included lightheadedness, ataxia, nausea, vomiting, and hypertension.  Stabilization of disease for ≥6 mo has been seen in heavily pretreated patients receiving PTK/ZK at higher doses.  Preliminary data suggest that PTK/ZK can be administered safely on a continuous daily dosing schedule, efficacy data look promising, and DCE-MRI correlates with biol. response.  DCE-MRI will be used to guide dose optimization of PTK/ZK and perhaps of other angiogenesis inhibitors in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN14homMHopbVg90H21EOLACvtfcHk0ljZB6ufZ26JjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFelt7w%253D&md5=068ee79572e3b628894f3c9cc9a602e6</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2FS0093-7754%2803%2900123-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0093-7754%252803%252900123-4%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DMorgan%26aufirst%3DB.%26aulast%3DDreves%26aufirst%3DJ.%26aulast%3DUnger%26aufirst%3DC.%26aulast%3DWiedenmann%26aufirst%3DB.%26aulast%3DVanhoefer%26aufirst%3DU.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DSteward%26aufirst%3DW.%2BP.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520PTK787%252FZK%2520222584%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26issue%3DSuppl.%25206%26spage%3D32%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span> </span><span class="NLM_article-title">ZD6474, a novel inhibitor of VEGFR and EGFR tyrosine kinase activity</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S6</span><span class="NLM_x">–</span> <span class="NLM_lpage">S13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=S6-S13&issue=Suppl.+1&author=A.+J.+Ryanauthor=S.+R.+Wedge&title=ZD6474%2C+a+novel+inhibitor+of+VEGFR+and+EGFR+tyrosine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26atitle%3DZD6474%252C%2520a%2520novel%2520inhibitor%2520of%2520VEGFR%2520and%2520EGFR%2520tyrosine%2520kinase%2520activity%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26issue%3DSuppl.%25201%26spage%3DS6%26epage%3DS13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo- 1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-+1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-%25201%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5375</span><span class="NLM_x">–</span> <span class="NLM_lpage">5388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0301641" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5375-5388&author=D.+E.+Gingrichauthor=D.+R.+Reddyauthor=M.+A.+Iqbalauthor=J.+Singhauthor=L.+D.+Aimoneauthor=T.+S.+Angelesauthor=M.+Albomauthor=S.+Yangauthor=M.+A.+Atorauthor=S.+L.+Meyerauthor=C.+Robinsonauthor=B.+A.+Ruggeriauthor=C.+A.+Dionneauthor=J.+L.+Vaughtauthor=J.+P.+Mallamoauthor=R.+L.+Hudkins&title=A+new+class+of+potent+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitors%3A+structure+activity+relationships+for+a+series+of+9-alkoxymethyl-12-%283-hydroxypropyl%29indeno%5B2%2C1-a%5Dpyrrolo%5B3%2C4-c%5Dcarbazole-5-ones+and+the+identification+of+CEP-5214+and+its+dimethylglycine+ester+prodrug+clinical+candidate+CEP-7055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1021%2Fjm0301641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0301641%26sid%3Dliteratum%253Aachs%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DReddy%26aufirst%3DD.%2BR.%26aulast%3DIqbal%26aufirst%3DM.%2BA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26aulast%3DVaught%26aufirst%3DJ.%2BL.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DA%2520new%2520class%2520of%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520structure%2520activity%2520relationships%2520for%2520a%2520series%2520of%25209-alkoxymethyl-12-%25283-hydroxypropyl%2529indeno%255B2%252C1-a%255Dpyrrolo%255B3%252C4-c%255Dcarbazole-5-ones%2520and%2520the%2520identification%2520of%2520CEP-5214%2520and%2520its%2520dimethylglycine%2520ester%2520prodrug%2520clinical%2520candidate%2520CEP-7055%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5375%26epage%3D5388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, E. S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span> </span><span class="NLM_article-title">Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1300</span><span class="NLM_x">–</span> <span class="NLM_lpage">1312</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm011022e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1300-1312&author=L.+F.+Hennequinauthor=E.+S.+E.+Stokesauthor=A.+P.+Thomasauthor=C.+Johnstoneauthor=P.+A.+Pleauthor=D.+J.+Ogilvieauthor=M.+Dukesauthor=S.+R.+Wedgeauthor=J.+Kendrewauthor=J.+O.+Curwen&title=Novel+4-anilinoquinazolines+with+C-7+basic+side+chains%3A+design+and+structure+activity+relationship+of+a+series+of+potent%2C+orally+active%2C+VEGF+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=10.1021%2Fjm011022e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011022e%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DStokes%26aufirst%3DE.%2BS.%2BE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26atitle%3DNovel%25204-anilinoquinazolines%2520with%2520C-7%2520basic%2520side%2520chains%253A%2520design%2520and%2520structure%2520activity%2520relationship%2520of%2520a%2520series%2520of%2520potent%252C%2520orally%2520active%252C%2520VEGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1300%26epage%3D1312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbet, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span> </span><span class="NLM_article-title">CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">5978</span><span class="NLM_x">–</span> <span class="NLM_lpage">5991</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=5978-5991&author=B.+Ruggeriauthor=J.+Singhauthor=D.+Gingrichauthor=T.+Angelesauthor=M.+Albomauthor=H.+Changauthor=C.+Robinsonauthor=K.+Hunterauthor=P.+Dobrzanskiauthor=S.+Jones-Bolinauthor=L.+Aimoneauthor=A.+Klein-Szantoauthor=J.-M.+Herbetauthor=F.+Bonoauthor=P.+Schaefferauthor=P.+Casellasauthor=B.+Bourieauthor=R.+Piliauthor=J.+Isaacsauthor=M.+Atorauthor=R.+Hudkinsauthor=J.+Vaughtauthor=J.+Mallamoauthor=C.+Dionne&title=CEP-7055%3A+a+novel%2C+orally+active+pan+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases+with+potent+antiangiogenic+activity+and+antitumor+efficacy+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DAlbom%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DAimone%26aufirst%3DL.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DHerbet%26aufirst%3DJ.-M.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DSchaeffer%26aufirst%3DP.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DBourie%26aufirst%3DB.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DIsaacs%26aufirst%3DJ.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DVaught%26aufirst%3DJ.%26aulast%3DMallamo%26aufirst%3DJ.%26aulast%3DDionne%26aufirst%3DC.%26atitle%3DCEP-7055%253A%2520a%2520novel%252C%2520orally%2520active%2520pan%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%2520with%2520potent%2520antiangiogenic%2520activity%2520and%2520antitumor%2520efficacy%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D5978%26epage%3D5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Beebe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jani, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higdon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkelstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atherton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soderstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastinejad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, W. G.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7301</span><span class="NLM_x">–</span> <span class="NLM_lpage">7309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7301-7309&author=J.+S.+Beebeauthor=J.+P.+Janiauthor=E.+Knauthauthor=P.+Goodwinauthor=C.+Higdonauthor=A.+M.+Rossiauthor=E.+Emersonauthor=M.+Finkelsteinauthor=E.+Floydauthor=S.+Harrimanauthor=J.+Athertonauthor=S.+Hillermanauthor=C.+Soderstromauthor=K.+Kouauthor=T.+Gantauthor=M.+C.+Noeauthor=B.+Fosterauthor=F.+Rastinejadauthor=M.+A.+Marxauthor=T.+Schaefferauthor=P.+M.+Whalenauthor=W.+G.+Roberts&title=Pharmacological+characterization+of+CP-547%2C632%2C+a+novel+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeebe%26aufirst%3DJ.%2BS.%26aulast%3DJani%26aufirst%3DJ.%2BP.%26aulast%3DKnauth%26aufirst%3DE.%26aulast%3DGoodwin%26aufirst%3DP.%26aulast%3DHigdon%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DEmerson%26aufirst%3DE.%26aulast%3DFinkelstein%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DE.%26aulast%3DHarriman%26aufirst%3DS.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DHillerman%26aufirst%3DS.%26aulast%3DSoderstrom%26aufirst%3DC.%26aulast%3DKou%26aufirst%3DK.%26aulast%3DGant%26aufirst%3DT.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DFoster%26aufirst%3DB.%26aulast%3DRastinejad%26aufirst%3DF.%26aulast%3DMarx%26aufirst%3DM.%2BA.%26aulast%3DSchaeffer%26aufirst%3DT.%26aulast%3DWhalen%26aufirst%3DP.%2BM.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26atitle%3DPharmacological%2520characterization%2520of%2520CP-547%252C632%252C%2520a%2520novel%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7301%26epage%3D7309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drevs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marme, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennig, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guenther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, C.</span><span> </span><span class="NLM_article-title">Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1291</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=1291-1299&author=K.+Mrossauthor=J.+Drevsauthor=M.+Mullerauthor=M.+Medingerauthor=D.+Marmeauthor=J.+Hennigauthor=B.+Morganauthor=D.+Lebwohlauthor=E.+Massonauthor=Y.+Y.+Hoauthor=C.+Guentherauthor=D.+Laurentauthor=C.+Unger&title=Phase+I+clinical+and+pharmacokinetic+study+of+PTK%2FZK%2C+a+multiple+VEGF+receptor+inhibitor%2C+in+patients+with+liver+metastases+from+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMross%26aufirst%3DK.%26aulast%3DDrevs%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DMedinger%26aufirst%3DM.%26aulast%3DMarme%26aufirst%3DD.%26aulast%3DHennig%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DB.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DMasson%26aufirst%3DE.%26aulast%3DHo%26aufirst%3DY.%2BY.%26aulast%3DGuenther%26aufirst%3DC.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DUnger%26aufirst%3DC.%26atitle%3DPhase%2520I%2520clinical%2520and%2520pharmacokinetic%2520study%2520of%2520PTK%252FZK%252C%2520a%2520multiple%2520VEGF%2520receptor%2520inhibitor%252C%2520in%2520patients%2520with%2520liver%2520metastases%2520from%2520solid%2520tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D1291%26epage%3D1299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Thomas, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsfield, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higginson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccio-Pick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward, W. P.</span><span> </span><span class="NLM_article-title">Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4162</span><span class="NLM_x">–</span> <span class="NLM_lpage">4171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1200%2FJCO.2005.09.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=15867205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1els78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=4162-4171&author=A.+L.+Thomasauthor=B.+Morganauthor=M.+A.+Horsfieldauthor=A.+Higginsonauthor=A.+Kayauthor=L.+Leeauthor=E.+Massonauthor=M.+Puccio-Pickauthor=D.+Laurentauthor=W.+P.+Steward&title=Phase+I+study+of+the+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+PTK787%2FZK+222584+administered+twice+daily+in+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer</span></div><div class="casAuthors">Thomas, Anne L.; Morgan, Bruno; Horsfield, Mark A.; Higginson, Anthony; Kay, Andrea; Lee, Lucy; Masson, Eric; Puccio-Pick, Marie; Laurent, Dirk; Steward, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4162-4171</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: PTK787/ZK 222584 (PTK/ZK) is an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor (VEGF) receptor tyrosine kinases, including VEGFR-1/Flt-1, VEGFR-2/KDR, VEGFR-3/Flt-4, the platelet-derived growth factor receptor tyrosine kinase, and the c-kit protein tyrosine kinase.  In this phase I dose-escalating study, PTK/ZK was administered bid to exploit the theor. advantage of maintaining const. drug levels above a threshold known from preclin. data to interfere with VEGF receptor signaling.  Patients and Methods: Forty-three patients with advanced cancers received single-agent PTK/ZK at doses of 150 to 1,000 mg orally bid.  Assessments for safety and pharmacokinetics were performed.  Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used as a pharmacodynamic marker of response.  Results: At 1,000 mg bid, the dose-limiting toxicity of reversible grade 3 lightheadedness was obsd.  Dose-related grade 3 fatigue and vomiting were obsd. but these were not dose-limiting.  Pharmacokinetic data confirmed that PTK/ZK exposure increased with increasing dose up to 500 mg bid and appeared to plateau at higher doses.  A greater than 40% redn. in the DCE-MRI bidirectional transfer const. (Ki) at day 2 predicted for nonprogression of disease.  Conclusion: The max.-tolerated oral dose of PTK/ZK is 750 mg orally bid.  DCE-MRI and pharmacokinetic data indicate that PTK/ZK ≥ 1,000 mg total daily dose is the biol. active dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Yk4cEJN4lLVg90H21EOLACvtfcHk0lh5r-D2xVe9zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1els78%253D&md5=3fb3917babe4a29e3e3d49788cf7ded6</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.034%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DMorgan%26aufirst%3DB.%26aulast%3DHorsfield%26aufirst%3DM.%2BA.%26aulast%3DHigginson%26aufirst%3DA.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMasson%26aufirst%3DE.%26aulast%3DPuccio-Pick%26aufirst%3DM.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DSteward%26aufirst%3DW.%2BP.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520PTK787%252FZK%2520222584%2520administered%2520twice%2520daily%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D4162%26epage%3D4171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Rini, B. I.</span><span> </span><span class="NLM_article-title">Sorafenib</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1517%2F14656566.7.4.453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=16503817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=453-461&author=B.+I.+Rini&title=Sorafenib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib</span></div><div class="casAuthors">Rini, Brian I.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Sorafenib is a small mol. inhibitor of several kinases involved in tumor proliferation and tumor angiogenesis including Raf, VEGFR and platelet derived growth factor receptor.  In vivo Raf kinase inhibition has been obsd. in pharmacodynamic studies.  Sorafenib is one of several VEGF-targeting compds. with recently demonstrated substantial anti-tumor effects in metastatic renal cell carcinoma.  Delay in time to disease progression has been demonstrated in cytokine-refractory metastatic renal cell carcinoma, and further investigation is ongoing in a wide variety of tumor types.  Sorafenib is well tolerated, with common toxicities including rash, diarrhea, hand-foot skin reaction, fatigue and hypertension, when administered as the std. dose of 400 mg b.i.d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTbL_e_cFYVbVg90H21EOLACvtfcHk0lh549UfMKQPsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVKgu78%253D&md5=07dddaf18041f4885a535485fa0dfa8a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F14656566.7.4.453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.7.4.453%26sid%3Dliteratum%253Aachs%26aulast%3DRini%26aufirst%3DB.%2BI.%26atitle%3DSorafenib%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2006%26volume%3D7%26spage%3D453%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Atkins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Sunitinib maleate</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=279-280&author=M.+Atkinsauthor=C.+A.+Jonesauthor=P.+Kirkpatrick&title=Sunitinib+maleate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAtkins%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BA.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DSunitinib%2520maleate%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D279%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwittay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottmann, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massimini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scigalla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossfeld, D. K.</span><span> </span><span class="NLM_article-title">A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">986</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=986-993&issue=3&author=W.+Fiedlerauthor=H.+Serveauthor=H.+Doehnerauthor=M.+Schwittayauthor=O.+G.+Ottmannauthor=A.+M.+O%E2%80%99Farrellauthor=C.+L.+Belloauthor=R.+Allredauthor=W.+C.+Manningauthor=J.+M.+Cherringtonauthor=S.+G.+Louieauthor=W.+Hongauthor=N.+M.+Bregaauthor=G.+Massiminiauthor=P.+Scigallaauthor=W.+E.+Berdelauthor=D.+K.+Hossfeld&title=A+phase+1+study+of+SU11248+in+the+treatment+of+patients+with+refractory+or+resistant+acute+myeloid+leukemia+%28AML%29+or+not+amenable+to+conventional+therapy+for+the+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DDoehner%26aufirst%3DH.%26aulast%3DSchwittay%26aufirst%3DM.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DAllred%26aufirst%3DR.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DBrega%26aufirst%3DN.%2BM.%26aulast%3DMassimini%26aufirst%3DG.%26aulast%3DScigalla%26aufirst%3DP.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DHossfeld%26aufirst%3DD.%2BK.%26atitle%3DA%2520phase%25201%2520study%2520of%2520SU11248%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520refractory%2520or%2520resistant%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520or%2520not%2520amenable%2520to%2520conventional%2520therapy%2520for%2520the%2520disease%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26issue%3D3%26spage%3D986%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talvenheimo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montestruque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span> </span><span class="NLM_article-title">AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">8715</span><span class="NLM_x">–</span> <span class="NLM_lpage">8721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8715-8721&author=A.+Polverinoauthor=A.+Coxonauthor=C.+Starnesauthor=Z.+Diazauthor=T.+DeMelfiauthor=L.+Wangauthor=J.+Breadyauthor=J.+Estradaauthor=R.+Cattleyauthor=S.+Kaufmanauthor=D.+Chenauthor=Y.+Ganauthor=G.+Kumarauthor=J.+Meyerauthor=S.+Neervannanauthor=G.+Alvaauthor=J.+Talvenheimoauthor=S.+Montestruqueauthor=A.+Taskerauthor=V.+Patelauthor=R.+Radinskyauthor=R.+Kendall&title=AMG+706%2C+an+oral%2C+multikinase+inhibitor+that+selectively+targets+vascular+endothelial+growth+factor%2C+platelet-derived+growth+factor%2C+and+Kit+receptors%2C+potently+inhibits+angiogenesis+and+induces+regression+in+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DZ.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DCattley%26aufirst%3DR.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DGan%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DAlva%26aufirst%3DG.%26aulast%3DTalvenheimo%26aufirst%3DJ.%26aulast%3DMontestruque%26aufirst%3DS.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26atitle%3DAMG%2520706%252C%2520an%2520oral%252C%2520multikinase%2520inhibitor%2520that%2520selectively%2520targets%2520vascular%2520endothelial%2520growth%2520factor%252C%2520platelet-derived%2520growth%2520factor%252C%2520and%2520Kit%2520receptors%252C%2520potently%2520inhibits%2520angiogenesis%2520and%2520induces%2520regression%2520in%2520tumor%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8715%26epage%3D8721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span> <span class="citation_source-book">Daylight</span>, version <span class="NLM_edition">4.41</span>; <span class="NLM_publisher-name">Daylight Chemical Information Systems, Inc.</span>: <span class="NLM_publisher-loc">Irvine, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">1995</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Daylight%2C+version+4.41%3B+Daylight+Chemical+Information+Systems%2C+Inc.%3A+Irvine%2C+CA%2C+1995."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DDaylight%26pub%3DDaylight%2520Chemical%2520Information%2520Systems%252C%2520Inc%26date%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMelfi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPietro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neervannan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roveto, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, R.</span><span> </span><span class="NLM_article-title">Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1667</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701097z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1649-1667&author=J.-C.+Harmangeauthor=M.+M.+Weissauthor=J.+Germainauthor=A.+J.+Polverinoauthor=G.+Borgauthor=J.+Breadyauthor=D.+Chenauthor=D.+Choquetteauthor=A.+Coxonauthor=T.+DeMelfiauthor=L.+DiPietroauthor=N.+Doerrauthor=J.+Estradaauthor=J.+Flynnauthor=R.+F.+Graceffaauthor=S.+P.+Harrimanauthor=S.+Kaufmanauthor=D.+S.+Laauthor=A.+Longauthor=M.+W.+Martinauthor=S.+Neervannanauthor=V.+F.+Patelauthor=M.+Potashmanauthor=K.+Regalauthor=P.+M.+Rovetoauthor=M.+L.+Schragauthor=C.+Starnesauthor=A.+Taskerauthor=Y.+Tefferaauthor=L.+Wangauthor=R.+D.+Whiteauthor=D.+Whittingtonauthor=R.+Zanon&title=Naphthamides+as+novel+and+potent+vascular+endothelial+growth+factor+receptor+tyrosine+kinase+inhibitors%3A+design%2C+synthesis%2C+and+evaluation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation</span></div><div class="casAuthors">Harmange, Jean-Christophe; Weiss, Matthew M.; Germain, Julie; Polverino, Anthony J.; Borg, George; Bready, James; Chen, Danlin; Choquette, Deborah; Coxon, Angela; DeMelfi, Tom; DiPietro, Lucian; Doerr, Nicholas; Estrada, Juan; Flynn, Julie; Graceffa, Russell F.; Harriman, Shawn P.; Kaufman, Stephen; La, Daniel S.; Long, Alexander; Martin, Matthew W.; Neervannan, Sesha; Patel, Vinod F.; Potashman, Michele; Regal, Kelly; Roveto, Phillip M.; Schrag, Michael L.; Starnes, Charlie; Tasker, Andrew; Teffera, Yohannes; Wang, Ling; White, Ryan D.; Whittington, Douglas A.; Zanon, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1649-1667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of naphthyl-based compds. were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors.  Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family.  Numerous analogs demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compds. possessed favorable pharmacokinetic (PK) profiles.  In particular, compd. I demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice.  A full account of the prepn., structure-activity relationships, pharmacokinetic properties, and pharmacol. of analogs within this series is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1vrmtgp3_m7Vg90H21EOLACvtfcHk0lh3UM3jqui5QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFOmsLs%253D&md5=25685f28450b2ab132ffd278e6c53598</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm701097z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701097z%26sid%3Dliteratum%253Aachs%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DPolverino%26aufirst%3DA.%2BJ.%26aulast%3DBorg%26aufirst%3DG.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DDeMelfi%26aufirst%3DT.%26aulast%3DDiPietro%26aufirst%3DL.%26aulast%3DDoerr%26aufirst%3DN.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLong%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNeervannan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DRoveto%26aufirst%3DP.%2BM.%26aulast%3DSchrag%26aufirst%3DM.%2BL.%26aulast%3DStarnes%26aufirst%3DC.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DZanon%26aufirst%3DR.%26atitle%3DNaphthamides%2520as%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1649%26epage%3D1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Mitotic kinases as regulators of cell division and its checkpoints</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1038%2F35048096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=11413462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=21-32&author=E.+A.+Nigg&title=Mitotic+kinases+as+regulators+of+cell+division+and+its+checkpoints"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic kinases as regulators of cell division and its checkpoints</span></div><div class="casAuthors">Nigg, Erich A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-32</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 115 refs.  Mitosis and cytokinesis are undoubtedly the most spectacular parts of the cell cycle.  Errors in the choreog. of these processes can lead to aneuploidy or genetic instability, fostering cell death or disease.  Here, I give an overview of the many mitotic kinases that regulate cell division and the fidelity of chromosome transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj12LIFIQmjrVg90H21EOLACvtfcHk0lh3UM3jqui5QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWms7o%253D&md5=b9eaea70872a755eb7c8c335c1919e84</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2F35048096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35048096%26sid%3Dliteratum%253Aachs%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DMitotic%2520kinases%2520as%2520regulators%2520of%2520cell%2520division%2520and%2520its%2520checkpoints%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D21%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Palacios, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, A.</span><span> </span><span class="NLM_article-title">Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">7990</span><span class="NLM_x">–</span> <span class="NLM_lpage">8000</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1038%2Fsj.onc.1208074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=15489916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosFyltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=7990-8000&author=E.+H.+Palaciosauthor=A.+Weiss&title=Function+of+the+Src-family+kinases%2C+Lck+and+Fyn%2C+in+T-cell+development+and+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation</span></div><div class="casAuthors">Palacios, Emil H.; Weiss, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">7990-8000</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The function of the Src-family kinases (SFKs) Lck and Fyn in T cells has been intensively studied over the past 15 yr.  Animal models and cell line studies both indicate a crit. role for Lck and Fyn in proximal T-cell antigen receptor (TCR) signal transduction.  Recruited SFKs phosphorylate TCR ITAMs (immunoreceptor tyrosine-based activation motifs) in the CD3 and ζ chains, which then serve as docking sites for Syk-family kinases.  SFKs then phosphorylate and activate the recruited Syk-family kinase.  Lck and Fyn are spatially segregated in cell membranes due to differential lipid raft localization, and may undergo sequential activation.  In addn. to the CD4 and CD8 coreceptors, a recently described adaptor, Unc119, may link SFKs to the TCR.  CD45 and Csk provide pos. and neg. regulatory control of SFK functions, resp., and Csk is constitutively bound to the transmembrane adapter protein, PAG/Cbp.  TCR-based signaling is required at several stages of T-cell development, including at least pre-TCR signaling, pos. selection, peripheral maintenance of naive T cells, and lymphopenia-induced proliferation.  SFKs are required for each of these TCR-based signals, and Lck seems to be the major contributor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC2s7PGSwBibVg90H21EOLACvtfcHk0lh3UM3jqui5QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosFyltb8%253D&md5=d9d1f2697ef4008ee8c8426ac806bd11</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208074%26sid%3Dliteratum%253Aachs%26aulast%3DPalacios%26aufirst%3DE.%2BH.%26aulast%3DWeiss%26aufirst%3DA.%26atitle%3DFunction%2520of%2520the%2520Src-family%2520kinases%252C%2520Lck%2520and%2520Fyn%252C%2520in%2520T-cell%2520development%2520and%2520activation%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D7990%26epage%3D8000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">He, M.; Kania, R. S.; Lou, J.; Zhou, R.</span><span> </span><span class="NLM_article-title">Preparation of Naphthalenecarboxamides and Their Derivatives as New Antiangiogenic Agents</span>. WO 2005/021553 A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+He&author=R.+S.+Kania&author=J.+Lou&author=R.+Zhou&title=Preparation+of+Naphthalenecarboxamides+and+Their+Derivatives+as+New+Antiangiogenic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Naphthalenecarboxamides%2520and%2520Their%2520Derivatives%2520as%2520New%2520Antiangiogenic%2520Agents%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Potashman, M.; Kim, T.; Bellon, S.; Booker, S.; Cheng, Y.; Kim, J. L.; Tasker, A.; Xi, N.; Xu, S.; Harmange, J.-C.; Borg, G.; Weiss, M.; Hodous, B. L.; Graceffa, R.; Buckner, W. H.; Masse, C. E.; Choquette, D.; Martin, M. W.; Germain, J.; Dipietro, L. V.; Chaffee, S. C.; Nunes, J. J.; Buchanan, J. L.; Habgood, G. J.; McGowan, D. C.; Whittington, D. A.</span><span> </span><span class="NLM_article-title">Preparation of Heteroaryl Substituted Naphthalenes as Inhibitors of Lck, VEGFR and/or HGF Related Activity</span>. WO 2005/070891 A2,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Potashman&author=T.+Kim&author=S.+Bellon&author=S.+Booker&author=Y.+Cheng&author=J.+L.+Kim&author=A.+Tasker&author=N.+Xi&author=S.+Xu&author=J.-C.+Harmange&author=G.+Borg&author=M.+Weiss&author=B.+L.+Hodous&author=R.+Graceffa&author=W.+H.+Buckner&author=C.+E.+Masse&author=D.+Choquette&author=M.+W.+Martin&author=J.+Germain&author=L.+V.+Dipietro&author=S.+C.+Chaffee&author=J.+J.+Nunes&author=J.+L.+Buchanan&author=G.+J.+Habgood&author=D.+C.+McGowan&author=D.+A.+Whittington&title=Preparation+of+Heteroaryl+Substituted+Naphthalenes+as+Inhibitors+of+Lck%2C+VEGFR+and%2For+HGF+Related+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Heteroaryl%2520Substituted%2520Naphthalenes%2520as%2520Inhibitors%2520of%2520Lck%252C%2520VEGFR%2520and%252For%2520HGF%2520Related%2520Activity%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">De, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogstad, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogstad, D. J.</span><span> </span><span class="NLM_article-title">Structure−activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">4918</span><span class="NLM_x">–</span> <span class="NLM_lpage">4926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980146x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4918-4926&author=D.+Deauthor=F.+M.+Krogstadauthor=L.+D.+Byersauthor=D.+J.+Krogstad&title=Structure%E2%88%92activity+relationships+for+antiplasmodial+activity+among+7-substituted+4-aminoquinolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm980146x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980146x%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DD.%26aulast%3DKrogstad%26aufirst%3DF.%2BM.%26aulast%3DByers%26aufirst%3DL.%2BD.%26aulast%3DKrogstad%26aufirst%3DD.%2BJ.%26atitle%3DStructure%25E2%2588%2592activity%2520relationships%2520for%2520antiplasmodial%2520activity%2520among%25207-substituted%25204-aminoquinolines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4918%26epage%3D4926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lindley, J.</span><span> </span><span class="NLM_article-title">Copper assisted nucleophilic substitution of aryl halogen</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1984&pages=1433-1456&author=J.+Lindley&title=Copper+assisted+nucleophilic+substitution+of+aryl+halogen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindley%26aufirst%3DJ.%26atitle%3DCopper%2520assisted%2520nucleophilic%2520substitution%2520of%2520aryl%2520halogen%26jtitle%3DTetrahedron%26date%3D1984%26volume%3D40%26spage%3D1433%26epage%3D1456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Nomoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teranishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span> </span><span class="NLM_article-title">Studies on cardiotonic agents. I. Synthesis of some quinazoline derivatives</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1990&pages=1591-1595&author=Y.+Nomotoauthor=H.+Obaseauthor=H.+Takaiauthor=T.+Hirataauthor=M.+Teranishiauthor=J.+Nakamuraauthor=K.+Kubo&title=Studies+on+cardiotonic+agents.+I.+Synthesis+of+some+quinazoline+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNomoto%26aufirst%3DY.%26aulast%3DObase%26aufirst%3DH.%26aulast%3DTakai%26aufirst%3DH.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DTeranishi%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKubo%26aufirst%3DK.%26atitle%3DStudies%2520on%2520cardiotonic%2520agents.%2520I.%2520Synthesis%2520of%2520some%2520quinazoline%2520derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1990%26volume%3D38%26spage%3D1591%26epage%3D1595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheetham, J.</span><span> </span><span class="NLM_article-title">An automated screening assay for determination of aqueous equilibrium solubility enabling SPR study during drug lead optimization</span> <span class="citation_source-journal">J. Assoc. Lab. Autom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1016%2Fj.jala.2005.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsFygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=364-373&issue=6&author=H.+Tanauthor=D.+Seminauthor=M.+Wackerauthor=J.+Cheetham&title=An+automated+screening+assay+for+determination+of+aqueous+equilibrium+solubility+enabling+SPR+study+during+drug+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An automated screening assay for determination of aqueous equilibrium solubility enabling SPR study during drug lead optimization</span></div><div class="casAuthors">Tan, Helming; Semin, David; Wacker, Maggie; Cheetham, Janet</div><div class="citationInfo"><span class="NLM_cas:title">JALA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">364-373</span>CODEN:
                <span class="NLM_cas:coden">JALLFO</span>;
        ISSN:<span class="NLM_cas:issn">1535-5535</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Aq. soly. is one of the most crit. physicochem. properties to be detd. in the process of drug lead optimization.  Particularly, an equil. soly. method is highly valuable to the study of structure property relationship (SPR), while meeting the needs of anal. sensitivity, reproducibility, and throughput.  In this report, an automated soly. assay in a 96-well library format was designed and developed by means of robotic liq. handling, centrifugal sepn., and HPLC-UV quantification.  Requiring 1 mg of solid compd., this assay was used to det. the equil. soly. in three user-selected media, i.e., 0.01 N HCl, phosphate buffer saline (PBS), and fasted state simulated intestinal fluid (SIF), with a throughput of up to 192 compds. a week.  The assay parameters, including the equilibration time and the sepn. technique, were optimized to ensure that the thermodn. soly. was measured at the presence of excess solid compd.  A fast gradient HPLC method was developed with single-point on-plate calibration for each compd., followed by a customized 96-well chromatog. data anal.  The reporting soly. range was 1-200 μg/mL, appropriate for oral drug candidate selection at the stage of discovery lead optimization.  Based on the test results obtained on the com. available drugs and Amgen research compds., this assay was considered to be equiv. to the conventional shake-flask methods.  Examples were given to demonstrate that the thermodn. soly. detd. by this assay enabled the SPR study to support drug lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXZS8kMVkXPrVg90H21EOLACvtfcHk0lghkzHUVPP3Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsFygsw%253D%253D&md5=0084938410823379c2bf44ae09e33f19</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jala.2005.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jala.2005.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DH.%26aulast%3DSemin%26aufirst%3DD.%26aulast%3DWacker%26aufirst%3DM.%26aulast%3DCheetham%26aufirst%3DJ.%26atitle%3DAn%2520automated%2520screening%2520assay%2520for%2520determination%2520of%2520aqueous%2520equilibrium%2520solubility%2520enabling%2520SPR%2520study%2520during%2520drug%2520lead%2520optimization%26jtitle%3DJ.%2520Assoc.%2520Lab.%2520Autom.%26date%3D2005%26volume%3D10%26issue%3D6%26spage%3D364%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanzlik, R. P.</span><span> </span><span class="NLM_article-title">Enzymatic N-dealkylation of an <i>N</i>-cyclopropylamine: an unusual fate for the cyclopropyl group</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja003048l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2001&pages=349-350&author=C.+L.+Shafferauthor=M.+D.+Mortonauthor=R.+P.+Hanzlik&title=Enzymatic+N-dealkylation+of+an+N-cyclopropylamine%3A+an+unusual+fate+for+the+cyclopropyl+group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fja003048l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja003048l%26sid%3Dliteratum%253Aachs%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DMorton%26aufirst%3DM.%2BD.%26aulast%3DHanzlik%26aufirst%3DR.%2BP.%26atitle%3DEnzymatic%2520N-dealkylation%2520of%2520an%2520N-cyclopropylamine%253A%2520an%2520unusual%2520fate%2520for%2520the%2520cyclopropyl%2520group%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2001%26volume%3D123%26spage%3D349%26epage%3D350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic functional groups</span> <span class="citation_source-journal">Curr. Drug. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+functional+groups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lgwZGfptiywAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520functional%2520groups%26jtitle%3DCurr.%2520Drug.%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Evans, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Drug−protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug%E2%88%92protein+adducts%3A+an+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug%25E2%2588%2592protein%2520adducts%253A%2520an%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><div class="note"><p class="first last">Radiolabeled compounds were prepared wherein the carbon of amide carbonyl was labeled with <sup>14</sup>C.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Radiolabeled+compounds+were+prepared+wherein+the+carbon+of+amide+carbonyl+was+labeled+with+14C."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0lgwZGfptiywAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Miles, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, E. M.</span><span> </span><span class="NLM_article-title">Vascular reactions to histamine, histamine-liberator,and leukotaxine in the skin of guinea pigs</span> <span class="citation_source-journal">J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1952</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=13000707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADyaG3sXmvVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1952&pages=228-257&author=A.+A.+Milesauthor=E.+M.+Miles&title=Vascular+reactions+to+histamine%2C+histamine-liberator%2Cand+leukotaxine+in+the+skin+of+guinea+pigs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular reactions to histamine, histamine-liberator, and leucotaxine in the skin of guinea pigs</span></div><div class="casAuthors">Miles, A. A.; Miles, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">1952</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-57</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">Capillary permeability increase in the depilated skin of the trunk and ear of albino guinea pigs was measured by estg. the size and intensity of the blue lesion induced in animals with Pontamine Sky Blue 6X in their circulation, by intradermal injection of hisamine (I), histamine-liberator 48/80 (a condensation product of p-methoxyphenethylmethylamine and HCHO (cf. Baltzly, et al., C.A. 43, 6593h)) (II), and leucotaxine (III).  In the dorsal trunk skin, the mean diams. of lesions from graded doses of I, II, and III in a const. vol., or for a const. dose in graded injection vols., were proportional to the log vol.  Both II and III were more strongly adsorbed by the skin than I as measured by a derived assay method employing const. dose measurements for estg. skin tissue affinity for I, II, and III; thus I spread readily to subcutaneous tissues and lymphatic channels.  I, II, and III all increased capillary permeability beginning 3-5 min. and ending 30 min. following injection.  The following antagonized I bluing: ether, chloroform, chloralose, bromethol, and Na pentobarbital anesthesia; cooling to 10°; shocking doses of Proteus vulgaris and Bacterium coli endotoxins; adenosine triphosphate, insulin, or intraperitoneal hypertonic glucose; and circulating (intravenous) neoantergan (mepyramine maleate) (IV).  These antagonistic effects appeared to be through a decrease in local intravascular pressures, except for direct antagonism by IV to I, II, and III.  High local concns. of I inhibited bluing, through local vasoconstriction during the period of increased permeability; high local concns. of II inhibited bluing by thrombosing the blood vessels.  I, II, and III injections induced considerable cross-immunity to one another, presumably owing to I release by II and III, causing immunization of the blood vessels, or exhaustion of I, or inhibition of the I-release mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIE5ggOAHowLVg90H21EOLACvtfcHk0li14OJcgggjOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG3sXmvVejug%253D%253D&md5=c2f5f333cec9f155ad4aa9b0666ebb78</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiles%26aufirst%3DA.%2BA.%26aulast%3DMiles%26aufirst%3DE.%2BM.%26atitle%3DVascular%2520reactions%2520to%2520histamine%252C%2520histamine-liberator%252Cand%2520leukotaxine%2520in%2520the%2520skin%2520of%2520guinea%2520pigs%26jtitle%3DJ.%2520Physiol.%26date%3D1952%26volume%3D118%26spage%3D228%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scully, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duryea, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feige, U.</span><span> </span><span class="NLM_article-title">Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2604</span><span class="NLM_x">–</span> <span class="NLM_lpage">2612</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm701098w&amp;key=10.1002%2Fart.10546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm701098w&amp;key=12384918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm701098w&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVWitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=2604-2612&author=A.+Coxonauthor=B.+Bolonauthor=J.+Estradaauthor=S.+Kaufmanauthor=S.+Scullyauthor=A.+Rattanauthor=D.+Duryeaauthor=Y.+L.+Huauthor=K.+Rexauthor=E.+Pachecoauthor=G.+Vanauthor=D.+Zackauthor=U.+Feige&title=Inhibition+of+interleukin-1+but+not+tumor+necrosis+factor+suppresses+neovascularization+in+rat+models+of+corneal+angiogenesis+and+adjuvant+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis</span></div><div class="casAuthors">Coxon, Angela; Bolon, Brad; Estrada, Juan; Kaufman, Stephen; Scully, Sheila; Rattan, Alana; Duryea, Diane; Hu, Yi-Ling; Rex, Karen; Pacheco, Efrain; Van, Gwyneth; Zack, Debra; Feige, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2604-2612</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To assess the capacities of the cytokine inhibitors interleukin-1 receptor antagonist (IL-1Ra; anakinra) and PEGylated sol. tumor necrosis factor receptor I (PEG sTNFRI; pegsunercept) to suppress neovascularization.  Methods: A corneal angiogenesis assay was performed by implanting nylon disks impregnated with an angiogenic stimulator (basic fibroblast growth factor or vascular endothelial growth factor) into one cornea of female Sprague-Dawley rats.  Animals were treated with IL-1Ra or PEG sTNFRI for 7 days, after which new vessels were quantified.  In a parallel study, male Lewis rats with mycobacteria-induced adjuvant-induced arthritis were treated with IL-1Ra or PEG sTNFRI for 7 days beginning at disease onset, after which scores for inflammation and bone erosion as well as capillary counts were acquired from sections of arthritic hind paws.  Results: Treatment with IL-1Ra yielded a dose-dependent redn. in growth factor-induced corneal angiogenesis, while PEG sTNFRI did not.  IL-1Ra, but not PEG sTNFRI, significantly reduced the no. of capillaries in arthritic paws, even though both anticytokines reduced inflammation and bone erosion to a similar degree.  Conclusion: These data support a major role for IL-1, but not TNFα, in angiogenesis and suggest that an addnl. antiarthritic mechanism afforded by IL-1 inhibitors, but not anti-TNF agents, is the suppression of the angiogenic component of pannus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbU43QxFbpkLVg90H21EOLACvtfcHk0lg7aOQcc-hF3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVWitrs%253D&md5=eb8cb76d17205401e1b0e12b1cbc7625</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fart.10546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.10546%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBolon%26aufirst%3DB.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DScully%26aufirst%3DS.%26aulast%3DRattan%26aufirst%3DA.%26aulast%3DDuryea%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DY.%2BL.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DPacheco%26aufirst%3DE.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DZack%26aufirst%3DD.%26aulast%3DFeige%26aufirst%3DU.%26atitle%3DInhibition%2520of%2520interleukin-1%2520but%2520not%2520tumor%2520necrosis%2520factor%2520suppresses%2520neovascularization%2520in%2520rat%2520models%2520of%2520corneal%2520angiogenesis%2520and%2520adjuvant%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2002%26volume%3D46%26spage%3D2604%26epage%3D2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8Q','PDB','3B8Q'); return false;">PDB: 3B8Q</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3B8R','PDB','3B8R'); return false;">PDB: 3B8R</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-si1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i61"><a href="/doi/suppl/10.1021/jm701098w">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_74466"></div></div></div></div></div><hr /></hr><p class="last">Tables of elemental analysis, HPLC anlysis, and X-ray data. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm701098w/suppl_file/jm701098w-file002.pdf">jm701098w-file002.pdf (102.13 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm701098w&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2008.51.issue-6%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm701098w%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm701098w" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                777KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b406bfd193ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
